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Abstract 
Background 
In Schizophrenia, Molecular genetics may provide the clinician with a useful tool in 
deciding which trinucleotide repeat expansion (TNR) expansion does not cause or 
play role in Schizophrenia (SCZ). Beside this data suggests that differences in TNR 
expansion in normal and Schizophrenia (SCZ) patient sample may help to create 
clinically meaningful genetic-based subgroups in Schizophrenia. Study of TNR 
polymorphism based on ethnicity may give insight into the genetic specifications at 
the loci studied in that population. 
Aim 
To study the association of the trinucleotide repeat expansion (TNR) polymorphisms 
of six gene loci encoded in our study as - Saml (CTG-B33), Sam2 (CTG37), Sam3 
(N0TCH4), Sam4(DTNBPl), Sam5 (GLUR6), Sam6 (CTG-Bl) with Schizophrenia, 
if any by comparisons between normal individual and Schizophrenia patient samples 
at these loci. 
Subjects and Methods 
The sample comprised of forty (40) North- Indian patients with DSM-IV diagnosis of 
Schizophrenia. There were also 40 control (normal) samples - twenty (20) males and 
twenty (20) females who were healthy blood donors. DNA was isolated from blood. 
Genotypes were determined using polymerase chain reaction (PCR) and direct 
sequencing and agarose gel electrophoresis for allelic discrimination between normal 
and Schizophrenic subjects of our study. The 40 Schizophrenic patients were 
categorized on the basis of-
1. Sex - 20 Males and 20 Females. Study was -
Intra-gender: Normal Male vs. Schizophrenic Male. 
Inter-gender: Normal Female vs. Schizophrenic Female. 
2. Disease intensity: 20 Schizophrenic (Mild-Avg.) and 20 Chronic 
Schizophrenic patients. 
Introduction: 
Molecular genetics is about 20-25 years old as a field of study in medicine. In 1980s, 
clinicians observed inherited differences in polymorphic TNR repeats. The discovery 
of the genetic variation in genes in the late 1980s was considered to be of major 
importance in psychiatric diseases as most microsatellite DNA markers containing 
multiple tandem copies of Di, Tri and Tetra nucleotide sequences were being 
considered for the appearance of many neuropsychiatric diseases. This hypothesis was 
being endorsed with positive results reported in many studies especially in Caucasian 
populations. Most of the multiple tandem copy studies reported trinucleotide repeat 
(TNR) expansions in 1980s, however, molecular genetic study of microsatellite DNA 
markers' properly began only about 10 years ago. 
Until now several polymorphisms in the genes have been associated with SCZ, 
however, relatively few of these results have been replicated in independent samples. 
In this thesis, the polymorphism of genes affecting brain development - CTG-B33, 
CTG-B37, N0TCH4, AAT21, GLUR6 and CTG-Bl were chosen for molecular 
genetic studies. The study focused on association of TNR expansion polymorphism 
with Schizophrenia by observing difference of TNR expansions between 
Schizophrenic patients and healthy controls at these loci. Effects on disease intensity 
and gender bias were also studied. 
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Introduction 
Introductory Review of Literature 
A'europsychiatric diseases inherited in intergenerational flow (Gilian B et al.; 1994) 
have always remained a matter of concern in medicinal arena. Like many other fields 
of disease research, endeavor to find the causes of neuropsychiatric diseases, being 
matter of concern and research since long time but got a major breakthrough with the 
emergence and development of molecular biology. This gave scientists a track to 
follow that had since long remained a mystery for science world, though a lot is yet to 
be elucidated. 
1. Molecular Genetics Approach 
1.1 Simple Sequence Repeats 
In the premolecular era, attempts to discern the underlying genetic mechanism 
consisted of 
? Segregation analysis, testing the fit of observed familial patterns to specific genetic 
formulations (e.g. single-major-locus, oligogenic and mutifactorial - polygenic 
models) 
? Searching for genetic susceptibility traits, also known as "biological markers" that 
segregate with the disorder in families (e.g. neurotransmitter enzymes, receptor 
proteins or metabolites, attentional and electroencephalographic measures; and 
indices based on brain imaging) and 
? Linkage studies that used classical gene markers (e.g. leukocyte antigen, blood 
groups or serum proteins) (Baron M; 2001). 
However, there is presently an explosion of knowledge and techniques 
relevant to discovering the genetic basis for the human disease. Analytic techniques 
have been developed to evaluate polygenetic disorders, and the gene substructure 
techniques now enable investigators to focus on candidate genes (La Spada et al.; 
1991). Molecular genetics has enabled to explore the systematic application of both 
reverse genetics (studying random, anonymous DNA markers spanning the genome) 
and forward genetics which tests the candidate gene polymorphism with presumed 
fiincfional relevance for the disease (Koide R etal; 1994, Nagafiichi et al.; 1994, Orr 
HT et al.; 1993) in research. One such discovery is the simple sequence repeat (SSR), 
a series of repeat sequences arranged in tandem array and are present throughout the 
genome, categorized as - Minisatellite - each nucleotide repeat unit consists of more 
than 5 nucleotides and Microsatellite - only 2-4 nucleotides in each repeat. 
The simple sequence repeat (SSR) or microsatellite markers, given by Alec 
Jeffreys (1984) are currently the preferred molecular markers due to their highly 
desirable properties for searching markers for genetic disease. This technique shows 
regions of DNA with variations in the number of tandem repeats which are known as 
Variable Number of Tandem Repeats (VNTRs). These VNTRs were observed as 
repeated over and over again next to each other. The VNTRs examined through 
Restriction Fragment Length Polymorphism (RFLP) determines the variation in the 
length of a defined DNA fragment and gives an impression of bar codes. Depending 
upon the length of the repeat unit, Microsatellite DNA or commonly known as Short 
Tandem Repeats (STR) or Simple Sequence Repeats (SSR), scattered throughout the 
human genome and occur on an average every 10,000 nucleotides named as-
* Di - nucleotide, CA, AT. 
* Tri - nucleotide, CAG, CCG, CGG, AAT. 
*Tetra -nucleotide, GACA, GATA, AACC, AACT, AACG, AAGC, AAGT, AATC. 
* Penta - nucleotide CAGGG. 
* Hexa - nucleotide 
2. Tri Nucleotide Expansion 
Genome analysis of Neuropsychiatric patients has helped a great deal to reveal the 
complexities and similarities at the DNA base sequence level. Sequential arrangement 
of nucleotides in DNA and presence of repeat sequences-both in number and size, 
have been identified as markers for identification of a particular Neuropsychiatric 
disease. In the year 1991, a kind of mutation resulting fi-om the unstable expansion of 
GC - rich trinucleotide repeats (TNR), tandemly repeated 3 bp units, was reported in 
individuals with fi-agile X syndrome and Spino bulbar muscular atrophy (La Spada et 
al.; 1991, Verkerk AJMH et al.; 1991, Warren ST; 1996). Neuropsychiatric patients, 
as has been observed, have varying and different trinucleotide repeat expansion in the 
genome (Gomes-Pereira M et al.; 2001). During the last few years, expansion of these 
trinucleotide repeats have been reported as the main cause of several 
neurodegenerative (Paulson HL et al.; 1996) and neurodevelopment diseases (Riess 
AL et al.; 1986). Normal people have these repeats but in small numbers, maintained 
up to an appropriate limit 5-50 depending on the disorder. The disorder results from 
the unstable expression of the TNR (40-2000) either or both numerically as well as 
length-wise, in affected individuals usually only in one allele, causing heritable 
mutational changes (Kubota S; 2001). Initially this remains a mild premutation, which 
if increased in the intergenerational flow, create expanded forms leading to increased 
severity of the disease alongwith the decreased age of onset in the proceeding 
generation - anticipation (Isashiki Y et al.; 2001, Brook JD et al.; 1992). Depending 
on the type of repeat expansion, more than 14 disorders have been described thus far, 
the expansion being -
2.1 Small-scale expansion -
Spinobulbar Muscular Atrophy or Kennedy's syndrome (SBMA, XL - Androgen 
Receptor Gene), Huntington diseases (HD). 
2.2 Large-scale expansion including -
Fragile-X syndrome, FRAXE mental retardation X (XL), Myotonic dystrophy 
(DM), Spinocerebellar ataxia (SCA). 
There are several on different chromosomes; they are example of locus heterogeneity 
as -
Dentatorubralpallisdoluysiah atrophy (DRPLA), Haw rivers syndrome, Macado-
Joseph disease, Friedreich ataxia (AR-TNR in an intron). Schizophrenia (SCZ). 
The genes involved are usually expressed in a variety of tissues and the 
researchers are looking at the functions of the normal gene products and the 
mechanism of expansion and instability of the repeats (Burke JR et al.; 1994, Koide R 
et al.; 1994, Nagafuchi S et al.; 1994, The Huntington's Diseases Collaborative 
Research Group; 1993, Knight SJL et al.; 1993, Orr H.T et al.; 1993, Mahadevan M et 
al.; 1992, Brook JD et al.; 1992, Fu YH et al.; 1992, La Spada AR et al.; 1991, 
Verkerk AJMH et al.; 1991). 
So far, analysis has predicted and identified these sequences differently in 
different disorders. Trinucleotide repeat motifs have played a very important role in 
expediting the genetic cause of neuropsychiatric diseases when physiological 
concepts for the abnormality, congenital or developed later at some stage of life, were 
not clear (Orr H.T et al; 1993). 
The distribution of all the trinucleotide microsatellite sequences in the 
GenBank database was surveyed to provide insight into human genetic disease 
syndromes that result from expansion of microsatellites (Stallings LR; 1994). 
Commonly observed and experimentally anticipated, trinucleotide repeats in the 
Neuropsychiatric patients are CAG - Dentatorubrpallidoluysian atrophy (DRPLA), 
Spinobulbular Muscular Atrophy (SBMA), Spinocerebellar Ataxia (SCA), 
Huntington's disease (HD), Schizophrenia (Ohara K; 2001, Hofinan-Radvanyi H et 
al.; 1989) (Table-1), CTG - Myotonic Dystrophy (DM), CCG/CGG - Fragile-X 
Syndrome (Sutcliffe JS et al.; 1992, Verkerk AJMH et al.; 1991) and GAA (Bit-
Avragim N et al.; 2001) (Table2) and the inheritance pattern at the genetic level is 
either X-linked or Autosomal (Table-1 and 2). 
3. CAG Repeat Expansion Disorders 
CAG repeat expansion based neurodegenerative disease, differing in the chromosome 
loci can be identified as follows 
3.1 Spinal and Bulbular Atrophy (SBMA) (Kennedy's Disease) 
Average onset age for adolescents is 15 years and for adults is 30 to 40 years (Lund A 
et al.; 2000, Sopher BL et al.; 2000) (Table- 4). 
A progressive male neurodegenerative X-linked (Xqll-12) disorder (Ohara K; 2001) 
(Table-1). 
Clinical abnormalities include lower motor neuron weakness, atrophy and 
fasciculation of the muscles of the face, lips, and tongue, Throat, vocal cords, trunk, 
and uppCT extremities followed by weakness and wasting of the muscles (after the age 
offifteen)(Table-3). 
In many cases gynecomastia and testicular atrophy, oligospermia infertility is 
observed. 
Female carriers are clinically asymptomatic (Table- 3). 
GENETICS 
The normal repeat length is 11-3 3 (CAG)n triplet repeat units, 33 being the highest 
normal repeat (Table-1) after which starts the onset of disease (Gillian B et al.; 1994). 
An inverse correlation has been set between repeat lengths' expansion and the 
age of onset with other aspects as sibling-pairs, monozygotic twins (Andrew S et al.; 
1993, Snell RG et al.; 1993). A correlation between repeat-length and the age of onset 
Table 1: Neurodegenerative Disorders Associated with Exonic Trinucleotide repeat (Polyglutamine) Expansions 
Disease 
Spinal and bulbar 
muscular 
atrophy(SBMA) 
Huntington's 
chorea (HD) 
Dentate rubro-
Pallidoluysian 
atrophy/ Haw 
River syndrome 
Spinocerebellar 
ataxia typel 
(SCA-1) 
Spinocerebellar 
ataxia type 2 
(SCA -2) 
Spinocerebellar 
ataxia type3 
Machado Joseph 
disease (SCA -3) 
Spinocerebellar 
ataxia type 6 
(SCA -6) 
Gene 
Androgen 
Receptor 
Huntingtin 
DRPLA 
Ataxin-1 
Ataxin- 2 
Ataxin- 3/ 
Machado Joseph 
disease Protein 6) 
Alpha 1 A-voltage 
dependent calcium 
channel 
Repeat 
motifs 
CAG 
CAG 
CAG 
CAG 
CAG 
CAG 
CAG 
Transmission 
X- linked 
Autosomal 
dominant 
Autosomal 
dominant 
Autosomal 
dominant 
Autosomal 
dominant 
Autosomal 
dominant 
Autosomal 
dominant 
Location 
Exon 1 
Exon 1 
Exon 5 
Exon 8 
Not known 
Not known 
Not known 
Chromosome 
Xq11-12 
4p16.3 
12p13.31 
6p22- 23 
12q24.1 
14q24.3-32.1 
9p13 
Normal 
repeats 
11-33 
6-37 
7-23 
6-40 
17-29 
1 3 ^ 0 
7-17 
Expanded 
repeats 
40-66 
35-74 
49-75 
41-81 
35-59 
62-79 
21-30 
Table 2: Neurodegenerative Disorders Associated with Non Coding Trinucleotide Repeat Expansions 
Disease 
Myotonic 
Dystrophy 
Fragile X 
FRAXA 
FRAXE 
FRA11B 
Freidriech's ataxia 
Gene 
Myotonin protein 
kinase 
FMR-1 Fragile X 
mental retardation-
Igene product) 
FMR-2 
CBL- 2 proto -
oncogene 
Frataxin 
Repeat 
motifs 
CTG (CAG) 
CCG 
(CGG) 
CCG 
(CGG) 
CCG 
(CGG) 
GAA 
Transmission 
Autosomal 
Dominant 
X- linked 
X- linked 
Autosomal 
dominant 
Autosomal 
recessive 
Location 
3'UTR 
5 'UTR 
Not known 
Not known 
Intron 
Chromosome 
19q13.3 
Xq27.3 
Xq27- 28 
11q23.3 
19q13 
Normal 
repeats 
5-35 
5-53 
6-25 
8-11 
8-22 
Expanded 
repeats 
50- 2000 
>200 
>200 
>200 
120-1700 
starts with the stair-cHmbing ability of a child (Ohara K; 2001, Igarashi S et al.; 
1992). 
SBMA follows the paternal line of transference, reported with an overall 
frequency of 20% - 47%. In SBMA, the CAG expansion (Table-1) lies within the 
coding region of the first exon of the Androgen Receptor (AR) and encodes a 
polyglutamine tract (Bailey CK et al.; 2002, McManamny P et al.; 2002, Chang C et 
al.; 1988). Although studies provide insight into the toxic function of the expanded 
polyglutamine protein (Mhafre AN et al.; 1993) intrinsic AR transactivational 
function is somewhat diminished in the presence of the expanded polyglutamine. This 
likely leads to the partial androgen insensitivity that characterizes patients with 
SBMA (Lund A et al.; 2000, Walcott JL et al.; 2002). 
Studies on ethnic bias in SBMA are being carried out. Haplotype analysis 
implies a common ancestor for the majority of Scandinavian SBMA patients (Lund A 
et al.; 2000). Studies are being reported in African (Moosa A et al.; 1990), French 
Canadian (Simard LR et al.; 1992), Arab (Haider MZ et al.; 1997), Japanese (Nishio 
H et al.; 1999) populations (Table-5). 
3.2 Spinocerebellar Ataxia (SCA) 
The general age of onset is 30-40 years and for Juveniles (4 years) (Gomes-Pereira M 
et al.; 2001, Harding AE; 1982) (Table-4). 
Autosomal Dominant Cerebellar Ataxias (ADCAs)/SCAs are clinically and 
genetically heterogeneous group of disorders with three clinical subgroups -
ADCA type I - SCA 1, SCA2, SCA3 (MJD); ADCA type II - SCA7 and; 
ADC A type III - SCA 6/EA 
SCA is a CAG expansion neurodegnerative disease involving spinocerebellar 
tracts, brain stem, and cerebellum has general clinical symptoms of Ataxia, 
opthalmoparesis and variable degree of motor weakness. ADCA type I -
Supranuclear ophthalmoplegia, optic atrophy, mild dementia, peripheral neuropathy 
or extrapyramidal dysftmction. ADCA type II - pigmentary macular dystrophy. 
ADCAIII - is a pure cerebellar syndrome (Table-4). 
Table 3: Clinical identification characteristics of Neuropsychiatric diseases 
Disease 
Spino bulbar muscular 
atrophy (SBMA) 
Dentatorubropallidoluysian 
(DRPLA) 
Spinocerebellar ataxia 
(SCA) 
Huntingtons disease 
(HD) 
Schizophrenia 
(SCZ) 
Fragile X Syndrome 
(FRAXA, FRAXE) 
Clinical features 
Kennedy's Syndrome, a motor neuron disease that is slowly progressive, only 
affects males. 
Uncontrollable twitching (fasciculations), followed by weakness and wasting of 
the muscles during early stage (15 years). 
Noticeable wealtness In adulthood, (30-50 years), with symmetrical and 
proximal muscle cramps, affecting initially the hip & shoulder muscles. 
SBMA patients frequently exhibit bulbar muscle weakness and atrophy. The 
muscles of the face, lips, tongue, mouth, throat, vocal cords, trunk, and upper 
extremities may be fasciculated. 
Gynecomastia and infertility observed in many cases. 
Female carriers are clinically asymptomatic. 
Early-onset DRPLA (below 20 years) 
Ataxia, myoclonus, seizures, progressive Intellectual deterioration. 
Adult-onset DRPLA (20 years and above) 
Ataxia, choreoathetosis, dementia, psychiatric disturbance. 
Eye movement abnomialities (nystagmus or jerkiness and double vision), 
blindness and damage to the retina and the macula in the eye (SCA 7), 
Supranuclear ophthalmoplegia. 
Gait ataxia, Dysarthria (speech difficulty). 
Peripheral neuropathy (damage to the peripheral nerves which causes the 
patient to have numbness or tingling in the hands and feet) seen in SCAs 
(SCA1, 2,3,4,7 and 8). 
Mild dementia, extra pyramidal dysfunction 
Behavior chanaes 
Personality changes, antisocial behaviors disorientation or confusion, 
restlessness, fidgeting. 
Psychosis, paranoia, hallucinations. Irritability, moodiness. 
Progressive dementia, loss of memory, loss of judgment, speech changes, 
loss of other functions (calculating, etc). 
PhenotvDic chanaes 
Unsteady gait, facial movements, grimaces, need to turn head to shift the 
gaze, speech impairment. 
Progressive development of abnormal (chore form) uncontrolled slow 
movements. Quick, sudden, jerking movements of arms, legs, face, trunk 
(movement, unpredictable- jerky). 
In congenital cases, generalized hypotonia (Infantile hypotonia) and diffuse 
muscle weakness. 
In infants, gradual improvement in muscle strength and tone but difficulty in 
swallowing, sucking, facial weakness 
Mental retardation (in 80% of cases) 
In children slow movement, tremor, rigidity, An-hythmias, cataracts, frontal 
baldness, loss of body hair 
Testicular atrophy. 
Insulin dependent diabetes mellitus (IDDM). 
Arthrogryposis of multiple joints +/- cervical spine, congenital dislocation of 
hips, foot deformities - talipes equinovarus. 
Formal thought disorder, common persecutory delusions, partition delusions, 
hallucinations especially auditory (can manifest in multiple modalities) 
Premorbid personality, social isolation, suspicious nature. 
Structural brain abnormalities, uncorrected excessive auditory, visual 
impairments in some patients. 
Bilateral facial weakness, tented upper lip, unilateral or bilateral ptosis, 
myotonia or ophthalmoplegia. 
Swallowing and feeding problems - gavage feeds, abdominal distention due to 
poor peristalsis. 
Neck weakness, respiratory distress. 
Undescended testes. 
Long face- coarsening of features, large-everted ears, increased head 
circumference. 
Macroorchidism in post-pubertal males. 
Generalised disorder of connective tissues, hypotonia. 
Behavioural disturbances- hyperactivity, autism. 
GENETICS 
In this case, the expansion of CAG repeats has been reported (Isashiki Y et al.; 2001). 
In SCAl, juvenile form is associated with longer expansions (Gomes-Pereira M et al.; 
2001) (Table-1). In SCA3, CAG repeat expansion results in a disease called Machado-
Joseph disease (Isashiki Y et al.; 2001). 
Autosomally dominant, the transmission of this disease follows the paternal 
line, the change in CAG repeats ranging from (-4 to +28 trimeric units). In maternal 
transmission, the changes in repeat size range from (-6 to+4 trimeric units) (Bit-
Avragim N et al.; 2001, Chung M et al.; 1993). Locus SCAl has 6-40 normal CAG 
repeat units with interrupting CAT sequence and/or the expanded forms of contiguous 
(CAG) n stretch. Interruption removal may be predisposition of the disease (Castaneda 
MA etal.; 2000) (Table-1). 
Prevalence of SCA on ethnic basis is being studied. Work has been done on 
the ethnic Chinese in Taiwan, and on Chinese patients with SCA6 in terms of clinical 
and molecular features. Machado-Joseph disease - SCAB was the most common type 
of autosomal dominant SCA in the Taiwanese cohort, accounting for 35 cases 
(47.3%), followed by SCA6 (8 [10.8%]), SCA2 (8 [10.8%]), SCAl (4 [5.4%]), SCA7 
(2 [2.7%]), and SCA8 (0%)[27]. Studies on Spanish population has revealed 15% 
SCA2, 15% SCA3, 6% SCAl, 3% SCA7, 1% SCA6 (Pujana MA et al.; 1999). SCA 
studies based on ethnic variation have been reported also from Korean (Jin DK et al.; 
1999), Japanese (Maruyama H et al.; 2002, Ikeuchi T et al.; 1997.) populations 
(Table-5). 
3.3 Dentatorubral-Pallidoluysian Atrophy (DRPLA) 
The age of onset is from one to sixty-two (1-62) years with a mean age of onset of 30 
years (Table-4). DRPLA is a progressive neurodegenerative, autosomally dominant 
disorder (12p 13.31) characterized clinically by- Ataxia, choreoathetosis, dementia or 
character changes (above 20 years) and Ataxia, myoclonus, epilepsy, progressive 
intellectual deterioration (below 20 years) (Table-3). 
GENETICS 
The CAG repeat length in patients with DRPLA ranges from 49 to 88 (Zhong N et al.; 
1996; Naito H and Oyanagi S; 1982), normal individuals range being from 6-35 
(Takano H et al; 1998, Ikeuchi T et al.; 1995, Naito H and Oyanagi S; 1982) (Table -
1). An intermediate repeat range exists which can expand on transmission resulting in 
occurrence of symptoms in the next generation. Truncated mutant DRPLA proteins 
with expanded polyglutamine stretches (the CAG repeat in the DRPLA gene is 
located in exon 5, 1462 bp downstream) results in processed mutant proteins, toxic to 
cells than full-length proteins (Igarashi S et al.; 1998, Ikeuchi T et al.; 1995, Sato K et 
al.; 1995, Koide R et al.; 1994). DRPLA is characterized by anticipation (Ikeuchi T et 
al.; 1995, Naito H and Oyanagi S; 1982) {offspring have symptoms 26-29 years 
earlier than their affected fathers and 14-15 years earlier than their affected mothers 
(Shimojo Y et al.; 2001, Sato K et al.; 1995)}. 
DRPLA has been reported to occur predominantly in Japanese individuals, 
(Igarashi S et al.; 1998, Jaworski A et al; 1995, Margolis RL et al.; 1995, Paschen W 
et al; Sutherland GR and Richards RI; 1995, Burke JR et al; 1994, Li SH et al ; 1993, 
Strand M et al ; 1993, Farmer TW et al; 1989, De Barsy TH et al; 1968, Titica J et 
al; 1946). DRPLA is relatively more common among Japanese compared to other 
ethnic populations (Burke JR et a l ; 1994, Koide R et al ; 1994). Rare in US, DRPLA 
has been discovered in a large African-American family in North Carolina and 
referred to as the Haw River Syndrome (Burke JR et a l ; 1994, Koide R et a l ; 1994) 
(Table-5). 
3.4 Huntington's Disease (HD) 
Age of onset in adults is 40-50 years (Gillian B et al ; 1994). In juvenile cases, the 
age of onset is before 21 yrs (Table-4). 
Huntington s disease (HD) is an inherited, autosomal dominant (4pl6.3) 
genetically transmitted disorder characterized clinically by behavior changes, 
antisocial behaviors, personality changes, disorientation or confusion, loss of 
memory, loss of judgment, psychosis, paranoia, hallucinations, progressive dementia, 
unsteady gait, progressive development of abnormal (choreiform) movements, 
uncontrolled jerking movements of arms, legs, face, trunk, anxiety, stress, and 
tension, speech impairment, difficulty in swallowing (Table-3). 
GENETICS 
Results from abnormally increased number of CAG repeat within IT-15 gene, 
chromosome 4, coding for huntingtin protein and is responsible for Huntington's 
disease (HD) (Wellington CL et al.; 2002, Zielonka D et a l ; 2002). Due to the higher 
incidence, this disease is categorized on the basis of repeat expansion into normal (37 
repeats), intermediate (30-38 repeats) and expanded (38-74 repeats) forms (Table-1) 
(Brandt J et al.; 2002, Moncke-Buchner E et al.; 2002, Barron LH et al.; 1993). The 
mutant alleles at HD locus are unstable in approximately 80% of the meiosis (Duyao 
M et al.; 1993, Snell RG et al.; 1993). Increase and decrease in trinucleotide repeats is 
observed more in maternal transmission (<5 repeat units). On paternal transmission, 
though increases and decreases in trinucleotide repeats, are again both observed, but 
there are higher percent of increases, some being very large - largest so far reported 
being 74 repeats (Moncke-Buchner E et al; 2002, Telenius H et al.; 1993). This 
justifies the consideration of line of transmission being paternal especially in large 
repeats (>55 repeats) including all juvenile patients (Duyao M et al.; 1993, The 
Huntington's Diseases Collaborative Research Group; 1993) (Table-1). 
CAG trinucleotide expansion is the molecular basis of the Huntington disease 
and has been studied worldwide and predisposition of the disease reported at the 
familial and ethnic level (Kremer B et al.; 1994) (Table-5). 
4. CTG Repeat Expansion Disorders 
4.1 Myotonic Dystrophy (DM) 
Onset age varies from congenital, early adult life (average 20) and old age (average 
40) (Wakimoto H et al.; 2002, Gillian B et al.; 1994) (Table-4). 
An autosomally dominant (19ql3.3), neuromuscular disease (Hoftnan-
Radvanyi H et al.; 1989) clinical abnormalities include - bilateral facial weakness 
tented upper lip, unilateral or bilateral ptosis, swallowing and feeding problems -
gavage feeds, abdominal distention due to poor peristalsis, severe generalized 
infantile hypotonia and diffuse muscle weakness, neck weakness, respiratory distress, 
myotonia or ophthalmoplegia, undescended testes. Also, arthrogryposis of multiple 
joints +/- cervical spine, congenital dislocation of hips, foot deformities - talipes 
equinovarus. In infants, arrhythmias, cataracts, frontal baldness, insulin dependent 
diabetes mellitus (IDDM), and loss of body hair testicular atrophy (Table-3). 
Table 4: Specificity of disease expression with age as the onset factor. 
Disease 
SpinobulbarMuscular atrophy (SBMA) 
Spinocerebellar ataxia( SCA) 
Dentatorubralpallisdoluysian atrophy (DRPL 
Huntington disease (HD) 
Schizophrenia (SCZ) 
Myotonic dystrophy (DM) 
Fragile-X syndrome ( FRAXA, FRAXE) 
Juvenile 
-
4 
1 
1.-10 
Congenital 
Age onset 
Adolescent 
15yrs 
-
>21 
Average 15 
Avg.20 
Congenital 
Adult 
30-40 
30-40 
30-60 
30-50 
Avg.40 
Table 5:Genetic origin (Founder effect) in Neuropsychiatric diseases 
Disease 
Spinobulbar Muscular Atrophy (SBMA) 
Dentatorubral pallisdoluysian atrophy 
(DRPLA) 
Spinocerebellar ataxia (SCA) 
SCA1 
SCA 2 
SCA 3 
SCA 6 
SCA 7 
SCA 10 
SCA 12 
SCA 17 
Huntington diseases (HD) 
Friedreich ataxia (FA) 
Schizophrenia (SCZ) 
Myotonic dystrophy (DM) 
Fragile-X syndrome, FRAX (XL) 
Ethnicity (founder effect) 
* Northern Europe (couple who settled in New France 
in 1657). 
*Very rare outside Japan (Haw River Syndrome in US 
*Angloceltic, Siberian 
'Italian (especially Southern), Indian 
* Portuguese, German, (French), Chinese 
'Everywhere but France 
* Uncommon everywhere 
* Mexican 
*Very rare in USA & UK (not found elsewhere yet) 
*May be common (Germany & Japan) 
*Western Europe (European sailor who came ashore 
* Rare in Blacks, absent in Orientals 
'Finland, Africa 
not known 
not known 
GENETICS 
A CTG- repeats expansion disease present at 500 bp from the poly-A tract in the 3 
untranslated region (UTR) of (DMPK) mRNA gene (Wakimoto H et al.; 2002, Fu YH 
et al.; 1993, Anvert M et al.; 1993, Barcelo JM et al.; 1993, Harley HG et al.; 1992). 
The normal repeat length is 5-35 CTG repeats, mildly affected individuals have 50-
80 repeats and those with congenital show expansion of more than 2000 (Barcelo JM 
et al.; 1993, Fu YH et al.; 1993, Lavedan C et al.; 1993, Harley HG et al.; 1992, 
Tsilfidis C et al.; 1992). Evidence for a familial predisposition to the type of disease 
(mild, adult, congenital) has been found (Isashiki Y et al.; 2001, Imbert G et al.; 1993, 
Lavedan C et al.; 1993). Maternal line of transmission is supported by the repeat size 
increase in the intergenerational flow irrespective of the maternal allele size (Warren 
ST; 1996, Warren ST; 1991, Hofrnan-Radvanyi H et al.; 1989). From the paternal 
side, there is seen decrease in the repeat number in the intergenerational flow usually 
(Lavedan C et al.; 1993) (Table-2). 
One of the world's highest prevalence estimates of Myotonic dystrophy (DM) 
has been reported in the Croatian region Istria (Medica I et al.; 2000). Association of 
low incidence of Myotonic Dystrophy with low number of CTG repeats has been 
reported in Chinese Hans population (Sizhong Z et al.; 2000), CTG repeats 
distribution at Myotonic dystrophy (DM) gene in Amhara and Oromo populations of 
Ethiopia has also been studied (Gennarelli M et al.; 1999) (Table-5). 
5. CGG / CCG Repeat Expansion Disorder 
5.1 Fragile-X Syndrome 
Fragile X syndrome, the most common congenital form of X-linked neuropsychiatric 
disease characterized clinically by - (Behavioral) - Poor eye contact, hand flapping, 
speech is halting and repetitive, hyperactive with attention deficit, aggressive 
outburst, and many features of autism. (Appearance) - High forehead, large ears, 
long face, prominent jaw, (Post-puberty) - Large testes (macroorchidism), connective 
tissues weaken, hyper extensible joint, stretch marks on skin (striae), mitral valve 
prolapse. Mental retardation is the most prominent characteristic, with men affected 
most, being hemizygous (XY), while women may be the carriers. This disease is 
associated with folate-sensitive fragile site on long arm of X chromosome thus named 
FRAX (Nussbaum R L et al.; 1986) (Table-3). 
GENETICS 
Gene involved in Fragile-X Syndrome is FMRl for Fragile Mental Retardation gene! 
(Kubota S; 2001, Oberle I et al.; 1991). Fragile X syndrome is mainly of two types-
FRAXA and FRAXE (Table-2). 
5.1.1 FRAXA 
FMRl is the gene for FRAXA. This disease is due to an amplified unstable CGG 
repeat element within the 5^  untranslated region (UTR) of Exonl of FMRl gene 
(Verkerk AJMH et al.; 1991). The repeat lies 250 base pair distal of a CpG island in 
the Fragile-X syndrome patients and the CGG repeat is the site of preferential 
chromosome breakage (Sutcliffe JS et al.; 1992). In general population, this CGG 
repeat is 5-53 repeat motifs normally. Two classes of unstable repeats are observed -
a) carrier males (Normal Transmitting Males-NTMs) and b) some carrier females, 
having relatively small size amplification referred to as permutation. These show 
repeat length of CCG from 43-200 and are asymptomatic (Oberle I et al.; 1991, 
Verkerk AJMH et al.; 1991). Affected individuals have larger amplifications - Full 
mutation, 200 triplets and may be more than 1000 in number (Oberle I et al.; 1991, 
Verkerk AJMH et al.; 1991). The FRAXA locus full mutation is associated with 
methylation of the adjacent CpG Island and CGG repeat which is unmethylated in 
normal and permutation. Localized Methylation of CpG island and CGG repeat shuts 
down transcription of the FMRl gene (Deboulle K et al.; 1993) causing loss of FMRP 
(protein of FMRl gene), also indicates Fragile-X syndrome is a single gene rather 
than a contiguous gene order (Siomi H et al.; 1993) (Table-2). 
FMRl gene, occupying a 38 Kb region on X chromosome with 17 exons has ±4.8 Kb 
transcript FMRl mRNA, (Ashley C Jr et al.; 1993, Devys D et al.; 1993, Eichler EE 
et al.; 1993, Knight SJL et al.; 1993, Verheij C et al.; 1993). Severity of the disease is 
interpreted due to missense (gain of function) mutation in FMRP rather than its 
absolute absence (Lindholm E et al.; 1999). Analysis of FMRl (CGG)n alleles and 
FRAXA microsatellite haplotypes in the population of Greenland (Larsen LA et al.; 
1999) has revealed the predispositional properties in the population intergenerational 
flow. CGG repeat expansion analysis has also helped in establishing the Asiatic origin 
of Greenlandic population (Larsen LA et al.; 1999). Predisposition of FRAXA disease 
has been also reported in Chinese (Chiang S C et al.; 1999, Chan S Y et al.; 1998), 
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South African (Goldman A et al.; 1998), Argentine (Bonaventure G et al.; 1998), 
Caribbean islandic, French West Indies (Elbaz A et al.; 1998), American (Mazzocco 
MM et al.; 1998) populations (Table-5). 
5.1.2 FRAXE 
This folate- sensitive fragile site identified from the screening for Fragile-X syndrome 
is with GCC repeat (Gillian B et al.; 1994). FRAXE gene, located 600 Kb distal to a 
CpG island in Xq28, is an unstable GCC repeat array identified lying adjacent to a 
CpG island, which is hypermethylated in affected males and unmethylated in normal 
males (Larsen LA et al.; 1999). 
Normal alleles have 6-25 GCC repeat units and the expansion causing mental 
retardation ranges from 200-2000 base pairs, thus there is an increase of 350-2600 
base pairs or 115-850 repeat units. However, carrier females with 350-400 base pairs 
did not express fragile site and those with over 200 repeat copies had fragile site and 
possibly suffered from mental impairment (Isashiki Y et al.; 2001) (Table-2). FRAXE 
phenotype is mild and may skip generations when the repeats contract (Larsen LA et 
al.; 1999). The GCC repeat alleles of FRAXE from three populafions - a New York 
Euro-American sample, a Chinese sample and Finnish sample were analyzed by 
polymerase chain reaction (Zhong N et al.; 1996) and predisposition in these 
populations was observed (Table-5). 
6. Polymorphism; a study approach 
Trinucleotide repeat sequences are characterized by their ability to undergo dynamic 
mutation or nucleotide alteration over only a few generations. Products of dynamic 
trinucleotide mutations may diverge fiirther from the original DNA on a subsequent 
meiosis with the probability of mutation being directly related to the number of 
repeating units (Sutherland and Richards; 1995) leading to polymorphism. Proposed 
mechanisms contributing to nucleotide repeat instability include transacting factors 
such as DNA enzymes involved in replication and repair (Jaworski et al.; 1995, 
Strand et al.; 1993). Uninterrupted perfect repeats are themselves inherently unstable 
(Sutherland and Richards 1993) and probably exert powerfiil destabilizing effects on 
DNA repeat sequences. The human genome arrays of tandem nucleotide repeats, is 
polymorphic across the population length-wise (Skaer TL et al.; 1992-1997, Kariin 
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Chromosomal Position Of The Genes Involved In Various 
Neuropsychiatric Diseases 
and Burge; 1996, Weber; 1990, Craig-Holmes and Shaw; 1971). Tandem repeated 
DNA sequences are widespread throughout the human genome and show sufficient 
variability among individuals in a population. Much of work has been done on the 
polymorphism of gene-specific locus in many diseases which includes 
neuropsychiatric diseases. The existence of inteipopulation differences in the 
frequencies of alleles (polymorphism) can be used as an informative genetic marker 
for examination of the genetic relationships as MAOA gene between Western 
Siberian populations. The data received provides a means to evaluate the role of the 
MAOA gene in various neurological and psychiatric diseases in which it has been 
implicated including Parkinsons' disease, alcoholism, suicides, schizophrenia, and 
maniac-depressive illness. 
Of the neuropsychiatric diseases involving trinucleotide expansion, our study 
focus being on Schizophrenia, an elaborate study and analysis of the disease done so 
far is as -
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Schizophrenia 
1. Clinical Diagnosis 
iSchizophrenia being among the most expressed psychiatric disease has the complex 
disadvantage of clinically not being diagnosed but by the behavioral aspect (Baron M; 
2001). Observed as a debilitating multifactorial mental disease, it is a severe 
psychiatric disorder presumed to be resulting from both genetic and environmental 
factors (Kendler KS et al; 1993). Its mode of inheritance is complex and non-
Mendelian (McGuffin P, et al.; 1995, McGue M et al.; 1989). A CAG repeat 
expansion disease, it is generally characterized clinically by -
• Disordered speech with psychiatric symptoms as catatonia, hallucination and 
delusions. Continuous, often loud, nonsensical unconnected speech; while 
talking, the patients shift from one topic to another completely unrelated topic 
without realizing they are making no logical sense. 
• Smiling and laughing to oneself without any obvious cause. Patient starts 
speaking to himself and making conversations and gestures with imaginary 
voices and people. When the patient is alone, he feels he can hear voices 
talking about him. 
• Acute violent, unprovoked behavior, tearing of one's clothes etc. Walking 
around without clothes and other forms of uninhibited behavior. 
• Work perfonnance, appearance and social relationships begin to deteriorate. 
Sitting in one position for hours or even days on end. The patient stops taking 
baths and starts looking unkempt, haggard and disheveled. 
• The patient becomes suspicious about relatives, neighbors and friends and 
feels that all have ganged up against him. The patient often feels that people 
are following him and spying upon him 
• Visual hallucinations as seeing non-existent things. The patient feels that 
somebody is controlling him (via laser beams, video cameras, magnetic 
powers etc) or that everybody can read or "hear" his thoughts. TV, radio, 
video and ordinary gestures of people around him acquire special meaning for 
him. The patient may feel that he is related to God, ministers, film stars and is 
endowed with special status and magical powers. 
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• Sleep rhythm is completely disrupted with the patient often not sleeping for 
days on end. 
• Even though the patient is mentally ill, he feels he is 100 per cent alright and 
denies illness altogether. 
The dilemma begins in early adulthood, resulting in lifelong social and occupational 
functioning disabilities (Anne SB et al.; 1994) (Table-3). 
1.1 Symptom categorization 
The symptoms of schizophrenia fall into three major groups -
Positive (non deficit) symptoms. 
Negative (deficit) symptoms. 
Cognitive impairment. 
A person may have symptoms from one, two, or all three groups (Tsai SJ et al.; 2006, 
William TC and Robert WB; Vol. 1, Ed. 6"'). 
1.1.1 Positive (nondeficit) symptoms 
Positive symptoms include -
Delusions, Hallucinations, Thought disorder, and Bizarre behavior. 
• Delusions are false beliefs that usually involve a misinterpretation of 
perceptions or experiences like 
1. Persecutory delusions - believing that they are being tormented, 
followed, tricked, or spied on. 
2. Delusions of reference - believing that passages from books, 
newspapers, or song lyrics are directed specifically at them. 
3. Delusions of thought withdrawal or thought insertion - believing that 
others can read their mind, their thoughts are being transmitted to 
others or that thoughts and impulses are being imposed on them by 
outside forces. 
• Hallucinations of sound, sight, smell, taste, or touch may occur. Hallucinations 
of sound (auditory hallucinations) are by far the most common. A person may 
"hear" voices commenting on his behavior, conversing with one another or 
making critical and abusive comments. 
• Thought disorder refers to disorganized thinking wiiich becomes apparent 
when speech is rambling, shifts from one topic to another, and loses its goal-
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directed quality. Speech may be mildly disorganized or completely incoherent 
and incomprehensible. 
• Bizarre behavior may take the form of childlike silliness, agitation, or 
inappropriate appearance, hygiene, or conduct. Catatonia is an extreme forni 
of bizarre behavior in which a person maintains a rigid posture and resists 
efforts to be moved or, in contrast, displays purposeless and unstimulated 
motor activity (Tsai SJ et al.; 2006, William TC and Robert WB; Vol. 1. Ed. 
6'"). 
1.1.2 Negative (deficit) symptoms 
Negative symptoms of schizophrenia include -
Blunted affect. Poverty of speech, Anhedonia, and Asociality. 
• Blunted affect refers to flattening of emotions like person's face may appear 
immobile; he makes poor eye contact and lacks emotional expressiveness. 
Events that would normally make a person laugh or cry produce no response. 
• Poverty of speech refers to diminishment of thoughts reflected in a decreased 
amount of speech. Answers to questions may be terse, perhaps one or two 
words, creating the impression of an inner emptiness. 
• Anhedonia refers to a diminished capacity to experience pleasure; the person 
may take little interest in previous activities and spend more time in 
purposeless ones. 
• Asociality refers to a lack of interest in relationships with other people. 
These negative symptoms are often associated with a general loss of, motivation, 
sense of purpose, and goals (Tsai SJ et al.; 2006, William TC and Robert WB; Vol. I, 
Ed. 6"^ 
1.1.3 Cognitive impairment 
Cognitive impairment refers to difficulty in -
Concentrating and remembering, organizing, planning and problem solving. 
• Person is unable to concentrate sufficiently to read, follow the story line of a 
movie or television show or follow directions. 
• Person is unable to ignore distractions or remain focused on a task. 
Consequently, work that involves attention to detail, involvement in 
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2. Delusions of control, influence or passivity, clearly referred to body or limb 
movements or specific thoughts, actions or sensations, delusional perception. 
3. Hallucinatory voices giving a running commentary on the patient's behaviour 
or discussing the patient among themselves or other types of hallucinatory 
voices coming from some part of the body 
4. Persistent delusions of the other kinds that are culturally inappropriate and 
completely impossible. 
5. Persistent hallucinations in any modality when accompanied either by fleeting 
or half- formed delusions without clear affective content or by the persistent 
over-valued ideas or when occurring every day for weeks or months or end. 
6. Breaks or interpolations in the train of thought, resulting in incoherence or 
irrelevant speech or neologism. 
7. Catatonic behaviour such as excitement, posturing or wavy flexibility, 
negativism, mutism and stupor. 
8. "Negative" symptoms as apathy, paucity of speech and blunting or incongruity 
of emotional responses usually resulting in social withdrawal and lowering of 
social performance. It must be clear that these are not due to depression or to 
neuroleptic medication. A significant and consistent change in the overall 
quality of some aspects of personal behaviour manifests as loss of interest, 
idleness, a self-absorbed attitude and social withdrawal (Michael G et al.; 
1996). 
Duration 
Syndrome should be present for six months before the diagnosis can be made. For a 
diagnosis of Schizophrenia to be made, symptoms must persist for atleast 6 months 
and be associated with significant deterioration of work, school, or social functioning. 
Information from family, friends, or teachers is often important in establishing when 
the disorder began (Michael G et al.; 1996). 
1.3 Classification of Schizophrenia in ICDIO and DSMIV 
1.3.1 Paranoid 
Well-organized paranoid delusions. Thought processes and mood are relatively spared 
and the patient may appear normal until his abnormal beliefs are uncovered. Follow-
up shows paranoid schizophrenia has a later and more acute onset than other subtypes 
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of Schizophrenia and tends to run a more a remittent course (Michael G et al.; 1996, 
Fenton and McGlashan; 1991). 
ICDIO * DSMIV * 
Paranoid Paranoid 
Hebephrenic Disorganized 
Catatonia Catatonia 
Undifferentiated Undifferentiated 
Residual Residual 
Simple schizophrenia 
Post-schizophreni a 
Other schizophrenia 
Unspecified schizophrenia 
* Michael G et al.; 1996. 
1.3.2 Hebephrenic 
Appear silly and childish in their behaviour. Affective symptoms and thought disorder 
are prominent. Delusions are common and not highly organized. Hallucinations also 
are common and are not elaborate (Michael G et al.; 1996). 
1.3.3 Catatonia 
Is characterized by motor symptoms and by changes in activity varying between 
excitement and stupor. Hallucinations, delusions and affective symptoms occur but 
are usually less obvious (Michael G et al.; 1996). 
1.3.4 Latent Schizophrenia 
People from early age behave oddly and show features in Schizophrenia 
1.3.5 Simple Schizophrenia 
People develop symptoms after a period of more normal development. Insidious 
development of odd behaviour. Gradual development of social withdrawal, lack of 
initiative and blunting of emotions. 
"Negative" behaviour not accompanied by "Positive" behaviour as hallucination, 
delusions (Michael G et al.; 1996). 
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1.3.6 Residual Schizophrenia 
Patients with full clinical picture of Schizophrenia in the past but no longer have all 
the symptoms required to make the diagnosis (Michael G et al.; 1996). 
1.4 Factors predicting the type of Schizophrenia 
Certain factors helpful in determining the Schizophrenia type (Michael G et al.; 1996) 
Mild-Average Schizophrenia 
Sudden onset 
Short period 
No previous psychiatric history 
Prominent affective symptoms 
Paranoid type of illness 
Older age of onset 
Married 
Good previous personality 
Good work record 
Good social relationships 
Positive (non deficit) subtype 
disorder. 
Chronic Schizophrenia 
Insidious onset 
Long period 
Previous psychiatric history 
Negative symptoms 
enlarged lateral ventricles; Male gender. 
Younger age of onset 
Single, separated, widowed, divorced 
Abnormal previous personality 
Poor work record. 
Social isolation. 
Negative (deficit) subtype of the 
of the disorder. 
1.5 Factors indicating severity of disease 
Although the severity and types of symptoms vary among different people with 
Schizophrenia, the symptoms are usually sufficient atleast during active phase of 
disease as to interfere with the ability to work, interact with people and care for 
oneself In some people with Schizophrenia, mental ability declines leading to an 
impaired ability to pay attention, think in the abstract and solve problems. The 
severity of mental impairment is a major determinant of overall disability in people 
with Schizophrenia (Sengupta S et al.; 2006, Tsai SJ et al.; 2006, William TC and 
Robert WB; Vol.1, Ed. 6"^ ). 
1.5.1 Mild Schizophrenia 
1.5.1.1 Typical symptoms in a person with Mild Schizophrenia condition 
• People with Mild Schizophrenia are unlikely to have any noticeable problems 
and cause little or no functional impairment on an every day basis. To the 
casual observer their demeanour would appear to be normal or perhaps mildly 
eccentric. 
• Their mood will be normal. 
• They will be alert and orientated with no evidence of confusion, memory loss, 
and poor concentration. 
• No evidence of disordered thinking or impaired judgement (Sengupta S et al.; 
2006, Tsai SJ et al.; 2006, William TC and Robert WB; Vol.1, Ed. 6'^ ). 
1.5.1.2 Care and Mobility 
• They may have attended a mental health clinic in the past or attend the clinic 
on an infrequent basis e.g. once a year. Many may be solely under the care of 
their general practitioners whom they consult infrequently. 
• Some may have a long history (many years) of the condition or give a history 
of a hospital admission followed by a good recovery. Compulsory admission 
is not always needed with relapses, if occur as the person gains more 
understanding of the condition. Most people with milder forms of 
Schizophrenia recover completely from such an episode and do not experience 
the illness again. 
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• A small dose of medication as olanzapine or chlorpromazine, if needed would 
be taken on a daily basis. Most people would take this medication themselves 
without any intervention from a relative. 
• People with Mild Schizophrenia and those who have recovered frilly from an 
acute episode, may be expected to be able to care for themselves i.e. maintain 
personal hygiene, prepare meals etc. 
• They would not require to be watched over to prevent abnormal or untoward 
behaviour. 
• A person with Mild Schizophrenia is likely to live independently, either alone 
or with their family. 
• They may work or if in the younger age group, be in education. 
• They would have no difficulty in finding their way around in familiar or 
unfamiliar surroundings, because they do not experience any confiision, 
inattention, memory loss or impaired judgement. 
• People with Schizophrenia have a satisfactory outcome with some of these 
experiencing only one or very few episodes of acute illness with complete 
recovery (Sengupta S et al.; 2006, Tsai SJ et al.; 2006, William TC and Robert 
WB; Vol.], Ed. 6''^ 
1.5.1.3 Prognosis 
• Full recovery occurs in the first two years. 
• Symptoms often non-existent in the later years of life. 
• Patients with good social outcome. 
• Complete remission and normal in mild form. 
• Over longer periods, people achieve significant and lasting improvement. 
1.5.2 Average (Moderate) Schizophrenia 
1.5.2.1 Typical symptoms in a person with Average (Moderate) Schizophrenia 
condition 
• People with moderate schizophrenia may experience hallucinations, delusions 
and disordered thinking such that they are unable to initiate or complete the 
usual tasks of daily living. 
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• Self-neglect, social isolation and social withdrawal may occur. 
• Confusion, incoherent speech, decreased memory and impaired judgement 
may be present. 
• Insight into their medical condition may be limited and the need for treatment 
denied (Sengupta S et al.; 2006, Tsai SJ et al.; 2006, William TC and Robert 
WB; Vol.1, Ed. 6*''). 
1.5.2.2 Care and MobUity 
• A person with Moderate Schizophrenia is likely to have the condition for 
some years or to be recovering from an acute episode treated over the last 12 
to 18 months. Those with a long history will have a record of hospital 
admissions. 
• People developing the condition in more recent years may have been treated in 
the community Mental Health institutes. 
• A person with Moderate Schizophrenia will make a regular visit to the 
psychiatric clinic e.g. every three months to be supervised on their medication 
and monitor their mental state and probably some will attend day center on a 
regular basis each week. 
• People with Moderate Schizophrenia will take their medication independently, 
many however will have their medication supervised, either in the form of 
injections or their carer will prompt them on a daily basis to take their tablets. 
• People with Moderate Schizophrenia at the less severe end of the spectrum 
may need attention to ensure that medication is taken, regular meals are 
prepared and personal hygiene is maintained. 
• Support mechanisms will be in place to maintain a stable routine for the 
individual and reduce the degree of social isolation. 
• Those whose impairment is at the more severe end of the spectrum may need a 
greater amount of supervision during the day. 
• Most live at home either on their own or with their families. Some live in 
sheltered accommodation - small flat or bedsit where a caretaker is on site or 
where support workers visit them a few times a week. Some may live in 
houses with a number of other people with mental health problems, where a 
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support worker will be present every day to be present in the event of an 
emergency, not to watch over the residents. 
• It is likely that people with this degree of psychological impairment will be 
able to find their way around in unfamiliar places. 
• Some people may exhibit a suicide risk, especially if more recently discharged 
from hospital. Some people show relapse and remission over the years but 
recover completely from such an episode and do not experience the illness 
again. 
• Respond to treatment moderately well and manage to live in the community 
with varying degrees of independence (Sengupta S et al.; 2006, Tsai SJ et al.; 
2006, William TC and Robert WB; Vol.1, Ed. 6*). 
1,5.2.3 Prognosis 
• Full recovery may occur in the first two to four years. 
• Symptoms often become less severe in the later years of life. 
• Patients with fair social outcome. 
• Over longer periods, people achieve some improvement with intermittent 
relapses and residual disabilities (Sengupta S et al.; 2006, Tsai SJ et al.; 2006, 
William TC and Robert WB; Vol.1, Ed. 6"^ ). 
1.5.3 Chronic (Severe) Schizophrenia 
1.5.3.1 Typical symptoms in a person with Chronic (Severe) Schizophrenia 
condition 
• Hallucinations, delusions and thought disorder impair ability to carry out 
normal tasks of daily life. 
• The person is disorientated, confused, has poor concentration and loss of 
memory. 
• Speech may be unintelligible. 
• At times behaviour is bizarre, anti social and very occasionally hostile or 
aggressive. 
• Some people may be very withdrawn and apathetic with minimal social 
interaction such that self-neglect is severe. 
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• Some may exhibit suicide risk especially if there is a history of a previous 
suicide attempt. 
• Insight into the illness may be very limited (Sengupta S et al.; 2006, Tsai SJ et 
al.; 2006, William TC and Robert WB; Vol.1, Ed. 6""). 
1.5.3.2 Care and Mobility 
They will have a long history of illness with multiple admissions to hospital, often 
prolonged stays. 
• They may attend a mental clinic regularly. They may also attend a day centre. 
• Medication will be supervised either in the form of depot injections or by a 
carer if given orally. Depot injections are likely to be given 2 or 3 weekly in 
higher doses. 3 or 4 drugs may be given with the anti-psychotic drugs in the 
higher dose range. 
• People with Severe Schizophrenia require regular daily supervision to prevent 
self-neglect and a decline into apathetic behaviour. 
• Intervention may be required from another if a person is deluded or 
hallucinated. In those with severely disturbed behaviour watching over at 
night may in addition be needed. 
• Suicide risk is greatest in those whose symptoms are not responding well to 
treatment often in the context of a recent relapse of the illness. 
• People in this category are likely to live in sheltered or supervised 
accommodation where staff is available on a twenty-four hour basis. 
• Inattention, confiision, incoherent speech, memory loss and impaired 
judgement are likely to indicate that a person would need guidance and 
supervision out of doors. Thus, formal aftercare in community including under 
section/supervised discharge is required. 
• Respond poorly and have significant long-term disabilities requiring a high 
degree of care in a supervised group home. 
• Once a person has had the illness for 5 years, there is unlikely to be any 
significant improvement (Sengupta S et al.; 2006, Tsai SJ et al.; 2006, William 
TC and Robert WB; Vol.1, Ed. 6""). 
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1.5.3.3 Prognosis 
• Full recovery occur seldom after five years of illness. 
• Symptoms often become more severe in the later years of life. Illness 
recurrent, a pattern of relapse and remission over the years, each subsequent 
episode usually resemble the first in its clinical features with the negative 
symptoms of the condition becoming more predominant as the years go by. 
• Patients tend to be impaired by the continual residual symptoms. 
• Patients with illness severity required long term sheltered care. 
• Over longer periods, experience severe and permanent incapacity (Sengupta S 
et al.; 2006, Tsai SJ et al.; 2006, William TC and Robert WB; Vol.1, Ed. 6"^ ). 
2. Historical recognition of Disease 
Historically, the most ancient document on Schizophrenia-like illness is only by 
Charaka, in Aurveda, written about 33 centuries ago which described the patient as 
one "who is gluttonous, filthy, walks naked, has lost his memory moves about in an 
uneasy manner". The knowledge fi-om the West, which has held its sway in the past 
few centuries, described Schizophrenia in more precise terms. Morel is generally 
credited for his description in 1860 of "demence precoce" akin to the present concept 
of schizophrenia though Haslam, earlier in 1801 had described the syndrome clearly. 
The crystallization of understanding about this disorder came only in 1896 when 
Emile Kraepelin formed the concept of "dementia precox" referring to mental 
deterioration starting early in life. He brought together, under the rubric different 
syndromes described earlier. Ktatonia by Kahlbaum (1868), Paranoia by Sander 
(1868) and Hebephrenia by Hecker (1870), Kraeplin emphasized the course and 
outcome of the disorder as a differentiating feature fi-om the other disorders. However, 
description of the illness as a deteriorating one did not correspond to what was 
observed at follow-up of the patients. One outcome of such an observation was the 
approach to diagnosis based on symptoms rather than outcome, adopted by Eugene 
Bleuler. He coined the term "Schizophrenia" in 1911, considering the illness to be 
group rather than a single entity. He described four primary symptoms - autism, 
ambivalence, loosening of association and affective flattening as the core of the 
disorder which underlie the clinical manifestations like delusions and hallucinations 
(Srinivasan TN Vol I, Lehman HE; 1975, Carpenter WT Jr and Strauss JS; 1973). 
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3. Multi-factorial study approach 
Study of Schizophrenia, started in 1846 by Emile Kraeplin, has since then been a 
debatable issue at genetic and molecular level. The etiology of Schizophrenia as 
genetic disease, though not readily identifiable, is proposed to involve interacting 
genes (Risch N; 1990). Inspite of numerous studies, the genetic underpinning of 
Schizophrenia remains elusive. Host of factors i.e. phenotypic diversity, etiological 
heterogeneity, incomplete penetrance, unknown mode of inheritance, uncertainty 
about the number of loci involved and about their interaction confound this disorder. 
Besides, the reports of existence of non-genetic cases or phenocopies were consigned 
to a complex, multifactorial etiology with no firmly established biological correlates 
(Ayton A et al.; 2002, Kendler KS et al.; 1993, Risch N; 1990, Baron M et al.; 1988). 
4. Neuropathology 
Morphological studies performed on the postmortem brains of affected individuals 
revealed disturbed brain development in numerous brain regions. This includes 
enlarged lateral ventricles (Andreasen NC et al.; 1994) and abnormalities in ft-ontal 
(Nopoulos P et al.; 1995) and temporal lobes (Harvey I et al.; 1993, Shenton ME et 
al.; 1992, Arnold SE et al.; 1991,Bergets B et al.; 1990) as well as in other regions 
such as parietal, occipital, thalamus and cerebellum (Buchsbaum MS et al.; 1996, 
Andreasen NC et al.; 1994, Schlaepfer TE et al.; 1994, Zipursky RB et al.; 1992, 
Nasrallah HA et al.; 1991). Thus, unlike other mental disorders such as AD and PD, 
where the pathophysiology is localized to a certain region of the brain. Schizophrenia 
involves multiple domains of the brain. Recent studies on first episode patients 
support the notion that Schizophrenia could be due to a progressive brain structural 
change (DeLisi LE et al.; 1997, 1997, Nopoulos P et al.; 1995, Ohnuma T et al.; 
Bilder RM et al.; 1994, DeLisi LE et al.; 1994, Degreef G et al.; 1992). However, 
attempts to establish relationships between the morphological changes and 
Schizophrenia are disappointing. This failure is mainly attributed to the variability of 
the disorder as well as overlap of the structural changes with control subjects 
(Wassink TH et al.; 1999, Wassink TH et al.; 1999, Gur RE et al.; 1994, DeLisi LE et 
al.; 1992, Shenton ME et al.; 1992, Andreasen NC et al.; 1990, Crow TJ; 1985). 
Additionally, in the past, there was a disagreement among clinicians regarding its 
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diagnosis but now there are several standardized diagnostic criteria and recent 
advancements such as sustained attention deficits, eye movement dysfunction and 
neurobehavioral deficits, which are also useful to identify predictors of illness 
(Calkins ME and lacono WG; 2000, Chen WJ and Faraone SV; 2000, Erlenmeyer-
Kimling L; 2000). While the exact etiology of Schizophrenia is not understood and 
there are no biological markers (e.g. plaques, tangles and Lewy body), however, 
epidemiological studies have identified a number of environmental factors associated 
with Schizophrenia. This includes place, season of birth and perinatal infection 
(Suvisaari JM et al.; 2001, Mortensen PB et al.; 1999, Crow TJ et al.; 1984). 
That a virus could cause a neuropsychiatric disease was confirmed when 
Pasteur isolated the rabies virus in 1881 (William TC and Robert WB; Vol.1, Ed. 6""). 
It was previously proposed that retroviruses might be etiological factors for the 
development of Schizophrenia (Lindholm E et al.; 1999). During pregnancy, 
retroviral infection is believed to cause impairment in fetal brain development. 
However, for quite some time, it was lacking support and remained unproved 
(Karlsson H; 2001). Recently, it was found that the cerebrospinal fluid of 28.6% of 
patients with recent onset Schizophrenia contained human endogenous retroviral 
sequence [(HERV)-W] and the gene is found to be transcriptionally activated in the 
postmortem frontal cortex of individuals with Schizophrenia (Karlsson H; 2001, 
Lewis DA; 2001). This is the first evidence supporting the previous proposal on viral 
etiology of Schizophrenia. If it is replicated by others in the future then it may mean 
that in some patients the onset of Schizophrenia could be due to the activation of a 
certain viral element in the brain which could change our understanding of the 
etiopatho-genesis of the disorder. 
5. Linkage studies 
In the case of non-Mendelian disorders with a complex mode of inheritance, 
identification of susceptibility loci by segregation and linkage analysis is difficult. For 
this purpose, association studies may help to identify genes contributing to the 
disorder (Risch N and Merikangas K; 1996). The association study is based on the 
assumption that a genetic marker occurs more fi-equently in conditions than in 
controls. Such polymorphic markers are likely to be associated with the susceptibility 
locus or in linkage disequilibrium with the susceptibility region (Gambaro G et al.; 
27 
Table 6: Putative genes and chromosomal regions studied for Schizophrenia using linkage 
and association strategies. 
Chromosome No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
X 
Y 
Chromosomal region 
1p 35-32 
1q 42.1 Translocation (1q44) 
1q21.3 
(2p15-14) 
2q21 
3D41 .2 .22 
3p24 
3q13. 3 
4p 
4q 24-32 
5p14. 1-13. 11 
5q21-23 
6P21.32 
6P22.3-24.1 
6p24-22 
6a16.3-q21 
6q 21-22. 3 
7q21. 1-q21.3 
8p22-21 
9q34. 3 
10p15-q21 
11p15. 5 
11 q 22-23 
11q 
12p 13.31 
12q 14.2 
13q14 
13q14. 1-q32 
13q32 
• 
15q13-q14 
• 
17q11.2-q12 
18p 
18q21. 1 
• 
20p 
• 
22q13 
22q11 
22q12-q13 
22q(D22S278) 
Pseudoautosomal locus 
Xp11 
Xq27-28 
Pseudoautosomal region 
Gene associated 
• 
• 
hSKCaS gene,CTG-B1(P66beta) 
• 
Balanced translocation 
CTG.B37 
• 
Dopamine receptor D3 gene 
• 
• 
• 
• 
N0TCH4 
DTNBP1 
• 
GRtK2 
HLA genes 
Eye tracking dysfunction gene 
• 
• 
Dopaminehydroxylase gene,a 
subunit of NMDA receptor gene 
• 
Dopamine D4 receptor gene 
Dopamine D2 receptor genes 
Translocations 
CTG-B37 
CTG-B33 
5HTR2a (serotonin receptor2a) 
• 
• 
• 
a7 nicotinic cholinergic receptor 
Subunit gene (CHRNA7) 
• 
Serotonin transporter gene(5HTT) 
• 
• 
• 
• 
IL2RB gene, COMT gene (catechol-o-
methyltransferase) 14-3-3-protein b-chain 
gene (YWHAH) 
Deletion in this region 
Indicates gene(s) locus not identified by genome scan studies 
2000, Altshuler D; 1998). Linkage studies are the mainstay of gene finding strategies 
adopted by present day investigators working on the molecular aspect in 
neuropsychiatric genetics. Because of the variability of the Schizophrenia phenotype 
as well as its complex mode of inheritance, identification of genes involved using 
traditional genetic strategies such as segregation and linkage analysis has become a 
challenging problem (Thaker GK and Carpenter WT Jr; 2000, Karayiorgou M and 
Gogos JA; 1997). Early linkage studies were based on traditional assumptions that a 
single dominant gene produced the illness. These were, in general, unsuccessful. Also, 
Initial attempts at modeling genetic transmission in families (using segregational 
analysis) suggested that heritability could not be explained by a single, dominant 
gene. Typically, linkage studies include dominant, recessive and mixed models 
(Thaker GK and Carpenter WT Jr; 2000). 
6. Genetics of Schizophrenia 
6.1 Twin, Adoption and Family studies 
Family, twin, and adoption studies have clearly provided consistent evidence that 
genes play a prominent role in the development of Schizophrenia (Riley and Kendler; 
2004). The concordance rate in monozygotic twins being reported as approximately 
50%, as compared to 10-14% for dizygotic twins, suggest that heritability typically 
range from 50-85% (Cardno et al.; 2002, Kringlen E; 2000, William TC and Robert 
WB; Vol.1, Ed. 6', Cardno AG and Gottesman II; 2000, Ingraham LJ et al.; 2000, 
McGuffin P, et al.; 1995, Warren ST; 1996, Heston LL; 1966) of the total risk, 
moreover the recent twin study suggest that thee is overlap between Schizophrenia, 
Schizoaffective disorder and Maniac syndromes (Sengupta S et al.; 2006, Cardno et 
al.; 2002). 
So far all adoption studies have shown that biological relatives of 
Schizophrenia patients have a higher risk of Schizophrenia (Riley and Kendler; 2004, 
Cardno et al.; 2002, Cardno AG and Gottesman II; 2000, Ingraham LJ et al.; 2000) 
and of Schizophrenia spectrum disorder (Tienari et al.; 2004). In several European 
studies, the risk of Schizophrenia has been about 10 times higher in the siblings or 
offspring of Schizophrenia patients were compared to general population (Riley and 
Kendler; 2004). 
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6.2 Genome-wide studies 
Search for Schizophrenic gene appeared to be off to an auspicious start when 
Sherrington etal (1988) reported strong statistical evidence of linkage to DNA 
markers on chromosome 5ql 1-13 in British and Icelandic population. They reported it 
under dominant model of inheritance and a broad disease definition but failure to 
replicate this finding in independent samples was a push back for the disease study 
(Baron M; 2001). Initial finding was, however, retracted after a more extensive 
analysis of the original sample and additional data (Kalsi et al.; 1999). Initial attempts 
to isolate major genes using linkage studies were unsuccessfiil, but more recent 
approaches using increasingly sophisticated methods have uncovered several 
chromosomal regions that may harbor genes of minor effect (William TC and Robert 
WB; Vol.1, Ed. 6"^ .^ 
An extensive genome wide linkage as well as family based analysis suggests 
multiple susceptibility loci on chromosomes, significant or suggestive evidences of 
linkage in case of Schizophrenic patients (Lander E et al.; 1995) has been reported in 
several chromosomes-lq21-22, lq32.2, lq32-41, 4q31, 5pl3-14, 5q22-31, 5q33.2, 
6q21-22, 6p21.3, 6p22-24, 7q22 8p21-22, 9q21-22, lOpll-15, llq23.3-24, 13ql4-32, 
15ql5, 20ql2.1-11.23, 22ql 1-13 and Xpll (Freedman R et al.; 1997, Kendler KS et 
al.; 1996, Pulver AE et al.; 1995). Additionally, several other studies have reported 
linkage to, 3p, 5q, 6p23, 6q, 8p, 9q, lOp, 13q32, 15q, 20p, 22q and Xp22 
(Brzustowicz LM et al.; 2000, Levinson DF et al.; 2000, Brzustowicz LM et al.; 1999, 
Milunsky J et al.; 1999, Wei J et al.; 2000, Lindholm E et al.; 1999,Matrinez M et al.; 
1999,Faraone SV et al.; 1999, Maziade M et al.; 1997, Lander E and Kruglyak L; 
1995, Straub RE et al.; 1995) (Table-6). 
The first published study to use Restriction Fragment Polymorphisms (RFLP) 
reported linkage between two markers on the long arm of chromosome 5 (5qll-13) 
and Schizophrenia (William TC and RobertWB; Vol.1, Ed. 6*). In recent years, 
however, RFLPs have been largely replaced by microsatellite DNA markers 
containing multiple tandem copies of simple di, tri and tetra nucleotide sequences. 
Using microsatellite markers and multiplex Schizophrenia families, evidence was 
found for linkage to the short arm of chromosome 6 (6p22) (William TC and Robert 
WB; Vol.1, Ed. 6' ). Supportive evidence for linkage to 6p22 was found in three 
independent studies. In addition to 6p22-24, atleast two other regions have yielded 
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regions have received attention but the evidence is less compeUing. These regions 
include, at present, 5q, 6q, 9p, 18p and 22q (Table-6). 
7. Pharmacogenetics 
7.1 Candidate gene approach 
A large number of putative genes chosen on the basis of biochemical and 
pharmacological evidence and candidate sites identified using genome scans have 
been tested for association or linkage with Schizophrenia (Table-6). Some of these 
receptors produce Schizophrenic symptoms (Aghajanian and Marek; 2000, Gargus et 
al.; 1998, Tsai et al.; 1998). Neurotransmitters have been implicated in the etiology of 
Schizophrenia since the time Dopamine hypothesis was conceived. The 
Monoaminergic group of neurotransmitters, their receptors and the genes involved in 
their uptake, synthesis, transport, reuptake and degradation may all play an important 
role in the pathogenesis of Schizophrenia (Prasad et al.; 1999). 
The Dopaminergic and Serotonergic groups (Table-7 and 8), role of other 
neurotransmitters and the genes involved in their metabolism like {>-amino-but>Tic 
acid (GABA) type A has also been evaluated. Some scientists support the view that 
excess of dopamine production is the cause of Schizophrenia, which is said to play a 
significant role in the mental workout of an individual susceptible to an abnormal 
psychiatric condition (Michelato A etal; 2004, Arrufat FJ et al.; 2000, Ueno S et al.; 
1999). 
Five Dopamine Receptors (Table-7) have been identified (Sunhara et al; 
1991,Van Tol et al.; 1991, Dearry; 1990, Giros et al.; 1990, Grandy et al.; 1989) so 
far, broadly classified into 2 families - Dl: family consisfing of two receptors-
Dopamine receptor Dl (DRDl) and DRD5 (Table-7) and D2: family consisting of 
three receptors - DRD2, DRD3 and DRD4 (Table-7) (Kebabian and Calne; 1979), 
each receptor comprise of about 400 amino acids and are transmembrane protein with 
seven hydrophobic domains spanning the neural membrane (Prasad et al.; 1999). 
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Table 7: Genes involved in Dopaminergic pathway. 
Gene 
OtiiiiHW 
DRD1 
DRD5 
D2fafHflv 
DRD2 
DRD3 
DRD4 
Position 
5q35.1 
4p 15.3 
11q22-q23 
3q15. 3 
11p15. 5 
Functions/ significance 
Involved in memory, emotion and cognition, the 
functions that are highly disturbed in 
schizophrenics. 
Several polymorphisms in 5' and 3' UTR of the 
gene. 
DRD5 is neuron specific and is localized vwthin 
the limbic regions of the brain. 
Displays high affinity for dopamine. 
Second most abundant dopamine receptor. 
Higher density of DRD2 in schizophrenic brain. 
Ser311/Cys311 polymorphism reported. 
Cys311 variant more in schizophrenics. 
Expression of DRD3 is restricted to the limbic 
areas of the brain, site for emotion and 
cognition that is highly disturbed in 
schizophrenics. 
Selective loss of DRD3 mRNA in parietal and 
motor regions of postmortem schizophrenic 
brains. 
A to G substitution polymorphism leading to 
creation of MscI site in exon 1 of DRD3 gene 
and Increased homozygosity at either allele is 
associate with schizophrenia. 
Higher affinity than other dopamine receptors 
for a typical anti-psychotic clozapine. 
Polymorphic 48 base pair repeat in putative 
third cytoplasmic loop. 
Table 8: Genes involved in Serotonergic pathway. 
Gene 
5HT2A gene 
5HT2A promoter 
SERT or 5HTT 
TPH gene 
Position 
13q14 
Chrom. 13 
17q11.2-q12 
Chrom. 11 
Functions/ significance 
Binds clozapine (antipsychotic) more effectively 
than dopamine. 
Both gene and promoter have been 
investigated. 
Gene polymorphism: T to C polymorphism viz. 
T102C. 
Regulatory region of 5HT2A gene and thus, 
mutations in this region can influence the 
5HT2a gene expression and its density. 
A to G polymorphism at position - 1438. 
VNTR in intron 2. 
44 base pair deletion/insertion in the 5HTT 
promoter region resulting in long and short 
variant. 
Short variant leads to reduced 5HTT 
expression. 
Rate limiting enzyme in the synthesis of 
serotonin. 
Polymorphic site resulting in U and L allele in 
the intron. 
TPH promoter | Chrom.11 | A to G transition at position 6526. 
Besides the dopaminergic receptors, Dopamine Transporter (DAT) gene, located on 
chromosome 5pl5.3 (Vandenbergh et al.; 1992a), involved in the reuptake of 
dopamine back in the presynaptic terminal, has also been considered as a possible 
candidate for Schizophrenia. A 40 bp VNTR polymorphism was identified in the 
3'untranslated region of this DAT gene. Alleles with 9 and 10 repeats have been 
observed to be predominant in most of the populations (Nakatome et al.; 1996, 
Perisco et al.; 1993, Vandenbergh et al.; 1992b) though association studies with a 
RFLP polymorphism due to Taql restriction site in the DAT gene have also not 
yielded any significant results (Pean et al.; 1995, Perisco et al.; 1995). 
Tyrosine hydroxylase (TH), rate-limiting enzyme in the dopaminergic pathway with 
a rare allele of tetranucleotide repeat HUMTHOl, located in the first intron of TH is 
suggested to be associated with Schizophrenia (Meloni et al.; 1995) but there are also 
several contrary reports (Burgert et al; 1998, Jonsson et al.; 1998). 
Serotonin, another important neurotransmitter that governs some of the 
behavioural aspects like sleep, moods, hallucinations and depression and besides 
brain, present in certain body tissues like smooth muscles and in blood platelets, is 
also a strong candidate for Schizophrenic establishment study. Till now seven 
serotonin receptors (Table-8) have been identified: 5HT-1, 5HT-2, 5HT-3, 5HT-4, 
5HT-5, 5HT-6, and 5HT-7. There is evidence that there are 5 distinct subtypes of 
5HT-2 and 3 distinct subtypes of 5HT-3 (Bames and Sharp; 1999, Matsumoto and 
Yoshioka; 2000). Polymorphism has been described in several genes in the 
serotonergic pathway and most of these genes have been studied to detect the 
association with Schizophrenia. These include Serotonin Transporter (SERT or 5-
HTT), serotonin receptors: 5-HTlA (Erdmann et al.; 1995), 5HTld beta (Nothen et 
al.; 1994, Sidenberg et al.; 1993), 5-HT2A (Warren et al.; 1993), 5-HT2C, 5-HT6 
(Shinkai et al.; 1999, Kohen et al.; 1996), 5-HT7 (Erdmann et al.; 1996). 
Monoamine oxidase (MAO) and Catechol O-methyitransferase (COMT) 
are two important enzymes involved in the catabolism of the neurotransmitters 
(Prasad et al.; 1999). MAO, present at both pre-synaptic terminal and post-synaptic 
cell, breaks down excess dopamine and serotonin. COMT (Table-6) is another 
inactivating enzyme present in postsynaptic cells of dopamine or NE synapse but not 
serotonin. Floderus et al (1981) reported a higher COMT activity in Schizophrenics 
not been replicated in many subsequent studies. COMT gene has been mapped to 
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chromosome 22ql3 and micro deletions in this region leading to a number of diseases 
including the velocardiofacial syndrome (VCFS) encompass the COMT locus 
(Dunham et al; 1992). Pulver et al. (1994) have reported VCFS patients to have a high 
risk for developing Schizophrenia. 
Presently, the above loci have been identified based on positive lod scores and 
some of them are found numerous times but none of the genes have been 
unequivocally mapped or cloned. Although some of the studies have not been 
replicated or they have been refuted (Cai G et al.; 2001, Dobrusin M et al.; 2001, 
Crow TJ et al.; 1997, Antonarakis SE et al.; 1995, Curling H et al.; 1995, Mowry BJ 
and Levinson DP et al.; 1995), it appears that there is no common gene or a single 
locus of major significance. In addition to the above linkage studies, several 
chromosomal abnormalities such as deletion, translocation and inversion have been 
reported (Bassett AS et al.; 2000, Milunsky J et al.; 1999, Shastry BS et al.; 1999). It 
seems likely that Schizophrenia is the result of the interaction of many genes, some of 
which also interact with environmental factors. It is possible that different 
combination of genetic and environmental factors affect specific neurobiological 
systems, leading to a tinal common pathway of neural dysfunction. 
8. Molecular Genetics 
8.1 Trinucleotide Repeat Expansion; an ethnic approach 
Although specific molecular evidence for the involvement of trinucleotide repeat 
expansion is still lacking, several studies methods as RED (repeat expansion 
detection) has found overrepresentation of large CAG/CTG arrays in Schizophrenic 
patients compared to Normal controls (Mclnnis MG et al.; 1999). Studies also 
indicate that the range of CAG/CTG Trinucleotide repeat expansion (TNP) sizes 
observed in Schizophrenic patients and in Normal controls overlap significantly 
(Joober R et al.; 1999). As already known, the expanded CAG repeats form excess of 
polyglutamine tracts which may interfere with the dopamine function, affecting the 
neurons both structurally and fiinctionally and hence the Central Nervous System of 
the individual having these expansions (McGuffin P, et al.; 1995, McGue M et al.; 
1989). Triplet repeat expansions play a role in the pathology of Schizophrenia .By 
using a method that screens the whole genome (The Huntington's Diseases 
Collaborative Research Group; 1993, Schalling M et al.; 1993, Biancalana F et al.; 
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1992, La Spada AR et al.; 1991, Carpenter WT Jr and Strauss JS; 1973), large CAG 
repeat regions have been shown to be more common in Schizophrenia than in normal 
controls (Morris AG et al.; 1995, O'Donovan MC et al.; 1995). Patients with 69-136 
CAG repeats in their genome appear to have significantly earlier age-at-onset than 
patients with fewer CAG repeats (Morris et al.; 1995) and patients with 35-68 repeats 
in their genome were found to have significantly higher negative symptom scores than 
those with no CAG expansion (Gaitonde EJ et al.; 1997, Morris AG et al.; 1995). This 
has led many researchers to look for evidence of TRE as a possible etiological cause 
for neuropsychiatric diseases such as bipolar affective disorder (BPAD), and 
Schizophrenia. 
In some cases of Schizophrenic patients, trinucleotide repeat expansion was reported 
to be involved in the etiology of Schizophrenia (Sengupta S et al; 2006, Joober R et 
al.; 1999, Moriniere S; 1999, Burgess CE et al.; 1998, Bassett AS and Husted J et al.; 
1997, Gorwood P et al.; 1996, Paulson HL et al.; 1996, Joober R; 1996, O'Donnovan 
MC et al.; 1996). However, in support of this notion, some of the positive studies 
reported were refuted by others (Huang CH et al; 2006, Tsutsumi T et al; 2004, 
Fortune MT et al.; 2003, Mclnnis MG et al.; 1999, Sidransky E et al.; 1998, Vincent 
JB et al.; 1998, Huang J and Vieland V; 1997, Vincent JB et al.; 1996) and not 
confirmed by many others with study based on inheritance factors as monozygotic 
twin study. Moreover, this dynamic mutation is not specific for Schizophrenia and has 
been observed in bipolar disorder as well as in other diseases. 
9. Disease onset 
Parents of patients with childhood-onset Schizophrenia have a higher rate of 
Schizophrenia spectrum disorders than parents of patients with adult-onset illness. 
This is consistent with the hypothesis that a childhood onset of Schizophrenia is due, 
at least in part, to a greater familial diathesis for the disorder (Tsai SJ et al.; 2006, 
Huang CH et al; 2006, Tsutsumi T et al; 2004, Fortune MT et al.; 2003, Nicholson R 
et al.; 2003). The interjection of a slightly different nucleotide triplet within the repeat 
seems to stabilize the repeat (e.g. CAA within the CAG repeats). Line of transmission 
may be maternal or paternal (Tsai SJ et al.; 2006, Huang CH et al; 2006, Tsutsumi T 
et al; 2004, Fortune MT et al.; 2003) 
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10. Epidemiology 
10.1 TNR polymorphism: Ethnic studies in Indian populations 
As mentioned earlier, a large number of studies for Schizophrenia have been 
conducted mainly in the Caucasoid population (Table-5). However, it is desirable to 
perform similar studies in different ethnic groups to reaffirm the status of the 
association. Indian population is very well suited for such studies as it satisfies many 
criteria required for the investigation of complex traits. Besides, Indian population is 
an attractive large reservoir of samples both due to its population size as well as the 
high rate of marital stability, the latter essential for family based analysis. Large CAG 
repeats have been reported to be more frequent in patients than in controls (normal) 
(Morris et al; 1995, O'Donovan et al; 1995). Therefore, genes with unstable 
trinucleotide repeats are being considered as suitable candidates for underlying 
pathology of Schizophrenia and are being analysed. Genes in the dopaminergic and 
serotonergic pathways in the brain have been studied in predominantly North Indian 
samples. Using family based association test, DRD3 locus did not show any 
association (Prasad et al.; 1999). In another study, four genes (5HT2A, TPH, COMT 
and DAT) involved in monoaminergic pathway evaluated using TDT, have also failed 
to show any significant association (Semwal et al.; 2001). An association between 
cytosolic phospholipase A2 (cPLA2) locus and Schizophrenia has also been evaluated 
in the family based samples among Indians but no significant association has been 
detected (Chowdari et al.; 2001). Of many Trinucleotide expansion polymorphism 
(TNP) study, a large difference in CAG repeat allele sizes in case of patients suffering 
from Schizophrenia compared to the confrols has been reported at the Machado-
Joseph Disease (MJD) locus. Though longer CAG repeat at MJD locus is not 
associated with Schizophrenia, the role of smaller unstable repeats in disease 
manifestation cannot be excluded (Saleem et al.; 1998). Saleem et al. (2000a) 
observed no association with serotonin fransporter (5-HT) in patients suffering from 
bipolar disorder based on case-control approach. Though no association has been 
observed with the hSKCa3 polymorphism by the same group (Saleem et al.; 2000b), 
they have shown that a large difference in allele sizes (greater than or equal to five) 
occurs in patients compared to controls (Normal). 
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11. Candidate Gene Studies 
11.1 Genes involved in our study 
Of the genes studied so far for the effect of Trinucleotide Repeat Expansion 
polymorphism (TNP) on population, our study was based on primers (Table-9) 
selected from sequences representing following genes-
11.1.1 Saml: Known as CTG B33 /RPL14 (L14; RL14; hRL14; CTG-B33; CAG-
ISL-7) (Table-6) - this gene encodes a ribosomal protein that is a component of the 
60S subunit. The protein belongs to the L14E family of ribosomal proteins, contains a 
basic region-leucine zipper (bZIP)-like domain. The protein is located in the 
cytoplasm. Localized on chromosome 3(3p22-p21.2) and 12(12ql4.2). This gene 
contains a trinucleotide (CTG) repeat tract whose length is highly polymorphic. Genes 
with triplet repeats are putative candidates for causing Schizophrenia, thus is one of 
the studied genes for Schizophrenia reported by studies in Caucasian population 
(Bengel D et al.; 1998). 
11.1.2 Sam2: Known as CTGB37 (aliases; NOD, ATNl, D12S755E, dentatorubral-
pallidoluysian atrophy DRPLA (+) gene, (atrophin-1), gene or CTG-B37) (Table-6) -
this gene encodes brain specific protein, where it appears to be widely expressed in 
both neurons and glia. The encoded protein includes a serine repeat and a region of 
alternating acidic and basic amino acids, as well as the variable glutamine repeat. 
Localized on chromosome 12pl3.31(exon 5), normal endogenous DRPLA protein 
being a phosphoprotein, the abnormal DRPLA protein seems to be slowly 
phosphorylated due to certain abnormal condition of c-Jun NH(2)-terminal kinase 
(JNK), one of the major factors involved in its phosphorylation. Kinetic studies in the 
JNK recombinant system showed that expanded polyQ (CAG) slightly reduced the 
affinity of JNK to the protein thus delaying the process of neuron sustenance 
(Okamura-Oho Y etal; 2003). This neurodegenerative disease has only rarely been 
reported in non-Japanese pedigrees and there are only a few neuropathological studies 
in genetically confirmed patients. CAG repeat expansion (Normal range is 6-35; 
Expansion range: 49 repeats and over) in CTG-B37 gene have been reported from 
Polish, North American and British populations (Michlewski G et al.; 2004, Becher 
MWetal.; 1997). 
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11.1.3 SamS: Known as N0TCH4 gene (Table-6) (aliases; INT3, N0TCH3, 
Neurogenic locus notch homolog protein 4 precursor (Notch 4) (hNotch4) - As an 
evidence for linkage to chromosome 6, in the vicinity of the major histocompatibility 
complex (MCH), investigation has brought to the fore by genome scans several 
candidate genes at this locus (Lambert JC et al.; 2004). NOTCH4 gene (exon 1) is one 
of the studied genes. Human counterpart of the mouse mammary tumor gene- int-3, it 
is localized near the boundary of the HLA class II and class III regions. Localized on 
chromosome 6p21.32, N0TCH4 gene is a member of the NOTCH gene family that 
play a role in a variety of activity of developmental processes affecting the 
implementation of differentiation, proliferation and apoptotic programs influencing 
organ formation and morphogenesis (Prathikanti S, et al.; 2004). Due to its 
chromosomal location and neurobiological roles, the human N0TCH4 gene is a 
candidate gene for Schizophrenia as has been reported to be associated with 
Schizophrenia in some studies (Glatt SJ et al.; 2005). Using linkage disequilibrium 
mapping of the human major histocompatibility complex (MHC) region in 1980s, 
Wei and Hemmings (Wei J et al.; 2000) found that NOTCH4 was highly associated 
with Schizophrenia, the (CTG)n repeat in exon 1 of British parent-offspring trios. A 
Japanese case-control association and more recent American study reported that these 
polymorphisms did not show significant associations (Glatt SJ et al.; 2005, Lambert 
JC et al.; 2004, Prathikanti S et al.; 2004, Imai K et al.; 2001). 
11.1.4 Sam4: Known as AAT21/DTNBP1 (Table-6) (aliases; DKFZP564K192, 
Dysbindin, FLJ30031, HPS7, MGC20210, My031, SDY, Dystrobrevin binding 
protein 1 (Dysbindin) - the gene for the dystrobrevin-binding protein 1, dysbindin, is 
located within the linkage peak on chromosome 6p22.3-24.1. Dysbindin binds to a-
and B-dystrobrevin in muscle and brain. In addition to its presence in muscles, it has 
been detected in axon terminals in the cerebellum and hippocampus of the adult 
mouse brain and a possible function in signal transduction pathways and 
glutaminergic synapses has been discussed (Benson et al.; 2001). Straub et al. (1995) 
who reported association of Schizophrenia with genetic variants in a candidate gene 
on 6p22,3-24.1, obtained a high degree of statistical significance for association of 
Schizophrenia with several DNA polymorphisms between exon 5 and exon 1 in the 
dysbindin gene in the German and Irish high-density pedigrees in which linkage had 
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been reported earlier (Straub et al.; 2002, Liao HM et al.; 2004) and British 
population (Craddock N et al.; 2005). 
11.1.5 SamS: Known as GluR6 kainate receptor (Table-6) (aliases; EAA4, GLR6, 
GLUR6, excitatory amino acid receptor 4, glutamate receptor, ionotropic, kainate 2) -
GRIK2 gene is a Schizophrenia susceptibility region as suggested by multiple linkage 
studies (Shibata H et al.; 2002). Glutamate is the principal excitatory neurotransmitter 
in the brain and is directly involved in cognitive functions such as memory and 
learning. Localized on chromosome 6ql6.3-q21, a trinucleotide repeat polymorphism 
detected in the 3' untranslated region of the kainate-selective GluR6 receptor gene 
(GRIK2) makes it possible to perform linkage and association studies with this high-
ranking candidate gene (Bah J et al.; 2004). 
11.1.6 Sain6: Known as CTG Bl (Table-6) (ahases; KIAAl 150, D1S961E, CTG-Bl-
1, CTG-Bl-2, CTG-Bl-l/CTG-Bl-2) - Human DNA sequence from clone RPll-
422P24 on chromosome 1 (between Ipter and Iqter, lq21.3) it contains the 5' UTR of 
the gene for transcription repressor p66 beta component of the MeCPl complex 
(P66beta). P66beta transcription repressor gene that codes for a component of the 
MeCPl protein complex, represses transcription through preferential binding, 
remodeling and deacetylation of methylated nucleosomes complex. Studies on 
Caucasian population and Japanese populations have been reported (Ohara K et al.; 
1997). 
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AIMS OF THE STUDY 
The line of selection of genes concerning Schizophrenia in this study, was focused on 
TNR expansion polymorphism on gene loci which were assessed in many other ethnic 
populations, both Caucasian as well as Asiatic. 
The aims of this thesis were -
1. To test the association of selected six candidate gene loci with TNR 
polymorphism and their association with appearance of Schizophrenia, if any. 
2. Association of Schizophrenia appearance with respect to gender bias -both 
Intra-gender and Inter-gender. 
3. Effect on intensity of Schizophrenia / risk of Schizophrenia in the sample 
subjects - Schizophrenia (Mild - Average) and Chronic Schizophrenia. 
METHODOLOGY 
ABBREVIATIONS 
DSM Diagnostic and Statistical Manual of Mental Disorders 
EDTA Ethylene Diamine Tetra Acetic acid 
RT Room Temperature 
TE Tris-EDTA 
OD Optical Density 
ds DNA double stranded DNA 
PCR Polymerase Chain Reaction 
Tm Annealing Temperature 
DNTP Di Nucleotide Triphosphate 
SCZ Schizophrenia 
MATERIAL REQUIRED 
Agarose 
Ammounium Chloride NH4CI 
Blood 
Chloroform CHCI3 
DNA 
Ethanol C2H5OH 
Ethylene Diamine 
Tetra acetic acid 
Magnesium Chloride 
Oligonucleotides 
Phenol 
Potassium Chloride 
Proteinase-K 
Tris- Ethylene Diamine 
Tetra acetic acid 
Tris Hydrochloric acid 
Sodium Acetate 
Sodium Chloride 
Sodium Hydroxide 
EDTA 
MgCl2 
CfiHsOH 
KCI 
Tris EDTA 
Tris-HCI 
CHjCOONa 
NaCl 
NaOH 
(Being a population -based study, motif repeat expansion or Variable Number of 
Tandem Repeats (VNTR) study was carried on the North Indian population. 
1. Subjects 
High intrabreeding status due to demographic, cultural and religious preferential 
options provided a chance of pure gene pool and possibility of preservation of 
population-based significant genes in North-Indian population. There has been shown 
strikingly distinct increase in the neuropsychiatric diseases during past decade or so, 
analysis of patients registered at psychiatric hospitals' show that with decrease in the 
age onset, there is predisposition of the neuropsychiatric diseases such as 
Schizophrenia thus making this study of great importance. The information collected 
for the identification of the patient was pro formed as: 
1. Patient's Name. 
2. Clinical Diagnosis. 
3. Age. 
4. Age of onset. 
5. Mother's Name and Age. 
6. Marriage Pattern of Parents. 
7. Number of Litter size. 
8. Number in the sib-size. 
9. Family member affected, if any. 
10.Any other information. 
11 .Pedigree analysis 
1.1 Sampling 
To ensure the pure-line sample collection, blood samples of only those normal 
individuals and Schizophrenic subjects were collected who were of pure North-Indian 
origin, atleast upto four generations. Both normal and patient age group averaged 
between 21-50 years. 
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1.2 Ethnic Status 
For broad-spectrum observation, subjects - Normal individuals and Schizophrenic 
patients representing the greater part of North India were included randomly. Without 
any ethnic bias, blood samples of subjects from UP, Kashmir, Punjab, were collected. 
Samples included one male patient from Ladakh and one female patient from a sub-
ethnic Gujjar population of Kashmir. Samples were collected strictly in accordance 
with the institutes' ethical committee, with the informed consent of the donors/ 
volunteers or their guardians in chronic cases for taking blood sample. 
2. Collection of Blood 
Our study was based on the DNA analysis isolated from blood collected from the 
forty (40) Schizophrenic patients of pure North-Indian origin -twenty (20) of the 
subjects were males and twenty (20) females. For comparative study, blood samples 
from normal twenty (20) male and twenty (20) female subjects also of pure North-
Indian origin were collected randomly. The normal individuals included in the study 
were healthy laboratory volunteers with no history of any psychiatric illness upto four 
generations. The S£imples were collected strictly in accordance to the clinical 
diagnostic for disease criteria (DSM-IV) of the disease established by the consultants 
and medicos in service. Patient blood samples were made available from Department 
of Mental Health Care and Psychiatry Hospital, Srinagar, Kashmir, Psychiatric 
Department of Jawaharlal Nehru Medical College (JNLMC), Aligarh Muslim 
University, Aligarh. 
For DNA isolation, using 0.5M EDTA, approximately 5 ml of peripheral 
blood sample was collected from each of the subject involved in our study. Blood 
samples from forty (40) patients - twenty (20) males and twenty (20) females with 
Schizophrenia anomalies were obtained for studying the polymorphic status of 
trinucleotide repeat expansions in the Schizophrenic patients specifically. Of these, 
twenty (20) subjects were suffering from Chronic Schizophrenia and twenty (20) 
subjects were in the range of Mild-Average type of Schizophrenia, SCZ (Mild-Avg.). 
Also forty (40) blood samples from healthy individuals with no mental illness records 
in either themselves or a first-degree relative were collected. Of those samples, twenty 
(20) were normal males and twenty (20) norma] females. 
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3. Isolation of Genomic DNA 
Total genomic DNA was isolated from blood following standard protocol (Miller SA, 
et al; 1988) as per the high-salt, phenol-chloroform method. Blood was collected in 
vacutainors containing 100 \i\ of 0.5M EDTA. Chilled lysis buffer (150 mM NH4C1, 
10 mM KCl, 0.1 mM EDTA) pH 7.8, was added in the ratio of 1:10 and the tubes 
were kept on ice for a minimum of 15 min. with intermittent gentle mixing. The cell 
pellet was harvested by spinning the sample at 5000 rpm at 4°C for 15 min. The 
pellet was resuspended in 5 ml of nuclease buffer (75 mM NaCl and 25 mM EDTA), 
0.2%SDS and 0.02mg/ml of proteinase-K. The tubes were incubated at 37^0 for 16 
hrs to facilitate the digestion of cellular/nuclear proteins by proteinase-K. After 
digestion, the mixture was subjected to one extraction with equal volume Phenol, 
followed by two extractions with equal volume of phenol: chloroform (1:1) and 
finally one extraction with chloroform: isoamyl alcohol (24:1). The DNA (aqueous 
phase) was precipitated with 0.1 volumes of 3 M sodium acetate (pH 5.2) and 2 
volumes of chilled ethanol at room temperature (RT), spooled out into an eppendorf 
tube and washed twice with 70% ethanol. The DNA samples were dried and finally 
dissolved in 1:0.1 TE (10 mM Tris HCl; 1 mM EDTA pH 8.0). 
3.1 Spectrophotometric Quantitation of DNA 
DNA concentration was estimated using spectrophotometric absorbance at 260 nm. 
DNA samples were reconstituted in 0.1 N NaOH. The concentration of DNA was 
estimated by using the following formula 
concentration = OD260nm* dilution factor* 0.04 mg/ml 
where 1 OD = 0.04 mg/ml (for ss DNA and RNA). 
* = Muhiplication. 
3.2 Dilutions of Genomic DNA for PCR Reaction 
Dilutions of same concentration (100ng/)al) were prepared from the stock DNA of the 
patient and normal samples using formula-
NiV,=N2V2 
3.3 Oligonucleotides for Southern Hybridization and PCR 
Oligonucleotides were purchased from Biobasic Inc (Canada) and Microsynth 
(Balgach) and purified on polyacrylamide gel electrophoresis. 
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The details of all the oligonucleotides used for PCR have been given in Table-9. 
4. Polymerase Chain Reaction 
4.1 Conditions for PCR Amplification 
Reactions were carried out in a total volume of 25 |il as per the following 
protocol. 
• To 25 ng (1 |il) DNA the following was added 
1 OX PCR buffer 2.5 |al 
(100mMTrisHClpH8.8; 500mMKCl; 0.8% Nonidet P40) 
Magnesium chloride 25 mM 1.5 JLII 
dNTP mix 1.25 mM 4.0 |al 
sense primer ~ 10 picomoles 
antisense primer -10 picomoles 
Taq DNA polymerase 0.25 units 
Volume was made upto 25 |.il with triple distilled water. 
• Gently mix and microfuge to contents for volume accumulation at the base of 
the tube. 
• The mixture was incubated for 95-96*'C for 2-15 minutes (Table-10) to 
denature. 
• The subsequent 32-35 cycles included denaturation at 94-96'^ C for 30 seconds-
2 minutes, annealing at appropriate Tm (Table-10) for 30 seconds-1 minute 
and extension at 72^C (30 seconds-1 minute per kb to be amplified). 
• Final extension was carried out at 72°C for 7-10 minutes as per the primer 
involved. 
• The reaction mixture was stored at 4°C until agarose gel electrophoresis. 
4.2 Agarose Gel Electrophoresis of Resultant Amplicons 
PCR generated amplicons were resolved on 1 - 2% agarose (depending on the 
amplicon size) in 1 X TAE buffer containing Ethidium bromide at 20 volts/cm 
following standard protocols (Sambrook et ai, 1989). The amplicon size was 
determined using a molecular size marker run alongwith the samples. The gel was 
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Table 9: Primers used to study Polvmorohic Repeat Expansions in Schizophrenic patients. 
Primer 
Sam1 
Sam 2 
Sam 3 
Sam 4 
Sam 5 
Sam 6 
Sequence 
5'CAA AAA AGC ACC TGG TAC TAA 3' 
5'GGG CTG GAG CCT TTT TAC TCG C 3' 
5'CAC CAG TCT CAA CAC ATC ACC ATC3' 
5'CCT CCA GTG GGT GGG GAA ATG CTC 3' 
5'CCC TGC CTG AAG AGG GAC AG 3' 
5TCT GGG TCT GAC CAC TGA GAC 3' 
6'GTC CTC AGT AAC CAA TG 3' 
5'AGA GCT GCC AGA AGG TGA 3' 
5'CAA CAC CTT TTC TCT AAC CCC 3' 
5'CTC GGC CAG TTT TTA CAA CTT G 3' 
5' CCT GAT GTG CTG ACA CCT GC 3' 
5'AAG CTC CGG AAT GTT GTC C 3' 
Chromosome 
12q14.2, 3p22-p21.2 
12p13.31 
6p21.32 
6p22.3-24.1 
6q16. 3-q21 
1 
Annealing-
Temp Ta (°C) 
59 
62 
62 
55 
55 
55 
Product size 
(bp) 
116 
144 
145 
222 
149 
126 
Note: 
Oligonucleotides were purchased from Blobasic Inc (Canada) and MIcrosynth (Balgach). 
photographed and the precise molecular weight of the amplicons analysed using gel-
documentation system UVIDoc Mw Version 99.03 for Windows. 
5. Sequencing Reaction 
Sequencing reactions were performed with dsDNA isolated from extraction and 
subsequent purification of PCR product using Sequenase Version 2.0 PCR Product 
Sequencing kit (USB) following Sanger's dideoxychain termination method (Sanger 
etai, 1977). 
Template for sequencing was prepared by denaturing 4-5 }ag of ds DNA with 
0.2 N NaOH and 2 mM EDTA at 37°C for 30 min. DNA was precipitated with 0.1 
volume of 3M sodium acetate (pH 5.2) and 2.5 volumes of pre-chiiled ethanol at -
70^C for 15 min. The tube was centrifuged at 13,000 rpm for 15 min. followed by 
two washes in 70% ethanol. The pellet was dried and dissolved in 7 |j,l of triple 
distilled water and left at RT for 30 min. Sequencing reaction was conducted as per 
the following protocols. 
• To 5 |al of PCR ampHfied dsDNA was added l^il of exonuclease I (lOU/ml in 
20mM Tris-HCl, pH 7.5, 5mM 2-mercaptoethanol, 50% glycerol) and l^il 
shrimp alkaline phosphatase (2U/ml in 25mM Tris-HCl, pH 7.6, ImM 
MgC12, O.lmM ZnC12, 50% Glycerol). Mix and incubate the mixture at 37"c 
for 15 min. This cleansed the PCR product before sequencing. 
• exonuclease I and shrimp alkaline phosphatase were inactivated by heating 
to80°Cfor 15mins. 
• Annealing was carried out in annealing buffer (40 mM Tris-Cl, pH 7.5; 20 
mM Magnesium chloride; 50 mM NaCl) with 5 |j,l ds DNA, 1 \i\ primer in a 
total reaction volume of 10 |al at lOO^C for 2-3 min. 
• The mixture was cooled quickly by placing the vial directly in an ice-bath for 
5 min. Sequenase version 2.0 DNA polymerase enzyme (1 \x\) was diluted 8 
fold in enzyme dilution buffer (10 mM Tris-Cl, pH 7.5; 5 mM DTT; 0.5 
mM(EDTA),50%glyceroI). 
• The dGTP labelling mix (1.5 |aM dGTP, dCTP, dTTP) was diluted 5 times in 
triple distilled water. 
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Table 10: PCR Reaction of the primers involved in the study 
Primer 
Sam 1 
Sam 2 
Sam 3 
Sam 4 
Sam 5 
Sam 6 
Pre-PCR cycles, 
Denaturation °C 
m ins ./sec 
96°C -2mins 
96°C -2mins 
95°C-15mins 
96°C -2mins 
96°C -2mins 
95°C -5mins 
PCR cycles 
°C mins/secs 
denaturation 96°C -1min 
annealing 59°C -1min 
extension 72°C -1min 
denaturation 96°C -2min 
annealing 62°C -1min 
extension 72°C -1min 
denaturation 94°C -30 sees 
annealing 62°C -30 sees 
extension 72°C -30 sees 
denaturation 96°C -2 min 
annealing 55°C -1 min 
extension 72°C -1 min 
denaturation 96°C -2 min 
annealing 55°C -1 min 
extension 72°C -1 min 
denaturation 96°C -2 min 
annealing 55°C -1 min 
extension 72°C -1 min 
Post-PCR 
cycles, 
Extension 
°C mins./secs 
72°C -lOmins 
72°C-10mins 
72°C-10mins 
72°C-10mins 
72°C-10mins 
72°C -7mins 
Number 
of 
cycles 
32 
32 
35 
32 
32 
35 
. To the 10 |il of ice cold annealed DNA mixture 1 ^1 DTT (0.1 M), 2 |il of 
diluted dGTP mix, 2 [i\ of diluted sequenase enzyme (3 units) and 5 |iCi [a-
^^ S] dATP typically 0.5 |J1 of 3000Ci/mM was added and incubated at RT for 
5 min. 
• Simultaneously 2.5 ^1 of each ddNTP termination mix (8 [iM of one ddNTP 
in addition to 80 |aM dATP, dTTP, dCTP and 50 mM NaCl) was dispensed 
into four separate eppendorfs labelled as G, A, T, C and prewarmed at 37°C 
for 5 min. 
• 3.5 ^1 of labelling reaction was added to each of the four termination tubes 
mixed and incubated at 37^C for 5 min. 
• Reactions were terminated by adding 4 fil of stop solution (95% Formamide; 
20 mM EDTA; 0.05% Bromophenol blue; 0.05% Xylene Cyanol FF), mixed 
thoroughly and stored at -20''C until loading on the sequencing gel. 
6. Polyacrylamide Gel Electrophoresis 
For resolving sequencing reaction, 6% polyacrylamide gel was prepared as follows 
Acrylamide 5.7 g 
Bis acrylamide 0.3 g 
Urea 48 g 
lOXTBE 10 ml 
(890 mM Tris-Cl; 890 mM Boric acid; 2 mM NaEDTA, pH 
8.2) 
Distilled water 40 ml 
The acrylamide solution was prepared fresh and volume adjusted with water to 
100 ml. Sequencing gel apparatus, (Bio-Rad, USA) of 38 cm X 50 cm with 0.4 mm 
spacers and 20 well 0.4 mm comb was used. The gel was prepared using 40 ml of 
acrylamide solution with 225 ^\ of 10% APS and 25 ^1 of TEMED and allowed to 
polymerize for 2-3 hours. 
The gel was pre-electrophoresed for 1 hour at 1900 constant volts to achieve 
the 50 C temperature. Prior to loading the reaction mixture on gel, samples were 
heated at 90 C for 10 min. and 5 yd of each sample was loaded for electrophoretic 
separation at the above mentioned temperature. After electrophoresis, the gel was 
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transferred onto 3 MM Whatman sheet, covered with saran wrap and dried at 80*^ 0 
under vacuum (Savant, Gel drying system). Gel was exposed to X-ray films (Konica, 
India or Hyperfilm p-max, Amersham) at RT for 16-48 hours. Developing and fixing 
of autoradiograms was done following the protocols described earlier. 
PCR products were used for automated sequencing on the commercially 
available automated sequencer (ABI, 377) using automated sequencing facility at 
Eukaryotic Gene Expression Laboratory, NIL 
6.1 Sequence Analysis 
The entire per contig of Saml, Sam2, Sam3, Sam4, Sam5, and Sam6 were analysed 
for the presence of short tandem repeats using programs as DN Asis (LKB/Pharmacia, 
Sweden) and GeneRunner programme (Hastings Software, USA). A database search 
was performed on the NIH mail server using BLASTX, BLASTN and FASTA 
programs for the sequence homology with the others in the Genbank using sites on 
default blast server as http://www.ncbi.nigh.gov.cgi-bin/Blast/nph-newblast. 
Some of the details pertaining to the sequence similarity as per our search were-
Saml/CTGB33 
Also known as: L14; RL14; hRL14; CTG-B33; MGC88594; CAG-ISL-7 
UniGene Hs.: 446522 
GDB: 373727. 
UniSTS: 86111 
Gene ID: 9045 (updated 21-Nov-2007) 
Genbank Accession No: D87735 
Definition: 60S ribosomal protein L14 (CAG-ISL 7). 
Databases: Uniprot/SWISSPROT P50914 
Official Symbol: RPL14 
Official Full Name: ribosomal protein LI4 
Primary source: HGNC: 10305 
Sam 2 /CTGB37 
Also known as: DRPLA, ATN1 
UniGene Hs: 143766 Atrophin 1 
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GDB: 293944 
UniSTS: 148888 
Gene ID: 1822 
Genbank Accession No: D12S755E 
Definition: Found by e-PCR in sequences from Homo sapiens and Pan troglodytes at 
chromosome 12, locus ATNl 
Databases: EMBL, SWISSPROT, TREMBL, WORMPEP. 
Official Symbol: ATNl 
Official Full Name: Atrophin 1 
Primary source: Atrophin 1 
Sam 3 /NOTCH4 
Also known as: DAQB-143M3.4, FLJ16302, INT3, MGC74442, NOTCH3 
UniGeneHs: 436100 
GDB: GOO-364-353 
UniSTS: 54644 
Gene ID: 4855 
Genbank Accession No: NM_004557 
Definition: Homo sapiens Notch homolog 4 (Drosophila) (N0TCH4). 
Databases: HCOP H-InvDB, Treefam Vega, Q99466, SwissProt, UniProt 
Official Symbol: NOTCH4 
Official Full Name: Notch homolog 4 (Drosophila) [Homo sapiens] 
Primary source: HGNC: 7884. 
Sam4/AAT21 (DTNBPl) 
Also known as: SDY, DBND, HPS7, My031, FU30031; MGC20210, 
DKFZP564K192 
UniGeneHs: 571148 
GDB: 11505970 
UniSTS: -
Gene ID: 84062 (updated 13-Nov-2007). 
Genbank Accession No: NM 183040 
Version: NM 183040.1 GI: 34304367 
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Deflnition: Human DNA sequence from clone RP3-322I12 on chromosome 6p22.3-
24.1 
Databases: EMBL, SWISSPROT, TREMBL, WORMPEP, UniProt. 
Official Symbol: DTNBPl provided by HGNC 
Official Full Name: dystrobrevin binding protein 1 (provided by HGNC) 
Primary source: HGNC: 17328 
Sam5/GLUR6 
Also known as: EAA4, GR1K2 EAA4, GLR6, MRT6, GLUR6, MGC74427 
UniGene Hs: 98262 
UniSTS: 156925 
Gene ID: 2898 
GDB: 373727 
Genbank Accession No: NM 175768 
Version: N M l 75768.1 GI: 28559002 
Definition: triple transcript variants encoding distinct isoforms identified for this gene 
Databases: Uniprot/SWISSPROT 
Official Symbol: GR1K2 
Official Full Name: Glutamate receptor, ionotropic, kainate 2 
Primary source: HGNC: 4580 
Sam6/CTGB1 
Also known as: FLJ37346, KIAAl 150, MGC138257, MGC138285, P66beta, RPl 1-
216N14.6 
UniGene Hs: 4779 
UniSTS: 463760 
Gene ID: 57459 (updated 13-Nov-2007). 
GDB: AF411836 
Genbank Accession No: NM 020699 
Definition: transcription repressor p66 beta component of the MeCPl complex 
Databases: SwissProt, UniProt 
Official Symbol: GATAD2B 
Official Full Name: GATA zinc finger domain containing 2B [Homo sapiens] 
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Primary source: HGNC: 30778 
7. Statistical Analysis 
The frequency distributions of the genotypes and alleles studied between patients and 
normal controls were statistically compared using Chi square test and Fishers exact 
test. Analysis was done using SPSS version 10.01 for Windows. The significance of 
the differences in Alleles and Genotype frequencies found on comparative basis in the 
Intra-gender studied populations'- Normal Male and Schizophrenic Male, Normal 
Female and Schizophrenic Female and Inter-gender population- Schizophrenic Male 
and Schizophrenic Female was calculated in aggregate by Chi square test and at 
individual frequencies with Fishers exact test. Same analytic tests were applied to 
study significance of TNR polymorphism between Schizophrenic (Mild-Avg.) and 
Chronic Schizophrenia. Our study on North-Indian population agreed to the 
polymorphic status of all the loci as had been reported by many earlier studies on 
different populations (Caucasian, Japanese, Chinese). Distribution of VNTR (Variable 
Number of Tandem Repeats) alleles or microsatellites in all the comparative 
population studies we had undertaken are shown in tables I- 1-5 and II- 1-5. 
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RESULTS 
12 13 14 15 16 17 18 19 20 
1.16 
Undigested DNA fragment amplitled by PCR with primer SamI 
Lane M ; Marker; >.( Lambda) 
Lane 1-5: Nonnal Male Sample ;5-10:Nomial Female Sample 
Lane 11-15: Palienl Male Sample ;I I-13-Chronie SCZ:14-15:Mild-Avg.SCZ 
Lane 15-20:Paticnt Female Sampie;l6-l7:fhronic SCZ:lS-20:Mild-Avg.SCZ. 
M I 3 4 5 6 7 8 9 10 II 12 13 14 15 16 17 18 19 20 
1.16 
Undigested DNA fragment amplified by PCR with primer SamI 
Lane M . Marker: A,(Lambda) 
Lane 1-5: Nonnal Male Sample ;5-10;Nonnal Female Sample 
Lane 11-15: Patient Male Sample ;I l-12-Chronic SCZ;l3-l5:Mild-Avg.SCZ 
Lane 16-20:Patienl Female Sample;l6-18:Chronic SCZ;l9-20:Mild-Avg.SCZ. 
M 
23.13 
9.416 
6.557 
4.361 
2.322 
2.027 
0.564 
0.125 
LI 
1.16 
L2 
1.16 
U 
1.16 
L4 
1.16 
L5 
1.16 
L6 
1.16 
L7 
1.16 
L8 
1.16 
L9 
1.16 
LIO 
1.16 
Lll 
1.16 
L12 
1.16 
L13 
1.16 
L14 
1.16 
L15 
1.16 
L16 
1.16 
L17 
1.16 
LIS 
1.16 
L19 
1.16 
L20 
LI6 
- -
Molecular weight of undigested DNA fragments amplified by PCR with primer Saml 
Lane M: Marker; X (Lambda) 
Lane; LI- L5: Norma! Male Sample; L5- LIO: Normal Female Sample 
Lane; Ll l - L15: Patient Male Sample; Lll- L13-Chronic SCZ; L14- L15; Mild-Avg.SCZ 
Lane; L15- L20: Patient Female Sample; L16- L17: Chronic SCZ; L18- L20: Mild-Avg.SCZ. 
M 
23.13 
9.416 
6.557 
4.361 
2.322 
2.027 
0.564 
0.125 
LI 
1.16 
L2 
1.16 
L3 
1.16 
L4 
1.16 
L5 
1.16 
L6 
1.16 
L7 
1.16 
L8 
1.16 
L9 
1.16 
LIO 
1.16 
Lll 
1.16 
L12 
1.16 
L13 
1.16 
L14 
1.16 
L15 
1.16 
L16 
1.16 
L17 
1.16 
L18 
1.16 
LI9 
1.16 
.. 
1.20 
1.16 
Molecular weight of undigested DNA fragments amplified by PCR with primer Saml 
Lane M: Marker; X (Lambda) 
Lane; LI- L5: Normal Male Sample; L5- LIO: Normal Female Sample 
Lane; LI 1- L15: Patient Male Sample; LI 1- L13-Chronic SCZ; L14- L15: Mild-Avg.SCZ 
Lane; L15- L20: Patient Female Sample; L16- L17: Chronic SCZ; L18- L20: Mild-Avg.SCZ. 
Molecular weight analysis as per gel-documentation system UVIDoc Mw Version 99.03 for Windows 
Saml (CTG-B33): Repeats present at Saml gene locus shown with flanking primer sequences. 
1. tctcccaaaaaagcacctggtactaari it atgctgctgctgctgctgctgctgctgcKaaaqt^ccaqcaaaa 
aagatcaccqccqcatcatttttccgagcgcctggggaqaaq 
3' 5' 
5^ 3' 
2. tctcccaaaaaagcacctggtactaa jq it ictgctgctgctgctgctgctgctgctgctgctaaagttccagca 
aaaaagat ra .;3q : :'j / > tea tttttccgagcgcc tgggga q a a q 
^' S' 
5' 3' 
3. t c t c c c a a a a a a g c a c c t g g t a c t a a ^ j q t ictgctgctgctgctgctgctgctgctgctgctgc^aaagttcca 
q c a a a d a a q a r . c a o c q c c q c q t c a t t t t t c c g a g c g c c t g g g g a q a a q 
. r f 
5' 3' 
4. tctcccaaaaaagcacctggtactaaqqqtactgctgctgctgctgctgctgctgctgctgctgctgctaaag^ 
ccaqcaaaaaaqatcaccqccqcqtcatttttccgagcgcctggggaqaaq 
T 
5. tctcccaaaaaagcacctggtactaaqqqtactgctgctgctgctgctgctgctgctgctgctgctgctgctaaa 
qttccaqcaaaaaaqatcaccqccqcqtcatttttccgagcgcctqqggaqaaq 
3' 
5' 3' 
6. tctcccaaaaaagcacctggtactaagggtictgctgctgctgctgctgctgctgctgctgctgctgctgctg-^ 
aaagttccaqcaaaaaaqatcaccqccqcqtcatttttccgagcgcctqqqqaqaaq 
3' 5' 
b^ 3' 
7. tctcccaaaaaagcacctggtactaagggtactgctgctgctgctgctgctgctgctgctgctgctgctgctgct 
g c t a a a g t t : : :aq -aaa-iaaga t c a c c q c c q c q t c a t t t t t c c g a q c g c c t q g g g iqaaq 
5' 3 ' 
8. tctcccaaaaaagcacctggtactaagggtactgctgctgctgctgctgctgctgctgctgctgctgctgctgct 
gc tgc c a a a q r i; c' J d J c ri a ^  a a -1 q a t c a c c g c c g c q t c a t t t t t c c q a q c q c c t g g g g a q a a g 
5' 3 ' 
9. t c t c c c a a a a a a g c a c c t g g t a c t a a g g g t a c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t 
g c t g c t g c t a a a q t t c c a q c a a d a a a q a t c a c c q c c q c q t c a t t t t t G c g a g c g c c t g g g g i qaaq 
1 0 . t c t c c c a a a a a a g c a c c t g g t a c t a a g g g t a c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t 
g c t g c t g c t g - t a a a q t t c c a q c a a a a a a q a t c a c c q c c g c q t c a t t t t t c c g a g c g c G t g g g q ; -]aaq 
3 ' 
V 3' 
11.tctc'caaaaaagcacctggtactaaqggtactgctgctgctgctgctgctgctgctgctgctgctgctgctgct 
gctgctgctgctg taacigt tc -agcaaaaaagatcaccgccgcqtcatttttccgagcgcctqqggaqaaq 
3' 
_^ 3' 
1 2 . t c t c c c a a a a a a g c a c c t g g t a c t a a g g g t a c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t 
g c t g c t g c t g c t g c t g c t a a a g ^ T t c c a g c a a a a a a g a t c a c c g c c q c q t c a t t t t t c c g a g c g c c t g g g g > ;:aaq 
3 ' o' 
13 14 15 16 17 18 19 20 
1.44 
Undigested DNA fragment amplified by PCR with primer Sam2 
Lane M: Marker ; >i(Lambda) 
Lane 1-5: Normal Male Sample ;5-10:Nonnal Female Sample 
Lane 1 M5: Patient Male Sample ; 11-13-Chronic SCZ;14-15:Mild-Avg.SCZ 
Lane 15-20:Palicnt Female Sample; 16-17:Chronie SCZ;lS-2():Mild-Avg.SCZ. 
18 19 20 
1.44 
Undigested DNA fragment amplified by PCR with primer Sam2 
Lane M: Marker; >4Lambda) 
Lane 1-5; Normal Male Sample ;5-10;Normal Female Sample 
Lane 11-15: Patient Male Sample ;11-12-Chronic SCZ;13-15;Mild-Avg.SCZ 
Lane 16-20:Paticnt Female Samplc;16-18:Chronic SCZ;19-20;Mild-Avg.SCZ. 
M 
23.13 
9.416 
6.557 
4.361 
2.322 
2.027 
0.564 
0.125 
LI 
1.44 
L2 
1.44 
L3 
1.44 
L4 
1.44 
LS 
1.44 
L6 
1.44 
L7 
1.44 
L8 
1.44 
L9 
1.44 
LIO 
1.44 
Lll 
1.44 
L12 
1.44 
L13 
1.44 
L14 
1.44 
LIS 
1.44 
L16 
1.44 
L17 
1.44 
L18 
1.44 
L19 
1.44 
L20 
1.44 
Molecular weight of undigested DNA fragments amplified by PCR with primer Sam2 
Lane M: Marker; X (Lambda) 
Lane; LI- L5: Normal Male Sample; L5- LIO: Normal Female Sample 
Lane; LI 1- LI 5: Patient Male Sample; Ll l - L13-Chronic SCZ; LI 4- LI 5: Mild-Avg.SCZ 
Lane; L15- L20: Patient Female Sample; L16- L17: Chronic SCZ; L18- L20: Mild-Avg.SCZ. 
M 
23.13 
9.416 
6.557 
4.361 
2.322 
2.027 
0.564 
0.125 
LI 
1.44 
L2 
1.44 
L3 
1.44 
L4 
1.44 
L5 
1.44 
L6 
1.44 
L7 
1.44 
L8 
1.44 
L9 
1.44 
LIO 
1.44 
Lll 
1.44 
L12 
1.44 
L13 
1.44 
L14 
1.44 
L15 
1.44 
L16 
1.44 
L17 
1.44 
L18 
1.44 
L19 
1.44 
L20 
1.44 
Molecular weight of undigested DNA fragments amplified by PCR with primer Sam2 
Lane M: Marker; X (Lambda) 
Lane; LI- L5: Normal Male Sample; L5- LIO: Normal Female Sample 
Lane; Ll l - L15: Patient Male Sample; LI 1- L13-Chronic SCZ; L14- L15: Mild-Avg.SCZ 
Lane; L15- L20: Patient Female Sample; L16- L17: Chronic SCZ; L18- L20: Mild-Avg.SCZ. 
** Molecular weight analysis as per gel-documentation system UVIDoc Mw Version 99.03 for Windows 
n2 (CTG -B37): Repeats present at Sam2 gene locus shown with flanking primer sequences. 
1. gccacccaccagtctcaacacatcaccatcaccaccaqcaacagcaacagcagcagcagcagcagcagcagcag; 
atcacggaaactctgggcGccctcctcctgctcgtaaagqggtgggtgacctcccc 
3 
5' 3' 
2. gccacccaccagtctcaacacatcaccatcaccaccagcaacagcaacagcagcagcagcagcagcagcagcagc 
agc a t c a c g g a a a c •; c t g g g c.J c c c t c c t c c t gctcgtaaaggggtgggtqacctccc c 
3' 5' 
3. gccaccGaccagtctcaacacatcaccatcaccaccaacaacaqcaacagcagcagcagcagcagcagcagcagc 
agcagcatcacggaaactctqqqccccctcctcctgctcgtaaaggggtgggtgacetccc' 
J' 5' 
5_; 3' 
4. g c c a c ^ c a c c a g t c t c a a c a c a t c a c c a t c a c c a c c a g c a a c a g c a a c a g c a g c a g c a g c a g c a g c a g c a g c a g c 
a g c a g c a g c a t c a c g g a a a c t , : t g g g c c c c c t c c t c c t q c t e g t a a a g g g g t g g g t g a c c t c c c 
3 ' 5 ' 
5 ' V 
5. gccac^Gaccagtctcaacacatcaccatcaccaccagcaacaaoaicagcagcagcagcagcagcagcagcagc 
agcagcagcagcatcacggaaactctqqqccccctcctcctgctcgtaaaggggtgggtgacctcc;-
5' 3' 
6. gccacccaccagtctcaacacatcacGatcaccaccagcaacagcaacagcagcagcagcagcagcagcagcagc 
agcagcagcagcagcatcdcqqaaactctggqccccctcctcctqctcgtaaaggggtgggtgacctccc 
3' 
D^ 3' 
7. gccac : c a c c a g t c t c a a c a c a t c a c c a t c a c c a c c a g c a a c a g c a a c a g c a g c a g c a g c a g c a g c a g c a g c a g c 
agcagcagcagcagcag : i*:Cti : : q q a a a c t c t q q q c c c c c t c c t c c t g c t c g t a a a g g g g t g g g t g a c c t c c c 
3' 3 ' 
V 3 ' 
8. gccacccaccagtctcaacacatcaccatcaccaccaqcaacagcaacaqcagcagcagcagcagcagcagcagc 
agcagcagcagcagcagcagcdccacqqaaactctqqqccccctcctcctgctcgtaaaggggtgggtgacctcc 
5' 3' 
9. gccac 'caccagtctcaacacatcaccatcaccaccagcaacagcaacagcagcagcagcagcagcagcagcagc 
agcagcagcagcagcagcagcagcatcacqqaaactctqqqccccctcctcctgctcgtaaaggggtgggtgacc 
tec • 
5' 
5_^ 3' 
10. gccacccaccagtctcaacacatcaccatcaccaccagcaacagcaacagcagcagcagcagcagcagcagca 
gcagcagcagcagcagcagcagcagcagcatcacgqaaactctqqqccccctcctcctqctcgtaaaggggtggg 
tgacctcc *' 
b_;_ 3' 
11 . gc :acccaccagtctcaaGacatcaccatcaccaccaqcaacaqcaacagcagcagcagcagcagcagcagca 
gcagcagcagcagcagcagcagcagcagcagcatcacqqaaactctqqqccccctcctcctqctcgtaaaggggt 
gggtgacctccc 3' 
5' 3' 
12. qccacccacGagtctcaacacatcaccatcaccaccagcaacagcaacagcagcagcagcagcagcagcagca 
gcagcagcagcagcagcagcagcagcagcagcagcatcacqqaaactctqqqccccctcotcctqctcgtaaagg 
ggtgggtgacctcc •' 
_^  ^ 
13 . gccaccGacGagtGtGaaGaGatGaGcatcaccaccagcaacagcaacagcagcagcagcagcagcagcagca 
gcagcagcagcagcagcagcagcagcagcagcagcatcacgqaaactctqqqccccctcctcctqctcgtaaagg 
ggtgggtgacctec :: i' 
'_^ .y_ 
14 . gcccd • " c a c c a g t c t c a a G a c a t c a c c a t c a c c a c c a g c a a c a g c a a c a g c a g c a g c a g c a g c a g c a g c a g c 
a g c a g c a g c a g c a g c a g c a g c a g c a g c a g c a g c a g c a g c a t c a c g g a a a c t c t q q g c c c c c t j c t J :•: q c t c g t a 
a a g g g g t g g g t g a c c t e c •' 
M 12 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1.45 
Lndijjested DNA fragment amplifled by PCR with primer Sam3 
Lane M Marker;/.(Lambda) 
Lane 1-5: Normal Male Sample ;5-10:Nonnal Female Sample 
Lane 11-15: Patient Male Sample ;1 l-13-(hronie SCZ;14-15;Mild-A\g.SC/. 
15-20:l'atient Female Sample;!6-17:Chromc SCZ;18-20:Mild-Avg.SC Z. 
M I 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 IS 19 20 
1.45 
Undigested Di\A fragment amplified by PCR with primer Sam3 
Lane M: Marker; >4LaiTibda) 
Lane 1-5 Nornial Male Sample ;5-10:NonTial Female Sample 
Lane 11-15: Patient Male Sainple ;11-12-Chronie SCZ;13-15:Mild-Avg.SCZ 
Lane 16-20:Palient Female Sample;16-]X:('lironie SrZ;l')-20:Mild-A\g.SCZ. 
M 
23.13 
9.416 
6.557 
4.361 
2.322 
2.027 
0.564 
0.125 
LI 
1.45 
1.2 
1.45 
1.3 
1.45 
L4 
1.45 
L5 
1.45 
L6 
1.45 
1,7 
1.45 
L8 
1.45 
L9 
1.45 
LIO 
1.45 
1.11 
1.45 
1.12 
1.45 
L13 
1.45 
1.14 
1.45 
1,15 
1.45 
1.16 
1.45 
1.17 
1.45 
1,18 
1.45 
1.19 
1.45 
1.20 
1.45 
Molecular weight of undigested DNA fragments amplified by PCR with primer Sam3 
Lane M: Marker; X (Lambda) 
Lane; LI- L5; Normal Male Sample; L5- LIO; Normal Female Sample 
Lane; Lli- L15: Patient Male Sample; Li I- Li3-Chronic SCZ; Li4- Li5: Miid-Avg.SCZ 
Lane; Li5- L20; Patient Female Sample; LI6- L17; Chronic SCZ; L18- L20: Mild-Avg.SCZ. 
M 
23.13 
9.416 
6.557 
4.361 
2.322 
2.027 
0.564 
0.125 
LI 
1.45 
L2 
1.45 
L3 
1.45 
L4 
1.45 
L5 
1.45 
L6 
1.45 
L7 
1.45 
L8 
1.45 
L9 
1.45 
LIO 
1.45 
Ll l 
1.45 
L12 
1.45 
L13 
1.45 
1,14 
1.45 
1,15 
1.45 
L16 
1.45 
L17 
1.45 
LIS 
1.45 
L19 
1.45 
1.20 
1.45 
' 
Molecular weight of undigested DNA fragments amplified by PCR with primer Sam3 
Lane M: Mariner; X (Lambda) 
Lane; LI- L5: Normal Male Sample; L5- LIO: Normal Female Sample 
Lane; Lll-LIS: Patient Male Sample; LI 1-L13-Chronic SCZ; LI4-L15: Mild-Avg.SCZ 
Lane; LIS- L20: Patient Female Sample; L16- L17: Chronic SCZ; LIS- L20: Mild-Avg.SCZ. 
Molecular weight analysis as per gel-documentation system UVIDoc Mw Version 99.03 lor Windows 
Sam3 (NOTCH4): Repeats present at SaiTi3 j^ene locus shown with tlankin*^ primer sequences. 
1. gaggtggctcctgccccagtgagagctct gagga^ccctgcctgaagagggacag la-i -r.-^ nn^-^ ^ -igagaagg 
ggctgtggaatgcagcccccttcactgctgctgctgctgctgctrat f caqaqteacGagtGtgggtGtgg 
3' 5' 
3' 
2 . g a g g t g g c t c c t g c c c c a g t g a g a g c t c t g a g g g t c c c t g c c t g a a g a g g g a c a g j g a c t g g g g c t t g g a g a a g J 
a q c t q t q a a a t q c a q c c c c c t t c a c t q r c t g c t q c t g c t g c t g c t g c t g c t g - t a ^ g t c a g a g t c a c c a q t c t g g g 
t c t g g 3' 
5' 
5^ Y 
3. gaggtggctcctgccccagtgagagctctgagggtccctgcctgaagagggacagjgactggggcttggagaagj 
qqctqtqqaatqcaqcccccttGactgctgctgctgetgctgctgctgctgctgc':atgtcaqagtcacGagtct 
qqgtctgg 3' 
5' 
4. g a g g t g g c t c c t g c c c c a g t g a g a g c t c t g a g g g t c c c t g c c t g a a g a g g g a c a g g g a c t g g g g c t t g g a g a a q q 
g g c t g t g g a a t g c a g c c c c c t t c a c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c * : a * : 3zcagaq tcaGcaq 
t c t g g g t c t g g 3 ' 
V 3 ' 
g a g g t g g c t c c t g c c c c a g t g a g a g c t c t g a g g g t c c c t g c c t g a a g a g g g a c a g g g a c t g g g g c t t g g a g a a g g 
g g c t g t g g d a t g c a g ' _ - : c c c c t t c a c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t g c t a t g t 
c a q a q t c a c c a g t c t g g q t c t g g 
19 20 
2.22 
Undigested DNA fragment amplitled b\ PCR nith primer Sam4 
Lane M: Marker ; WLambda) 
Lane 1-5: Nomial Male Sample :5-10:Noniial Female Sample 
Lane 1 M5: Palient Male Sample ;1 1-13-C'hronie S('Z;14-15;Mild-Avg.SCy. 
Lane l5-20:Patienl Female Saniple:16-17:Chronie SCZ;18-2():Milci-Avg.SCZ. 
7 S 9 Ml II 12 13 14 15 16 17 IS 19 20 
2.22 
Undigested DNA fragment amplitled by PCR with primer Sam4 
Lane M : Marker ;>.(Lambda) 
Lane 1-5: Nomial Male Sample ;5-10:Normal Female Sample 
Lane 11-15: PalienI Male Sample ;1 l-12-Chronic SCZ;13-15:Mild-Avg.SCZ 
16-20;Paticnl Female Samplc;l6-l8-.Chron(c SCZ-.l9-20-.MUd-Avg.SCZ. 
M 
23.13 
9.416 
6.5S7 
4.361 
2.322 
2.027 
0.564 
0.125 
LI 
2.22 
L2 
2.22 
L3 
2.22 
L4 
2.22 
L5 
2.22 
L6 
2.22 
L7 
2.22 
L8 
2.22 
L9 
2.22 
LIO 
2.22 
Lll 
2.22 
L12 
2.22 
L13 
2.22 
L14 
2.22 
LIS 
2.22 
L16 
2.22 
L17 
2.22 
L18 
2.22 
L19 
2.22 
L20 
2.22 
Molecular weight of undigested DNA fragments amplified by PCR with primer Sam4 
Lane M: Marker; X (Lambda) 
Lane; LI- L5: Normal Male Sample; L5- LIO: Normal Female Sample 
Lane; L\\-L\5-. Patkrt Ma\e Sample;L\\- LlS-ChTomcSCZ; L14- LIS'. MUd-Avg.SCZ 
Lane; L15- L20: Patient Female Sample; L16- L17: Chronic SCZ; L18- L20: Mild-Avg.SCZ. 
M 
23.13 
9.416 
6.SS7 
4.361 
2.322 
2.027 
0.564 
0.125 
LI 
2.22 
L2 
2.22 
L3 
2.22 
L4 
2.22 
LS 
2.22 
L6 
2.22 
L7 
2.22 
L8 
2.22 
L9 
2.22 
LIO 
2.22 
Lll 
2.22 
L12 
2.22 
L13 
2.22 
L14 
2.22 
LIS 
2.22 
LI6 
2.22 
LI7 
2.22 
LIS 
2.22 
L19 
2.22 
L20 
2.22 
Molecular weight of undigested DNA fragments amplified by PCR with primer Sam4 
Lane M: Marker; X (Lambda) 
Lane; LI- L5: Normal Male Sample; L5- LIO: Normal Female Sample 
Lane; LI 1- L15: Patient Male Sample; LI 1- L13-Chronic SCZ; L14- L15: Mild-Avg.SCZ 
Lane; L15- L20: Patient Female Sample; L16- LI7: Chronic SCZ; L18- L20: Mild-Avg.SCZ. 
** Molecular weight analysis as per gel-documentation system UVIDoc Mw Version 99.03 for Windows 
Sam4 (AAT21): Repeats present at Sam4 gene locus shown with flanking primer sequences. 
c c a g a g c t g G c a g a a g g t g a c t t t g a a g g c t t t t t t c c c c a a a a g c t c c a a t q a a g t t g c c t t t : c tac tc tc 
a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t a a 
t a a t a a f c a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t g a a a a 
g tgaaggg tgggqg^g ' r tggccacc t ccca t t t c t t t gcc tggg tgg tgg tgacca tggcgccc t tg tg t cc 
t t t c c a t q t a a c c a a t q a c t c c t g c 
j ' 5 ' 
2. ccagagctgccagaaggtgactttgaaggcttttttccccaaaaqctccaatgaagttgcctttctactct n 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaataataataataataataataataataataataataa 
taa taa taa taataataataataataataataataataataa taataataataataataa taa taa taa tg a 
aaagtgaaggat :)3-.(a7*: :i :^gaccacctcccat 11 ctttgcctgggcggtggcgac jatggcgcccttgtg 
tcctttccatgtaaccaatgactcctgc 
J' 5' 
ccagagctgccagaaggtgactttgaaggcttttttccccaaaagctccaatgaagt tgcct *: iT'^ ta'-t^ ct-
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaataataataataataataataataataataataataa 
taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa 
tgaaaagtgaagggLgggggtgct ggcca 3Ctccca" ttct ttgcctgggt gyt ggt gaccat jgcg .:cct • 
gtgtcctttccatgtaaccaatgactcctgc 
3' 5' 
5' 3' 
ccagagctgccagaaggtgactttgaaggcttttttccccaaaagctccaatcjaagttgccttt:cta!::tct : 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaataataataataataataataataataataataataa 
taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa 
taatgaaaagtgaaqggtgggggtgctggccacctcccatttctttgcctggqtggtggtgac;atqgcgcJ 
cttgtgtcctttccatgtaaccaatqactcctqc 
3' 5' 
ccagagctgccagaaggtgactttgaaggcttttttccccaaaagctccaa^gaagt':gcctt- tcita'-tc^  • 
aaaaaa i^aa _u a i a i -. i x a aaaaaaaaaaaaaa a aa taa taa taa taa taa taa taa taa taa taa taa taa 
taataataataataataataataataataataataataataataataataataataataataataataataa 
taa taa tgaaaagtgaagggtggggq'; j •*: gg jcacctcccatttctttgcct gggcggtggc jaccatgg •. 
gcccttgtgtcctttccatgtaaceaatgactcctgc 
5' 
6 . ccagagctgccagaaggtgactttgaaggcttttttccccaaaagctccaatgaagttgcctt tctactct ; 
aaaaaaaaaaaaaa-ia aaaaaaaaaaaaaaaaaaaataataataataataataataataataataataataa 
taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taa taataataa 
taataataatgaaaagtgaagggtgggggtgctggccacctcccatttctttgcctgggtggt ggtgaccat 
ggcgcGcttgtgtcctttccatgtaaccaatgactcctgc 
3' 5' 
4 15 16 17 18 19 20 
1.49 
Lndigested DNA fragment ampliflid by PCR with primer SamS 
Lane M: Marker ;>.(Lambda) 
Lane 1-5: Normal Male Sample ;5-10:Nonnal Female Sample 
Lane 11-15: Patient Male Sample :l l-13-Chronie SCZ;l4-l5:Mild-Avg.SCZ 
Lane l5-2():Paticnt Female Sample;16-l7:Chronic SCZ;IX-2():Mild-Avg.SCZ. 
19 20 
1.49 
Lndigested DISA fragment amplified b> PC R with primer SamS 
Lane M: Marker :>-(Lambda) 
Lane 1-5: Normal Male Sample ;5-10:Nomial Female Sample 
Lane I 1-15: Patient Male Sample :l 1-12-Chronic SCZ;13-15:Mild-A\g.S( Z 
Lane l6-20:Patienl Female Sample;l6-lS:Chronie S(Z;19-20:Mild-A\g.S(;Z. 
M 
23.13 
9.4)6 
6.557 
4.361 
2.322 
2.027 
0.S64 
0.125 
LI 
1.49 
L2 
1.49 
L3 
1.49 
L4 
1.49 
LS 
1.49 
L6 
1.49 
L7 
1.49 
L8 
1.49 
L9 
1.49 
LIO 
1.49 
LU 
1.49 
L12 
1.49 
L13 
1.49 
L14 
1.49 
LIS 
1.49 
L16 
1.49 
L17 
1.49 
L18 
1.49 
L19 
1.49 
L20 
1.49 
Molecular weight of undigested DNA fragments amplified by PCR with primer Sam5 
Lane M: Marker; X (Lambda) 
Lane; LI- L5: Normal Male Sample; L5- LIO: Normal Female Sample 
Lane; LI J- LJ5: Patient Male Sample; LJ I- U3-Chronic SCZ; U4- L15: Mild-Avg.SCZ 
Lane; L15- L20: Patient Female Sample; L16- L17: Chronic SCZ; L18- L20: Mild-Avg.SCZ. 
M 
23.13 
9.416 
6.557 
4.361 
2.322 
2.027 
0.564 
0.125 
LI 
1.49 
L2 
1.49 
L3 
1.49 
L4 
1.49 
L5 
1.49 
L6 
1.49 
L7 
1.49 
L8 
1.49 
L9 
1.49 
LIO 
1.49 
LU 
1.49 
L12 
1.49 
L13 
1.49 
L14 
1.49 
L15 
1.49 
L16 
1.49 
L17 
1.49 
L18 
1.49 
L19 
1.49 
L20 
1.49 
Molecular weight of undigested DNA fragments amplified by PCR with primer Sam5 
Lane M; Marker; X (Lambda) 
Lane; LI- L5: Normal Male Sample; L5- LIO; Normal Female Sample 
Lane; LI 1- L15: Patient Male Sample; Lll- L13-Chronic SCZ; L14- L15: Mild-Avg.SCZ 
Lane; L15- L20; Patient Female Sample; L16- L17: Chronic SCZ; L18- L20: Mild-Avg.SCZ. 
Molecular weight analysis as per gel-documentation system UVIDoc Mw Version 99.03 for Windows 
Sam5(GRIK2): Repeats present at Sam5 gene locus shown with nanking primer sequences. 
1. c c a a c a c c t t t t c t c t a a c G c c c a t a t c c c a a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t a a t a a 
t a a t a a t a a t a a t a a t a a a a q c a q t q q t t c a q t q a t t c t q a a t t a a a a q q a t a a t q t t t t q c a a t q t t c a a q g t t 
c a a c a t t t t t q a c c g g c t c a t 3 ' 
5' 
5_^ J ' 
2. c c a a c a c c t t t t c t c t a a c c G c c a t a tcccaaataataa taataataataa t a a t a a t a a t a a t a a taataa t a a 
t a a t a a t a a t a a t a a t a a t - . . l a a q c a g t t g g t t c a g t g a t t c t q a a t t a a a a g g d C a a t g t t t t g > / a a t g t t c a d 
q q t t c a a c a t t t t t g a c c q q c t c a t 
3 ' 5 ' 
3' 
3. ccaacacottttctctaacGcccatatcccaaataataataataataataataataataataataataataataa 
taataataataataataataataaaagcagttggttcagtgattctgaattaaaaggataatgttt tgcaatgtt 
caaqqttcaacatttttqaccggctcat 
V 3' 
4. ccaacaccttttctctaacccc:atatcccaaataataataataataataataataataataataataataataa 
taataataataataataataataataaaagcagttggttcagtgattctgaattaaaaggataatgttttgca-jT 
gttcaaqgttcaacatttttqaGcggctca^ 
3' 5' 
5. ccaacaccttttctctaaccGCcatatcccaaataataataataataataataataataataataataataataa 
taataataataataataataataataataaaagcagttggttcagtgattctgaactaaaaggataatgtttt jc 
aatgttcaa ggttGaacatttttgaccggGtcat 
3' 5' 
5^ y 
6 . ccaacacGttttctctaacGCc at at: cccaaa taa taa taa taa taa taa taa taa taa taa taa taa taa taa 
taa taa taa taa taa taa taa taa taa taa ta a a a g c a g 11 g g r t c a g t g a 11 c t -J a a 11 a a a a g a a t a a t g t " t 
tqcaatgttcaaggttcaacatttttgaccggctcat 
3' 5' 
7. CGaacaccttttctctaacccccatatcccaaataataataataataataataataataataataataataataa 
taataataataataataataataataataataataaaagcagt tggttcagtgattctgaattaaaaggataatg 
ttttgcaatgttcaa ggttcaacatttttgaccggctcat 
16 17 18 m 2(1 
1.26 
Undigested DNA fragment amplitled by PCR with primer Sam6 
Lane M : Marker; MLambda) 
Lane 1-5: Normal Male Sample ;5-10:NonTial Female Sample 
Lane 1 1-15; Patient Male Sample ;11-12-Chronie SC7.:l.V15:Mild-Avg.SCZ 
16-20:Patient Female Sample; 16-lK:Clirome SCZ;l')-2();Mikl-Avg.SCZ. 
14 2(1 
1.26 
Undigested DNA fragment amplilled by PCR with primer Sam6 
1-ane M: Marker; X(Lambda) 
Lane 1-5: Normal Male Sample ;5-l():Nonnal Female Sample 
Lane 11-15: Patient Male Sample :1 l-12-Chronie SCZ;13-15:Mild-Avg.SCZ 
16-20:Patient Female Sample:16-IX:Chronie SCZ;19-20:Mild-Avg.SCZ. 
M 
23.13 
9.416 
6.557 
4.361 
2.322 
2.027 
0.564 
0.125 
LI 
1.26 
1,2 
1.26 
L3 
1.26 
14 
1.26 
L5 
1.26 
1 
L6 
1.26 
L7 
1.26 
1,8 
1.26 
L9 
1.26 
1,10 
1.26 
1,11 
1.26 
1,12 
1.26 
1,13 
1.26 
1.14 
1.26 
1,15 1.16 
1.26 1.26 
1,17 
1.26 
1,18 
1.26 
1.19 
1.26 
1,20 
1.26 
Molecular weight of undigested DNA fragments amplified by PCR with primer Sam6 
Lane M: Marker; X (Lambda) 
Lane; LI- L5: Normal Male Sample; L5- LiO: Normal Female Sample 
Lane; LI 1- LI5: Patiem Male Sample: LI I- LI3-Chronic SCZ; LI4- LI5: Mild-Avg.SCZ 
Lane; 1,15- L20; Patient Female Sample; LI6- LI7: Chronic SCZ; LI8- L20: Mild-Avg.SCZ. 
M 
23.13 
9.416 
6.557 
4.361 
2.322 
2.027 
0.564 
0.125 
L I 
1.26 
1,2 
1.26 
L3 
1.26 
L4 
1.26 
L5 
1.26 
L6 
1.26 
1,7 
1.26 
1,8 
1.26 
L9 
1.26 
1,10 
1.26 
111 
1.26 
L12 
1.26 
1,13 
1.26 
1,14 
1.26 
1,15 
1.26 
1,16 
1.26 
L I 7 
1.26 
1,18 
1.26 
1.19 
1.26 
1,20 
1.26 
Molecular weight of undigested DNA fragments amplified by PCR with primer Sani6 
Lane M: Marker; X (Lambda) 
Lane; LI- L5: Normal Male Sample; L5- LIO: Normal Female Sample 
Lane: LI 1- LIS; Patient Male Sample; LI I- LI3-Chronic SCZ; LI4- L15: Mild-Avg.SCZ 
Lane; 1,15- L20: Patient Female Sample; LI6- LI7: Chronic SCZ: LIS- L20: Mild-Avg.SCZ. 
** Molecular weight analysis as per gel-documentation system UVIDoc Mw Version 99.03 for Windows 
Sam6 (CTG-Bl): Repeats present at Sam6 gene locus shown with tlanking primer sequences. 
3' 
1. ccaagctccggaatgttgtcct jggggctgctcagttccgccagcccttgagagaacggcaacagcagcagcagc 
agcagcagcagcagcagcagcaggacqtccacaqtcqtgtagttc 
3' 5' 
S^ 3' 
2 . ccaagctccggaatgttgtcctgggggctgetcagttccgccagcccttgagagaacggcaacagcagcagcagc 
a gca gca. gca gca gca gca gca gca gca gq a CQtccacaqtcqtqtaqttc 
3' 5' 
b^ 3' 
3. ccaagctccggaatgttgtcctgggggctgetcagttccgccagcccttgagagaacggcaacagcagcagcagc 
agcagcagcagcagcagcagcagcgcagcaggacqtccacaqtcgtqtagttc 
3' 5' 
3' 
4. ccaagctccggaatgttgtcct gggggctgetcagttccgecagcccttgagagaaeggeaacagcagcagcagc 
agcagcagcagcagcagcagcagcagcagcagcaggacgtccacagtcqtqtaqttc 
3' 5' 
TNR Allele Frequency Results 
(I) 
Table 1.1: Allele distribution of candidate loci in Normal Indivduals and Schizophrenic patients and P values using Fishers exact 
and Chi square test. 
Locus 
Sam-, 
Sam, 
Samj 
Sam, 
Sam, 
Sam, 
Repeat 
Observed 
CTG 
CAG 
CTG 
AAT 
AAT 
CAG 
Allele 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
6 
1 
2 
3 
4 
5 
6 
7 
1 
2 
3 
4 
No. of 
Repeats 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
6 
9 
10 
11 
13 
35 
36 
37 
38 
39 
40 
20 
21 
22 
23 
24 
25 
26 
12 
14 
15 
16 
Normal Individual 
No. of 
Chromosomes 
4 
4 
4 
8 
16 
4 
20 
4 
4 
8 
4 
0 
4 
4 
4 
4 
8 
16 
12 
0 
4 
8 
8 
0 
4 
4 
0 
16 
28 
32 
4 
0 
24 
8 
20 
20 
8 
0 
4 
8 
12 
12 
40 
4 
0 
28 
44 
4 
4 
Frequency 
% age 
5 
5 
5 
10 
20 
5 
25 
5 
5 
10 
5 
0 
5 
5 
5 
5 
10 
20 
15 
0 
5 
10 
10 
0 
5 
5 
0 
20 
35 
40 
5 
0 
30 
10 
25 
25 
10 
0 
5 
10 
15 
IS 
50 
5 
0 
35 
55 
5 
5 
Schizophrenic patient 
No. of 
Chromosomes 
4 
4 
4 
8 
12 
0 
20 
4 
4 
12 
4 
4 
4 
4 
4 
0 
4 
8 
16 
4 
8 
8 
8 
4 
4 
4 
0 
16 
20 
32 
8 
4 
20 
4 
32 
12 
8 
4 
4 
4 
4 
8 
48 
8 
4 
16 
44 
12 
8 
Frequency 
%age 
5 
5 
5 
10 
15 
0 
25 
5 
5 
15 
5 
5 
5 
5 
5 
0 
5 
10 
20 
5 
10 
10 
10 
5 
5 
5 
0 
20 
25 
40 
10 
5 
25 
5 
40 
15 
10 
5 
5 
5 
5 
10 
60 
10 
5 
20 
55 
15 
10 
Alleles,Patient vs Normal 
Fishers exact 
P- value 
0.640 
0.640 
0.640 
0.603 
0.267 
0.060 
0.572 
0.640 
0.640 
0.237 
0.640 
0.060 
0.640 
0.640 
0.640 
0.060 
0.184 
0.060 
0.267 
0060 
0.184 
0.603 
0.603 
0060 
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Figure 1.1.1: Bar diagram representing the comparative CTG repeat size in 
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I.l. TNR Allele Polymorphism for Normal vs. Schizophrenia: Lack of 
Association with Schizophrenia Expression. 
1.1.1 Saml: The Saml (CTG-B33) CTG repeat locus w^s highly polymorphic with 
Twelve (12) (CTG)(n) repeat alleles (Table I.l) in the range of 9-20 CTG TNR in 
Normal and Schizophrenic subjects of our study sample. The allele with 15 CTG 
repeats was most prominent in both samples (25%), allele with highest repeat 20 was 
observed in only patient samples of our study (5%) (Fig.I.1.1). Statistical analysis as 
per Chi Square test at .01 level (P=0.588) rendered the allele frequency difference 
between the Normal and Schizophrenic patients insignificant (Table 1.1). Also, using 
Fisher's exact test (Table I.l) at all the repeat numbers, a non-significant difference 
was persistent throughout. We conclude that susceptibility to Schizophrenia was not 
influenced by variation at the Saml (CTG-B33) repeat locus in North-Indian 
population as per our study sample. 
1.1.2 Sam2: Repeat locus (CTG-B37) was highly polymorphic with Fourteen (14) 
(CAG)(n) repeat alleles (Table I.l) in the range of 9-22 repeats in Normal and 
Schizophrenic patient samples of our study. (CAG) triplet allele with 14 repeats was 
the most prominent of all the repeat alleles present in Normal sample (20%) while as 
allele with 15 repeats in patients (20%) (Fig.I.1.2). Expression of allele with highest 
CAG repeats (22) at this locus in both Normal and patient samples was 5% in 
proportion. Statistical analysis of our data in aggregate as per Chi Square test 
(P=0.161) suggested no significant difference in allele fi-equency between Normal and 
SCZ patients at Sam2 locus in our study sample (Table I.l). Fishers exact test analysis 
individually at all the repeat allele fi-equencies (Table I.l) also showed a persistent 
non-significant difference throughout. Thus we found no evidence for association of 
expansion of triplet repeat CAG at Sam2 (CTG-B37) locus with Schizophrenia in 
patients observed when compared to Normal individuals in our North-Indian 
population study sample. 
1.1.3 Saiii3: Polymorphic status existed in allele expression at Sam3 (NOTCH4) gene 
locus with Eight (8) (CTG)(n) repeat alleles (Table I.l) in the range of 6-13 repeats 
observed in our Normal -Schizophrenia study sample. The allele with 10 repeats was 
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Figure 1.1. 4: 2-D Bar diagram representing Standard Deviation -SD of comparative 
AAT repeat size in Normal individuals and Schizophrenic patients at Sam4 locus 
the most expressed allele in both Normal and Schizophrenic samples (40%) of our 
study. Allele with 13 repeats was present only in Schizophrenic (5%) sample 
(Fig.I.1.3). Analysis of allele frequency of microsatellite markers (CTG)(n) observed 
between these two groups at this locus in aggregate as per Chi square test (P=0.155) 
showed no differences in our study (Table I.l). Fisher's exact test analysis (Table 1.1) 
individually at all the repeat frequencies of Sam3 locus also showed a non-significant 
difference persistent throughout. Thus our results did not support association of 
polymorphic trinucleotide repeat expansion at Sam3 (NOTCH4) locus with 
expression of disease in Schizophrenic patients when compared to Normal individuals 
as per our North-Indian study sample. 
1.1.4 Sam4: Polymorphism was observed with Six (6) trinucleotide (AAT)(n) repeat 
alleles (Table I.l) present in the range of 35-40 repeats at this locus. The allele with 
highest number of repeats (40) was observed in patient sample (5%). Allele with 35 
repeats was prominent in Normal sample (25%) with 37 repeat allele found most 
prominently in patient sample (40%) of our study (Fig.I.1.4). Allele frequency data 
analysis (Table I.l) showed Chi square P value (P=0.063) between Normal and 
Schizophrenic samples of our study was insignificant. Fishers exact test analysis at all 
allele repeats also showed non-significance (Table I.l). These observations as per our 
study sample indicated that the Sam4 (DTNBPl) gene locus was unlikely to be a 
major susceptible gene for Schizophrenia in patients of North-Indian descent. 
1.1.5 SamS: Our study has revealed Seven (7) polymorphic (AAT)(n) alleles at Sam5 
locus with (AAT)(n) repeats (Table I.l) in the range of 20-26. Allelic frequency 
observations showed allele with highest repeat number (26) present in patient sample 
of our study (5%). Of all the repeat alleles present in Sam5 gene locus, allele with 24 
repeats was most commonly present allele in both Normal (50%) and Schizophrenics 
(60%) samples (Fig.I.1.5). The frequency and size range of rest of the trinucleotide 
alleles (VNTRs) at locus Sam5 (GRIK2) was 5-10% in proportion in our comparative 
study samples. Statistically there was no significant Chi Square difference (P=0.058) 
in allele frequencies (Table I.l) between the Normal and Schizophrenic pafient 
groups. Using Fisher's exact test at all the repeat allele frequencies, a nonsignificant 
difference was persistent throughout (Table I.l). These observations indicate no 
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Figure 1.1.6: 2-D Bar diagram representing Standard Deviation -SD of comparative 
CAG repeat size in Normal individuals and Schizophrenic patients at Sam6 locus 
positive association of Sam5 gene locus with Schizophrenia as per our North-Indian 
study sample. 
1.1.6 Sain6: Sam6 (CTGBl) locus showed Five (5) (CAG)(n) polymorphic alleles 
(Table I.l) in the range of 12-16 CAG repeats. The allele with highest number of the 
repeats (16) was observed in both the Normal and Schizophrenic patient study 
samples with percent proportion more in patient sample (5% in Norm, and 10% in 
SCZ). Repeat allele 14 was most prominent allele in both samples of comparative 
study (Fig.I.1.6). However, the data analysis (Table I.l) as per Chi Square test (P= 
0.035) did not show significant microsatellite (VNTR) allele frequency difference at 
the Sam6 locus between Normal and Schizophrenic population. Fishers exact test 
analysis at all the allele frequencies also showed a non-significant difference was 
persistent throughout (Table I.I). Thus our results suggested no role of Sam6 
(CTGBI) locus in Schizophrenia expression in patients suffering from the disease 
atleast in North-Indian population as per our study sample. 
50 
Table \2: Allele distribution of candidate loci in Schizophrenic Male and Schizophrenic Female patients and P values using Fishers exact 
and Chi square test. 
Locus 
Sam, 
Sain2 
Sam] 
Sam4 
Sams 
Samt 
Repeat 
Ol^serv^d 
CTG 
CAG 
CTG 
AAT 
AAT 
CAG 
Allele 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
6 
1 
2 
3 
4 
5 
6 
7 
1 
2 
3 
4 
No. Of 
Reoeats 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
6 
9 
10 
11 
13 
35 
36 
37 
38 
39 
40 
20 
21 
22 
23 
24 
25 
26 
12 
14 
15 
16 
Schizophrenic Male 
No. of 
Chromosomes 
4 
0 
4 
4 
4 
0 
8 
4 
0 
8 
4 
0 
4 
0 
4 
0 
4 
4 
8 
0 
4 
4 
4 
0 
4 
0 
8 
12 
16 
4 
0 
12 
0 
16 
8 
4 
0 
4 
0 
4 
4 
24 
4 
0 
8 
24 
4 
^ 
Frequency 
% aae 
10 
0 
10 
10 
10 
0 
20 
10 
0 
20 
10 
0 
10 
0 
10 
0 
10 
10 
20 
0 
10 
10 
10 
0 
10 
0 
20 
30 
40 
10 
0 
30 
0 
40 
20 
10 
0 
10 
0 
10 
10 
60 
10 
0 
20 
60 
10 
10 
Schizophrenic Female 
No. of 
Chromosomes 
0 
4 
0 
4 
8 
0 
12 
0 
4 
4 
0 
4 
0 
4 
0 
0 
0 
4 
8 
4 
4 
4 
4 
. 4 ' 
0 
4 
8 
8 
16 
4 
4 
8 
4 
16 
4 
4 
4 
0 
4 
0 
4 
24 
4 
4 
8 
20 
8 
4 
Frequency 
%aae 
0 
10 
0 
10 
20 
0 
30 
0 
10 
10 
0 
10 
0 
10 
0 
0 
0 
10 
20 
10 
10 
10 
10 
10 
0 
10 
20 
20 
40 
10 
10 
20 
10 
40 
10 
10 
10 
0 
10 
0 
10 
60 
10 
10 
20 
50 
20 
10 
Alleles.SCZ J vs SC2 $ 
Fishers exact 
P-value 
0.058 
0.058 
0.058 
0.644 
0.174 
0.000 
0.220 
0.058 
0.058 
0.174 
0.058 
0.058 
0.058 
0.058 
0 058 
0.000 
0058 
0.644 
0.610 
0.058 
0.644 
0.644 
0.644 
0.058 
0.058 
0.0S8 
0.610 
0.220 
0.590 
0.644 
0.058 
0.220 
0.058 
0.590 
0.174 
0.644 
0.058 
0.058 
0.058 
0.058 
0.644 
0.590 
0.644 
0.058 
0.610 
0.250 
0.174 
0.644 
Chi square 
P- value 
0.000 
0.001 
0308 
0.072 
0.014 
0 636 
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I.2.Intra-Gen(ler bias and TNR Polymorphic Allele Frequency 
between Normal Male/ Schizophrenic Male: No Role in 
Schizophrenia Expression 
1.2.1 Saml: Twelve (12) different alleles of (CTG)(n) TNR (Table 1.2) were 
identified in our study sample of Normal Male and Schizophrenic Male. Overall 9-20 
(CTG)(n) repeat alleles were identified. Normal Males had allele with 15 repeats in 
maximum proportion (30%) whereas in Schizophrenic Male 15 and 18 repeats were 
expressed in maximum proportion (20%) equal. Besides, the allele with highest 
repeats -19 (CTG)(n) repeats at this locus was present in Schizophrenic Male in our 
study sample (10%) (Fig.I.2.1). Statistical analysis of our data as per both Chi square 
(P=0.127) and Fishers exact test (Table 1.2) showed no significant differences in allele 
frequencies in aggregate or individually between Normal Male and Schizophrenic 
Male samples. The results thus suggested lack of association between the triplet 
repeat polymorphic Saml (CTG-B33) gene locus and Schizophrenia expression in 
North-Indian Male population as per our study. 
1.2.2 Sain2: Our study sample of Normal Male and Schizophrenic Male detected 
Thirteen (13) different TNR (CAG)(n) (Table 1.2) alleles at Sam2 locus in the range 
of 9-21 repeats. 14 repeat allele in Normal Male samples (20%) and 15 repeat allele in 
Schizophrenic Male (20%) were observed in most of the sample. The longest 
(CAG)(n) repeat allele of 21 repeats was present in both Normal and Schizophrenic 
Male subjects of our study sample (10%) (Fig.I.2.2). Stafistical analysis of allelic 
frequencies of (CAG) repeats of the Sam2 (CTG-B37) gene locus with Chi square test 
(P=0.299) (Table 1.2) did not show any significant associations with Schizophrenia. 
Fishers exact test analysis (Table 1.2) at all the individual allelic frequencies also 
showed that non-significant difference was persistent throughout. The data strongly 
suggested that Sam2 (CTG-B37) locus was not a significant susceptibility locus for 
Schizophrenia in Male population atleast of North-Indian descent as per our study. 
1.2.3 Sam3: Four (4) (CTG)(n) repeat alleles (Table 1.2) were detected in our study 
sample of Normal Male and Schizophrenic Male in the range of 6-11 (CTG)(n) 
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AAT repeat size in Normal Male and SCZ Male at Sam4 locus 
40 
repeats. Same proportion of all alleles on Sam3 (N0TCH4) locus in both the Normal 
Male and Schizophrenic Male were present. Allele with (CTG) repeat 10 was the 
allele with highest frequency in both samples (40%) (Fig.I.2.3). Statistical analysis of 
the allelic frequencies between Normal Male and Schizophrenic Male samples in 
aggregate as per Chi square test (P= 1.000) and individually as per Fishers exact test 
(Table 1.2) showed no significance. Thus intra-gender bias of our samples at this locus 
found that the TNR expansion on Sam3 (N0TCH4) gene locus does not confer 
susceptibility to Schizophrenia in North-Indian Male as per our study. 
1.2.4 Sani4: Five (5) specific alleles (Table 1.2) with (AAT)(n) polymorphic repeat 
expansion were identified in Normal Male and Schizophrenic Male at Sam4 
(DTNBPl) locus of our study sample. (AAT)(n) repeats observed were in the range of 
35-39 repeats. 35 and 38 allele repeats in Normal Male (30%) while as 37 repeat 
allele in Schizophrenic Males (40%) were observed in maximum proportion in our 
study sample (Fig.1.2.4). Other repeat alleles were present almost in same proportion 
in both Normal and Schizophrenic Males. Statistical analysis of allele frequencies of 
the comparative groups either in aggregate by Chi square test (P=0.334) or 
individually by Fishers exact test (Table 1.2) revealed non-significance of (AAT)(n) 
repeat expansion. Thus no significant association was detected between Schizophrenia 
expression and (AAT)(n) polymorphism at Sam4 (DTNBPl) locus in Schizophrenic 
Male compared to Normal Male of North-Indian origin as per our study sample. 
1.2.5 SamS: Study sample of Normal Male and Schizophrenic Male detected Six (6) 
different (AAT)(n) alleles (Table 1.2) at Sam5 locus. (AAT)(n) repeats in alleles were 
in the range of 20-25 on the locus. The maximum number of (AAT)(n) repeats -25, 
were observed in Schizophrenic Male (10%)of our sample. 24 repeat allele was 
present in maximum proportion in both the Normal Male (50%) and Schizophrenic 
Male (60%) samples of our study (Fig.I.2.5). Statistical analysis of allele frequencies 
between Normal Male and Schizophrenic Male subjects at Sam5 (GRIK2) locus was 
performed in aggregate with Chi square (P=0.084) and individually with Fisher's 
exact test (Table 1.2) showed insignificant values. Thus our results suggested that the 
(AAT) TNR polymorphism at Sam5 (GRIK2) locus does not appear to be associated 
with Schizophrenia in the North-Indian Male population. 
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Figure 1.2.6: Bar diagram representing Standard Deviation -SD of comparative 
CAG repeat size in Normal Male and SCZ Male at Sam6 locus 
1.2.6 Sam6: Four (4) specific alleles with (CAG)(n) polymorphic repeat expansion 
(Table 1.2) were identified in Normal Male and Schizophrenic Male of our study 
sample. 12-16 (CAG)(n) repeat alleles were present except the 13 repeat allele. Of the 
expressed alleles, 14 repeat allele was in maximum proportion in both Normal Male 
(50%) and Schizophrenic Males (60%) while as 16 repeat (CAG)(n) repeat allele was 
present in Schizophrenic Males (10%) (Fig.I.2.6). Statistically, as per aggregate Chi 
square (P=0.071) and individual Fishers exact test analysis of allelic fi-equencies at 
Sam6 (CTGBl) locus (Table 1.2), no significant difference in polymorphic alleles was 
observed between the Normal Male and Schizophrenic Male subjects of our study 
sample. Thus our study provided no evidence for association between the 
polymorphic repeat expansion at Sam6 (CTGBl) gene locus and Schizophrenia 
expression in the North-Indian Male population. 
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Table 1.3: Allele distribution of candidate loci in Schizophrenic (Mild - Avg.) and Chronic Schizophrenic patients & P values 
using Fishers exact and Chi square test 
Locus 
Sam, 
Sam2 
Sam3 
Sam4 
Sams 
Samg 
Repeat 
Observed 
CTG 
CAG 
CTG 
AAT 
AAT 
CAG 
Allele 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
6 
1 
2 
3 
4 
5 
6 
7 
1 
2 
3 
4 
Schizophrenic (Mild - Avg.) 
No. of 
Repeats 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
6 
9 
10 
11 
13 
35 
36 
37 
38 
39 
40 
20 
21 
22 
23 
24 
25 
26 
12 
14 
15 
16 
No. of 
Chromosomes 
4 
0 
4 
4 
8 
0 
8 
4 
0 
4 
4 
0 
4 
0 
4 
0 
4 
4 
8 
0 
4 
4 
4 
0 
4 
0 
8 
12 
16 
4 
0 
8 
4 
16 
8 
4 
0 
4 
4 
0 
4 
24 
4 
0 
8 
20 
8 
4 
Frequency 
%aae 
10 
0 
10 
10 
20 
0 
20 
10 
0 
10 
10 
0 
10 
0 
10 
0 
10 
10 
20 
0 
10 
10 
10 
0 
10 
0 
20 
30 
40 
10 
0 
20 
10 
40 
20 
10 
0 
10 
10 
0 
10 
60 
10 
0 
20 
60 
20 
10 
Chronic Schizophrenic 
No. of 
Chromosomes 
0 
4 
0 
4 
4 
0 
12 
0 
4 
8 
0 
4 
0 
4 
0 
0 
0 
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Frequency 
%aoe 
0 
10 
0 
10 
10 
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10 
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10 
0 
10 
0 
0 
0 
10 
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10 
10 
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10 
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0 
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Fishers exact 
P- value 
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0.058 
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U.Intra-Gender TNR Allele frequency between Normal Female/ 
Schizophrenic Female: Polymorphism not cause of Schizophrenia 
1.3.1 Saml: Twelve (12) alleles due to expansion of (CTG)(n) trinucleotide repeat at 
locus Saml (CTG-B33) (Table 1.3) were identified in the range of 9-20 repeats. 15 
(CTG)(n) repeat allele in Schizophrenic Female (30%), 13 and 15 repeats alleles 
(20%) were expressed in maximum proportion in our study sample The longest repeat 
allele- 20 repeats was seen only in Schizophrenic Female (10%)) (Fig.I.3.1). Allele 
frequency analysis as per both Chi square (P=0.119) and Fishers exact test (Table 1.3) 
found no significant difference in frequencies of the twelve polymorphisms observed 
between the Normal Female and Schizophrenic Female. Thus our data indicated that 
the polymorphism at Saml (CTG-B33) locus was unlikely to be a major susceptible 
gene for Schizophrenia expression in North -Indian Female population. 
1.3.2 Sain2: The Sam2 (CTG-B37) (CAG)(n) repeat locus was highly polymorphic 
with Fourteen (14) TNR repeat alleles (Table 1.3) ranging from 9-22 in our study 
sample of Normal Female and. Schizophrenic Female. 14 and 15 (CAG)(n) repeat 
alleles in Normal Female (20%) whileas 15 (CAG)(n) repeat allele in Schizophrenic 
Females (20%) were most commonly proportioned alleles in our study sample. 22 
(CAG)(n) repeat allele marker was present in both the samples(10%) (Fig.1.3.2). 
Statistical analysis of allele frequencies between these two sample groups in 
aggregate as per Chi square (P=0.148) and individually as per Fishers exact test 
(Table 1.3) showed no significant difference values. Hence, no evidence for 
involvement of TNR expansion at the Sam2 (CTG-B37) locus in inducing 
Schizophrenia disease in Female patients of study sample was observed and as per our 
study polymorphism did not play any role in the pathogenesis of Schizophrenia in the 
North-Indian Female population. 
1.3.3 Sain3: In Normal Female and Schizophrenic Female samples of our study. Five 
(5) alleles (Table 1.3) due to expansion of (CTG)(n) trinucleotide repeat at Sam3 
(NOTCH4) locus were observed. 6, 9, 10, 11 andl3 (CTG)(n) repeats were identified 
in our study sample. 9 and 10 (CTG)n repeat alleles were predominant in Normal 
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Figure 1.3.4: Bar diagram representing Standard Deviation -SD of comparat ive 
AAT repeat size in Normal Female and SCZ Female at Sam4 locus 
Female sample (40% each) whileas 10 repeat allele in Schizophrenic Female (40%) of 
our samples. 11 and 13 repeat allele were present only in Schizophrenic Female 
sample (10%)) (Fig.I.3.3). Allele frequencies' analysis of sample groups as per 
aggregate Chi square (P=0.031) as well as individual Fishers exact test (Table 1.3) 
showed insignificant values. Thus in our study sample, we did not find any 
association between the (CTG)n polymorphism at Sam3 (NOTCH4) gene locus and 
Schizophrenia expression indicating that the human Sam3 (N0TCH4) locus was not 
likely to be a major susceptible gene for Schizophrenia in North-Indian Female 
population. 
1.3.4 Sam4: Six (6) polymorphic (AAT)(n) repeat alleles in the range of 35-40 
(AAT)(n) were identified (Table 1.3) on Sam4 (DTNBPl) locus in our Female study 
sample. Interestingly, 38 (AAT)(n) repeat allele was proportionally predominant in 
Normal Female (30%)) while as 37 (AAT)(n) repeat allele was prominent in 
Schizophrenic Female (40%). However, 40 repeat allele, the highest TNR allele of 
our study sample range was present in Schizophrenic Female (10%)) (Fig.1.3.4). 
Aggregate Chi square analysis of allele frequencies (P=0.043) in both Normal and 
Schizophrenic Female samples of our study (Table 1.3), showed non-significant value. 
Repeat number analysis as per Fishers exact test (Table 1.3) also showed no 
significant association. Our results as per our study sample thus indicated that TNR 
polymorphism at Sam4 (DTNBPl) gene locus played no significant role in genetic 
efiology of Schizophrenia in North-Indian Female population. 
1.3.5 Sam5: Six (6) different TNR alleles of (AAT)(n) in the range of 21-26 
(AAT)(n) repeats (Table 1.3) were detected in our Normal and Schizophrenic Female 
study sample. 24 (AAr)(n) repeat allele was the highest proportioned repeat allele 
present in both Normal (50%o) and Schizophrenic Female (60%) study samples. 26 
(AAT)(n) repeat allele marker was observed only in Schizophrenic Female (10%) of 
the study sample (Fig.I.3.5). Aggregate Chi square (P=0.084) and individual Fishers 
exact test analysis (Table 1.3) found no significant difference in allele frequencies of 
Normal and Schizophrenic Female samples. Thus as per our study sample, our data 
suggested lack of associafion between the triplet repeat polymorphism ut Sam5 
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Figure 1.3.6: Bar diagram representing Standard Deviation -SD of comparat ive 
CAG repeat size in Normal Female and SCZ Female at Sam6 locus 
(GRIK2) gene locus and Schizophrenia expression in the North-Indian Female 
population. 
1.3.6 Sam6: Four (4) polymorphic TNR alleles (Table 1.3) were identified at Sam6 
(CTGBl) locus -12, 14, 15 and 16 (CAG)(n) repeats in our both Normal and 
Schizophrenic Female study samples. 14 (CAG)(n) repeat allele was proportionally 
the most common of all alleles present in our both Normal (60%) and Schizophrenic 
(50%) Female samples. 15 repeat allele was present in Schizophrenic Female only 
(20%). However, 16 repeat allele, the highest in the range was also present in both 
Normal and Schizophrenic (10%) Female (Fig.I.3.6). Aggregate P-value as per Chi 
square test (P=0.027) (Table 1.3) showed no significant difference in polymorphic 
allele frequencies observed on the Sam6 (CTGBl) gene locus between the Normal 
and Schizophrenic Female samples. Fishers exact test analysis at individual allelic 
repeats showed a significant difference at 15 repeat alleles, however all other alleles 
showed non-significant values (Table 1.3). Hence, our study suggested though 15 
repeat allele might play a role in Schizophrenia susceptibility in Female patients but 
all other repeats showed no evidence in support of association of (CAG)(n) TNR 
polymorphism on Sam6 (CTGBl) locus and Schizophrenia expression in the North-
Indian Female population as per our study sample. 
56 
Table 1.4: Allele distribution of candidate loci in Normal Male and Schizophrenic Male and P values using 
Fishers exact and Chi square test. 
Locus 
Sam, 
Sam2 
Sam3 
Sam4 
Sanfij 
Same 
Repeat 
Observed 
CTG 
CAG 
CTG 
AAT 
AAT 
CAG 
Allele 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
6 
1 
2 
3 
4 
5 
6 
7 
1 
2 
3 
4 
No. of 
Repeats 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
6 
9 
10 
11 
13 
35 
36 
37 
38 
39 
40 
• 20 
21 
22 
23 
24 
25 
26 
12 
14 
15 
16 
Normal Male 
No. of 
Chromosomes 
4 
0 
4 
4 
8 
0 
12 
4 
0 
4 
0 
0 
4 
0 
4 
4 
4 
8 
4 
0 
0 
4 
4 
0 
4 
0 
8 
12 
16 
4 
0 
12 
4 
12 
8 
4 
0 
4 
4 
4 
8 
20 
0 
0 
16 
20 
4 
0 
Frequency 
% aqe 
10 
0 
10 
10 
20 
0 
30 
10 
0 
10 
0 ^ 
0 
10 
0 
10 
10 
10 
20 
10 
0 
0 
10 
10 
0 
10 
0 
20 
30 
40 
10 
0 
30 
10 
30 
20 
10 
0 
10 
10 
10 
20 
50 
0 
0 
40 
50 
10 
0 
Schizophrenic Male 
No. of 
Chromosomes 
4 
0 
4 
4 
4 
0 
8 
4 
0 
8 
4 
0 
4 
0 
4 
0 
4 
4 
8 
0 
4 
4 
4 
0 
4 
0 
8 
12 
16 
4 
0 
12 
0 
16 
8 
4 
0 
4 
0 
4 
4 
24 
4 
0 
8 
24 
4 
4 
Frequency 
%aqe 
10 
0 
10 
10 
10 
0 
20 
10 
0 
20 
10 
0 
10 
0 
10 
0 
10 
10 
20 
0 
10 
10 
10 
0 
10 
0 
20 
30 
40 
10 
0 
30 
0 
40 
20 
10 
0 
10 
0 
10 
10 
60 
10 
0 
20 
60 
10 
10 
Alleles.Normal vs. SCZ Male 
Fishers exact 
P- value 
0.644 
0.000 
0.644 
0.644 
0.174 
0.000 
0.220 
0.644 
0.000 
0.174 
0.058 
0.000 
0.644 
0.000 
0.644 
0.058 
0.644 
0.174 
0.174 
0.000 
0.058 
0.644 
0.644 
0.000 
0.644 
0.000 
0.610 
0.596 
0.590 
0.644 
0.000 
0.596 
0.058 
0.241 
0.610 
0.644 
0.000 
0.644 
0.058 
0.644 
0.174 
0.250 
0.058 
0.000 
0.043 
0.250 
0.644 
0.058 
Chi square 
P- value 
0.127 
0.229 
1.000 
0.334 
0.084 
0.071 
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Figure 1.4.1: Bar diagram representing comparative CTG repeat size in SCZ 
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CTG repeat size in SCZ Male and SCZ Female at Sam1 locus 
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Figure 1.4.2: 2-D Bar diagram representing Standard Deviation -SD of comparative 
CAG repeat allele size in SCZ Male and SCZ Female at Sam2 locus 
I.4.TNR Allele Polymorphism in Schizophrenic Male vs. 
Schizophrenic Female: No/Inter-Gender Association. 
1.4.1 Saml: In Male and Female Schizophrenic patient samples of our study, a highly 
polymorphic frequency of (CTG)(n) repeat alleles-Twelve (12) in the range of 9-20 
(CTG)(n) repeats (Table 1.4) were observed at this locus. Highest number of triplet 
repeat expansion (20 repeats) was detected in Female Schizophrenic patient (10%) of 
our study sample. 15 (20%) and 18 (30%) repeat alleles were the most frequent allelic 
conditions in Male sample and 15 (20%) in Female study samples (Fig.I.4.1). An 
aggregate Chi Square test analysis of allele frequencies of CTG repeats at Saml 
(CTG-B33) locus (Table 1.4) between our comparative samples revealed difference 
was highly significant (P=0.000). Fisher exact test calculated individually at all the 
repeat allele frequencies (Table 1.4), however, showed a non-significant difference 
between all the allele frequencies of these two groups. Thus in our gender bias study 
sample, though none of the specific repeat allele at Saml (CTG-B33) locus was 
responsible for disease expression but the overall repeat expansion might possibly 
play a strong role of association between the CTG repeats and the Schizophrenia 
expression in Female Schizophrenic compared to Male patients atleast in North-
Indian population. 
1.4.2 Sam2: A highly polymorphic repeat locus with Fourteen (14) (CTG)(n) repeat 
alleles (Table 1.4) in the range of 9-22 repeats observed in our Schizophrenic Male 
and Schizophrenic Female study sample at Sam2 (CTG-B37) locus. Allele with 15 
(CTG) repeats was observed in maximum proportion in both Male (20%) and Female 
(20%) Schizophrenic samples. All other alleles present in either group were present in 
10% proportion (Fig.I.4.2). Application of Chi Square test on allele frequencies at this 
locus in our samples (Table 1.4) endorsed statistically significant results (P=0.001) for 
genetic association of polymorphism with Schizophrenia in gender bias at this Sam2 
(CTG-B37) locus. However, Fishers exact test at all the alleles showed a persistent 
non-significant difference throughout (Table 1.4). Thus, on basis of gender bias of the 
study samples though no unusually long alleles that would suggest abnormal 
expansion of the TNR were observed for any of the alleles. But evidence for a strong 
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Figure 1.4,4: 2-D Bar diagram representing Standard Deviation -SD of comparative 
AAT repeat allele size in SCZ Male and SCZ Female at Sam4 locus 
role of this rNR-containing gene locus in expressing Schizophrenia in Female patient 
compared to Male patient involved was found in our North-Indian study sample. 
1.4.3 Sam3: All samples. Schizophrenic Male and Schizophrenic Female had Eight 
(8) (CTG)(n) repeat alleles in the range of 6-13 CTG repeats (Table 1.4) at this locus. 
Repeat alleles were present in varied proportion in both Male and Female SCZ patient 
at Saml gene locus in our samples. (CTG) repeat allele with 10 repeats was present in 
both samples in highest proportion equally (40%). Though allele with longest number 
of TNR repeat that is 13 was present in Female Schizophrenic patient (5%) (Fig.1.4.3) 
but our data on statistical analysis as per Chi Square test (Table 1.4) rendered the 
difference in allele frequency at Sam3 locus insignificant (P=0.308). Also, Fishers 
exact test for all the repeats at Sam3 locus (Table 1.4) showed a non-significant trend 
persistently throughout. This suggests that expansion at Sam3 (NOTCH4) gene locus 
was not linked with the Schizophrenia disease in our gender bias study samples. Thus 
on comparative basis, as per our study sample, we found no evidence of association of 
(CTG)(n) triplet repeat expansion at Sam3 gene locus with Schizophrenia expression 
in any of the gender population of North-Indian descent. 
1.4.4 Sam4: In our Schizophrenic Male and Schizophrenic Female sample study, we 
observed Six (6) TNR (AAT)(n) alleles in the range of 35-40 repeats (Table 1.4) on 
the polymorphic repeat locus of Sam4 (DTNBPl). Of all the alleles present on this 
locus, TNR allele 37 was most prominently present equally in both the Male and 
Female (40%) Schizophrenic samples of our study. Though 40 repeat allele was found 
in Female Schizophrenia (10%) (Fig.I.4.4), as per the aggregate Chi Square (P=0.072) 
and individual Fishers exact test of allele frequencies, the statistical analysis (Table 
1.4) did not support the involvement of gender with expansion of trinucleotide 
(AAT)(n) on Sam4 locus in our study. Thus, we observed that susceptibility to 
Schizophrenia was not influenced by poljanorphic expansion at the Sam4 (DTNBPl) 
gene locus in Female gender compared to Male gender of North-Indian descent. 
1.4.5 SamS: In our study sample, we observed overall Seven (7) alleles (20-27) of 
(AAT)(n) repeat expansion (Table 1.4) at SamS (GRK12) locus in Schizophrenic Male 
and Schizophrenic Female groups. Of all the alleles, 24 repeat allele was most 
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comparartive CAG repeat size in SCZ Male and SCZ Female at Sam6 locus 
frequently observed in both Male and Female (60%) Schizophrenic patients under 
study. The 26 TNR allele was seen in Female Schizophrenics (10%) (Fig.I.4.5), 
However, the aggregate statistical analysis of the allele frequencies between 
comparative Schizophrenic subjects as per Chi square test (Table 1.4) showed no 
significance (P=0.014). Fishers exact test also persistently showed no significant 
difference in allele frequencies individually between Male and Female Schizophrenic 
subjects (Table 1.4). Thus no association was determined between the Sam5 (GRIK2) 
locus polymorphism and Schizophrenia of Female gender compared to Male patient 
gender of North-Indian population as per our study. 
1.4.6 Sain6: Five (5) Trinucleotide Repeat TNR (CAG)(n) alleles with repeats in the 
range of 12-16 (Table 1.4) were observed in our study samples at Sam6 (CTG-Bl) 
locus. Allele with highest number of (CAG) repeats-16 was present in both 
Schizophrenic Male and Schizophrenic Female subjects of our study sample (10%). 
Of all the alleles observed, 14 repeat allele was present in maximum proportion in 
both Male (60%) and Female (50%) Schizophrenic study samples (Fig.I.4.6). 
However, the aggregate and individual statistical analysis of the allelic frequencies 
between the comparative groups at this locus as per both Chi square (P=0.638) and 
Fishers exact test (Table 1.4) showed insignificance. Thus, our study sample observed 
that TNR polymorphic expansion of gene locus Sam6 (CTG-Bl) showed no positive 
association of expression of Schizophrenia with Female gender in comparison to Male 
patient gender of North-Indian descent. 
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Table 1.5; Allele distribution of candidate loci in Normal Female and Schizophrenic Female patients and P values using 
Fishers exact and Chi square test. 
Locus 
Sami 
Sam2 
Sarri] 
Sam4 
Sams 
Same 
Repeat 
Observed 
CTG 
CAG 
CTG 
AAT 
AAT 
CAG 
Allele 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
6 
1 
2 
3 
4 
5 
6 
7 
1 
2 
3 
4 
No. of 
Repeats 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
6 
9 
10 
11 
13 
35 
36 
37 
38 
39 
40 
20 
21 
22 
23 
24 
25 
26 
12 
14 
15 
16 
Normal Female 
No. of 
Chromosomes 
0 
4 
0 
4 
8 
4 
8 
0 
4 
4 
4 
0 
0 
4 
0 
0 
4 
8 
8 
0 
4 
4 
4 
0 
0 
4 
8 
16 
16 
0 
0 
12 
4 
8 
12 
4 
0 
0 
4 
4 
8 
20 
4 
0 
12 
24 
0 
4 
Frequency 
% age 
0 
10 
0 
10 
20 
10 
20 
0 
10 
10 
10 
0 
0 
10 
0 
0 
10 
20 
20 
0 
10 
10 
10 
0 
0 
10 
20 
40 
40 
0 
0 
30 
10 
20 
30 
10 
0 
0 
10 
10 
20 
50 
10 
0 
30 
60 
0 
10 
Schizophrenic Female 
No. of 
Chromosomes 
0 
4 
0 
4 
8 
0 
6 
0 
4 
4 
0 
4 
0 
4 
0 
0 
0 
4 
8 
4 
4 
4 
4 
4 
0 
4 
a 
8 
16 
4 
4 
8 
4 
16 
4 
4 
4 
0 
4 
0 
4 
24 
4 
4 
8 
20 
8 
4 
Frequency 
%age 
0 
10 
0 
10 
20 
0 
30 
0 
10 
10 
0 
10 
0 
10 
0 
0 
0 
10 
20 
10 
10 
10 
10 
10 
0 
10 
20 
20 
40 
10 
10 
20 
10 
40 
10 
10 
10 
0 
10 
0 
10 
60 
10 
10 
20 
50 
20 
10 
Mleies.Normal vs SCZ Female 
Fishers exact 
P- value 
0.000 
0.644 
0.000 
0.644 
0.610 
0.058 
0.220 
0.000 
0.644 
0.644 
0.058 
0.058 
0.000 
0.644 
0.000 
0.000 
0.058 
0.174 
0.610 
0.058 
0.644 
0.644 
0.644 
0.058 
0.000 
0.644 
0.610 
0.043 
0.610 
0.058 
0.058 
0.220 
0.644 
0.043 
0.024 
0.644 
0.058 
0.000 
0.644 
0.058 
0.174 
0.250 
0.644 
0.058 
0.220 
0.250 
0.003 
0.644 
Chi square 
P- value 
0.119 
0.148 
0.031 
0.043 
0.084 
0.027 
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Figure 1.5.1: 2-D Bar diagram representing Standard Deviation -SD of 
comparartive CTG repeat size in SCZ(Mild-Avg.)and Chronic SCZ patients at 
Sam1 locus 
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Figure 1.5.2: 2-D Bar diagram representing Standard Deviation -SD of comparative 
CAG repeat size in SCZ(Mild-Avg.)and Chronic SCZ at Sam2 locus 
1.5. No/ Association of TNR Allele polymorphism with Schizophrenia 
between Schizophrenia (Mild-Avg.)/Chronic Schizophrenia 
1.5.1 Saml: Twelve (12) (CTG)(n) repeat alleles (Table 1.5) were detected in the 
range of 9-20 repeats in our comparative study samples of Schizophrenia (Mild-Avg.) 
and Chronic Schizophrenia. 13 and 15 (CTG)(n) repeat alleles in Schizophrenia 
(Mild-Avg.) (20%) while 15 repeat allele in Chronic Schizophrenia (30%) were 
expressed in maximum proportion in our study samples. The 20 repeat allele was 
observed only in Chronic Schizophrenia (10%), however, other alleles observed in 
either sample group were present in 10-20% proportion (Fig.I.5.1). Statistically 
aggregate allelic frequency analysis at Saml (CTG-B33) locus as per Chi square test 
(P=0.000) (Table 1.5) showed highly significant value. However, Fishers exact test 
analysis at all the individual allelic frequencies (Table 1.5) showed insignificant 
differences. Thus our investigation of the effect of an exotic (CTG)(n) polymorphism 
at Saml (CTG-B33) locus on the disease intensity though showed no evidence of 
association of specific repeat expansion at this locus with Schizophrenia. However, 
overall a highly positive association of the polymorphism at this locus with the 
disease expression intensity within the respective Schizophrenic comparison groups 
as per our North-Indian study sample was observed. 
1.5.2 Sam2: Trinucleotide repeat polymorphism was quiet evident with detection of 
Fourteen (14) TNR (CAG)(n) alleles in the range of 9-22 repeats (Table 1.5) in our 
Schizophrenia (Mild-Avg.) and Chronic Schizophrenia study sample. (CAG)(n) TNR 
allele with 15 repeats was the most expressed allele (20%) in both our comparative 
sample groups. 22 repeat allele, the highest at this locus in our study was observed in 
Chronic Schizophrenic (10%) sample (Fig.I.5.2). Chi-square statistical analysis of 
overall allelic frequencies at this locus between Schizophrenia (Mild-Avg.) and 
Chronic Schizophrenia samples (Table 1.5) showed a highly significant (P=0.001) 
value. Fishers exact test analysis at all individual repeats, however, was insignificant 
(Table 1.5). Thus we identified evidence of connection between expansion of 
(CAG)(n) trinucleotide repeat alleles of the Sam2 (CTG-B37) locus to intensity of the 
disease expression in North-Indian Schizophrenic subjects as per our study sample 
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Figure 1.5.4: 2-D Bar diagram representing Standard Deviation -SD of comparative 
AAT repeat sizr in SCZ(Miid-Avg.) and Chronic SCZ at Sam4 locus 
though none of the repeat expansion at this locus was specifically identified as 
involved in Schizophrenia expression intensity. 
1.5.3 Sam3: Eight (8) (CTG)(n) polymorphic Trinucleotide Repeat alleles in the range 
of 6-13 repeats (Table 1.5) were identified at this locus in our Schizophrenia (Mild-
Avg.) and Chronic Schizophrenia sample study. 10 repeat allele was the most 
expressed allele (40%) in both samples under study. Allele with highest (CTG) 
repeats -13 repeats was present in Chronic Schizophrenia (10%) (Fig.I.5.3). 
Aggregate stafisfical analysis on the basis of Chi square test (P=0.308) and Fishers 
exact test at individual allelic frequencies (Table 1.5) showed insignitlcant values 
which did not support any correlation between the (CTG)(n) polymorphism and 
disease expression in our Schizophrenia subtypes' study samples. Thus Sam3 
(N0TCH4) locus allelic variability due to triplet expansion was not correlated with 
intensity of the disease expression in our comparative North-Indian Schizophrenia 
(Mild-Avg.) and Chronic Schizophrenia study samples. 
1.5.4 Sam4: At this locus Six (6) polymorphic (AAT)(n) alleles in the range of 35-40 
(AAr)(n) repeats (Table 1.5) were detected in our Schizophrenia (Mild-Avg.) and 
Chronic Schizophrenia study samples. Of all the alleles present, 37 repeat allele was 
expressed proportionally the maximum (40%) in both the samples. Highest number of 
TNR allele, i.e.40 repeat was present in Chronic Schizophrenic (10%) (Fig.I.5.4). 
Statistical analysis as per Chi square test (P=0.()72) and Fishers exact test (Table 1.5) 
showed no significant difference in allele frequencies between Schizophrenic (Mild-
Avg.) and Chronic Schizophrenic patients in our study sample. Thus as per our 
comparative North-Indian Schizophrenia subtypes' sample study, there was no 
significant association on Sam4 (DTNBPl) locus between investigated polymorphic 
allelic variants due to (AAT)(n) expansion and intensity of disease expression in 
Chronic Schizophrenia compared to Schizophrenics (Mild-Avg.) and our study does 
not support the view that the investigated Sam4 (NOTCH4) locus had major influence 
on susceptibility to Schizophrenia intensity. 
1.5.5 Sam5: Based on the data of allele frequencies obtained after sequencing PCR 
product, Seven (7) types of (AAT)(n) TNR alleles (Table 1.5) were detected in 
Schizophrenic (Mild-Avg.) and Chronic Schizophrenia of our study sample at this 
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locus. (AAT)(n) repeat alleles identified were 20-26 repeats range. Of all the alleles 
present, 24 repeat allele was the most prominent allele expressed in both 
Schizophrenics (Mild-Avg,) and Chronic Schizophrenia (60%) (Fig.I.5.5). 26 repeat 
allele was present in Chronic Schizophrenia (10%). The statistical analysis for effect 
of TNR expansion on disease intensity of Schizophrenic patients with respect to locus 
Sam5 (GRIK2) as per Chi square test (P=0.014) and Fishers exact test analysis on 
individual allelic frequencies (Table 1.5) was insignificant. Thus as per our study, we 
failed to find any association between the TNR (AAT)(n) polymorphic expansion at 
Sam5 (GRIK2) locus and Schizophrenia expression intensity between subgroups of 
Schizophrenia in our North-Indian Schizophrenia study sample. 
1.5.6 Sam6: Five (5) polymorphic repeat alleles with (CAG)(n) repeats in the range of 
12-16 repeats (Table 1.5) were observed at this locus in our Schizophrenic (Mild-
Avg.) and Chronic Schizophrenia patient study sample. Highest repeat allele - 16 
repeats was present in both the Schizophrenics (Mild-Avg,) and Chronic 
Schizophrenia samples, allele with 14 (CAG) was proportionally the most common 
allele in both samples equally (60%) (Fig.I.5.6). Both aggregate Chi square (P=0.638) 
and individual Fishers exact test analysis of allele frequencies between our 
comparative study samples (Table 1.5) showed non-significant values. Thus our 
results showed no association between the (CAG)(n) repeat allele polymorphism at 
Sam6 (CTGBl) locus and the disease intensity indicating that a significant role for the 
Sam6 (CTGBl) gene locus in Schizophrenia expression might be ruled out atleast in 
the North-Indian Schizophrenic population as per our study sample. 
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TNR Genotype Polymorphism Results 
(11) 
Table 11.1: Frequency of genotypes of gene loci studied with Variable Number of Tandem Repeats (VNTR) 
in Normal Individuals and Schizophrenic patients and P-values. 
Locus 
Sam^ 
Sam2 
Samj 
Sam4 
Sams 
Same 
Genotype 
9 - 1 1 
1 0 - 1 0 
1 2 - 1 3 
1 ? - 1 4 
1 2 - 1 5 
1 3 - 1 5 
1 3 - 1 6 
1 3 - 1 7 
1 5 - 1 5 
1 5 - 1 6 
1 5 - 1 8 
1 8 - 1 9 
1 8 - 2 0 
9 - 1 1 
1 0 - 1 0 
1 2 - 1 3 
1 3 - 1 4 
1 4 - 1 4 
1 4 - 1 8 
1 5 - 1 5 
1 5 - 1 6 
1 5 - 1 7 
1 5 - 1 8 
1 9 - 2 1 
1 9 - 2 2 
2 0 - 2 0 
6 - 6 
6 - 9 
6 - 1 0 
6 - 1 1 
6 - 1 3 
9 - 9 
9 - 1 0 
9 - 1 1 
9 - 1 3 
1 0 - 1 0 
3 5 - 3 5 
3 5 - 3 6 
3 5 - 3 7 
3 5 - 3 8 
3 5 - 3 9 
3 6 - 3 7 
3 6 - 3 8 
3 7 - 3 7 
3 7 - 3 8 
3 8 - 3 9 
3 9 - 4 0 
2 0 - 2 0 
2 1 - 2 1 
2 1 - 2 2 
2 1 - 2 3 
2 2 - 2 3 
2 3 - 2 4 
2 4 - 2 4 
2 4 - 2 5 
2 4 - 2 6 
1 2 - 1 2 
1 2 - 1 4 
1 2 - 1 5 
1 2 - 1 6 
1 4 - 14 
1 4 - 1 5 
1 4 - 1 6 
Control /Normal 
No. of 
Individuals 
4 
2 
2 
4 
2 
6 
4 
4 
4 
0 
4 
4 
0 
4 
2 
4 
4 
2 
8 
4 
0 
4 
0 
4 
4 
0 
4 
2 
4 
2 
0 
8 
8 
2 
0 
10 
4 
2 
4 
8 
2 
4 
2 
4 
4 
6 
0 
2 
2 
2 
2 
6 
8 
14 
4 
0 
6 
12 
2 
2 
14 
2 
2 
Frequency 
0.1 
0.05 
0.05 
0.1 
0.05 
0.15 
0.1 
n 1 
0.1 
0 
0.1 
0.1 
0 
0.1 
0.05 
0.1 
0.1 
0.05 
0.2 
0.1 
0 
0.1 
0 
0.1 
0.1 ' 
0 
0.1 
0.05 
0.1 
0.05 
0 
0.2 
0.2 
0.05 
0 
0.25 
0.1 
0.05 
0.1 
0.2 
0.05 
0.1 
0.05 
0.1 
0.1 
0.15 
0 
0.05 
0.05 
0.05 
0.05 
0.15 
0.2 
0.35 
0.1 
0 
0.15 
0.3 
0.05 
0.05 
0.35 
0.05 
0.05 
Schizophrenic Patient 
No.of 
Indh^iduals 
4 
2 
4 
0 
4 
2 
2 
4 
4 
2 
4 
4 
4 
4 
0 
4 
4 
0 
0 
4 
8 
4 
2 
4 
4 
2 
2 
4 
2 
4 
2 
4 
2 
4 
2 
14 
4 
2 
2 
6 
2 
2 
0 
12 
4 
2 
4 
2 
2 
0 
0 
4 
4 
16 
8 
4 
4 
2 
4 
2 
14 
8 
6 
Frequency 
0.1 
0.05 
0.1 
0 
0.1 
0.05 
0.05 
n i 
0.1 
0.05 
0.1 
0.1 
0.1 
0.1 
0 
0.1 
0.1 
0 
0 
0.1 
0.2 
0.1 
0.05 
0.1 
0.1 
0.05 
0.05 
0.1 
0.05 
0.1 
0.05 
0.1 
0.05 
0.1 
0.05 
0.35 
0.1 
0.05 
0.05 
0.15 
0.05 
0.05 
0 
0.3 
0.1 
0.05 
0.1 
0.05 
0.05 
0 
0 
0.1 
0.1 
0.4 
0.2 
0.1 
0.1 
0.05 
0.1 
0.05 
0.35 
0.2 
0.15 
Fishers exact 
P-value 
0.644 
0.692 
0.338 
0.058 
0.338 
0.132 
0.338 
0 644 
0.644 
0.247 
0.644 
0.644 
0.058 
0.644 
0.247 
0.644 
0.644 
0.247 
0.003 
0.644 
0.003 
0.644 
0.247 
0.644 
0.644 
0.247 
0.338 
0.338 
0.338 
0.338 
0.247 
0.174 
0.044 
0.338 
0.247 
0.232 
0.644 
0.692 
0.338 
0.385 
0.692 
0.338 
0.247 
0.024 
0.644 
0.132 
0.058 
0.692 
0.692 
0.247 
0.247 
0.338 
0.174 
0.409 
0.174 
0.058 
0.369 
0.003 
0.338 
0.692 
0.593 
0.044 
0.132 
Chi square 
P-value 
0.301 
0.020 
0.166 
0.191 
0.121 
0.032 
Genotype <' s"'^  .^ ^ >^ 
• f t ) -
I Normal indiv. 
I Schizophrenic 
Normal indiv. 
5!>- r,Q-
-s^ ^ .^^^ .^^^ / 
Figure 11.1.1: Histogram showing comparative frequency of genotypic combinations 
observed in Normal individuals and Schizophrenic patients at Sami locus 
I Normal indivi. 
I Schizophrenic 
Genotype 
Figure 11.1.2: Histogram showing comparative frequency of genotypic combinations 
observed in Normal individuals and Schizophrenic patients at Sam2 locus 
II.l. Genotype frequency between Normal and Schizophrenia: 
Negative / Positive effect of TNR expansion on disease 
11.1.1 Saml: In Normal individuals and Schizophrenic patients of our study sample, 
highly polymorphic genotype distribution was found at Saml (CTG-B33) locus with 
overall Thirteen (13) combinations (Table II.l). The frequencies of genotypes 
observed in these two groups were in 5-10% in proportion. Normal sample had 
highest of 13/15 CTG repeat allele marker genotype (15%) and had no combination of 
15/16 and 18/20 genotypes observed in Schizophrenic patients. Schizophrenic patient 
samples did not show 12/14 repeat combination (Fig. II.l.l). Statistical analysis of 
genotypic frequencies for TNR microsatellite marker (CTG)(n) at Saml (CTG B33) 
locus as per Chi square test (P=0.301) (Table II.l) showed insignificant value. As per 
Fishers exact test, analysis at individual genotypic frequencies between the Normal 
and Schizophrenia groups showed significant value at 12/14 genotypic combination 
(P=0.003) but all other frequencies showed insignificant values (Table II.l). Odds 
ratio at this genotype calculated (8.14) showed the risk to be prominent in this 
combination. Thus, as per our study sample, the combination 12/14 of the locus may 
be the cause of Schizophrenia susceptibility. However, in aggregate no risk to 
Schizophrenia expression due to (CTG) repeat length variation at Saml (CTG-B33) 
locus in North-Indian population was observed. 
11.1.2 Sain2: Total of Thirteen (13) TNR (CTG)(n) genotypic combinations (Table 
II.l) were found in our study sample, a highly vague and spread out result. 
Proportionally the most common genotype combination in Normal individuals was 
14/18 (20%) with 15/16, 15/18 and 20/20 genotypes present in SCZ patients, absent. 
Schizophrenic sample had 15/16 (20%) genotype as the common genotype with 
10/10, 14/18 and 14/14 genotypes of Normal individuals absent (Fig. II. 1.2). 
Genotype analysis for association of (CTG)(n) repeat expansion with Schizophrenia 
susceptibility at Sam2 (CTG-B37) locus in Normal and Schizophrenic population is 
negative as shown by the calculated Chi square P value (P=0.020) (Table II.l). 
Fishers exact test analyses at individual genotypic repeat combinations showed 
significance at 14/18 (P=0.003) and 15/16 (P=0.003) combinations (Table II.l). Odds 
ratio calculated at these two combinations showed a prominent risk of susceptibility to 
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Figure 11.1.4: Histogram showing comparative frequency of genotypic combinations in 
Normal individuals and Schizophrenic patients at Sam4 locus 
Schizophrenia. All other genotypes observed showed insignificant values. Thus our 
observations as per study sample were that though two genotypic combinations at this 
locus may play a role in Schizophrenia expression but overall a negative role has 
beeen analysed of this locus in Schizophrenia susceptibility. 
11.1.3 Sam3: Total of Ten (10) genotypes (Table II. 1) were seen in our study sample 
at this Sam3 (NOTCH4) locus. 10/10 genotype was proportionally the most prominent 
of genotypes present in both Normal (25%) and Schizophrenic patient (35%) sample 
with 6/13, 9/13 combinations absent in Normal sample of our study. However in 
Schizophrenic patient sample rest of the genotypes were expressed in 5-10% 
proportion (Fig. II. 1.3). Genotype analysis for microsatellite marker (CTG)(n) studied 
in Normal and Schizophrenia for Sam3 locus showed no significant difference as per 
Chi square test (P=0.166). Fishers exact test analysis at individual genotypic 
combinations (Table II. 1) also showed non-significant values throughout. These 
results did not support association between (CTG)(n) triplet repeat expansion at Sam3 
(NOTCH4) locus and Schizophrenia susceptibility in North-Indian population as per 
our study sample. 
11.1.4 Sain4: We genotyped Eleven (11) trinucleotide (AAT)(n) microsatellite 
polymorphic repeats within the Sam4 (DTNBPl) gene locus (Table II. 1) in our 
Normal and Schizophrenic patient study sample. In Normal sample of our study, 
35/38 was the most common genotype (20%) detected. 39/40 genotype was however, 
absent. In Schizophrenic patients, 37/37 homozygous was the most common genotype 
(30%) in the study sample with 36/38 combinafion absent (Fig. II.1.4). Stafistical 
calculation of the genotypic combination frequencies at this locus with Chi square test 
(P=0.191) could not detect significant value of association (Table II. 1) between the 
Normal and Schizophrenia samples of our study. Fishers exact test analysis of 
individual genotypic frequencies at polymorphic Sam4 locus (Table II.I) also showed 
non-significant values throughout. In conclusion, our results as per study sample 
suggest that TNPs genotype in the Sam4 (DTNBPl) locus was unlikely to play a 
major role in the pathophysiology of Schizophrenia in North-Indian population. 
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Figure 11.1.6: Histogram showing comparative frequency of genotypic combinations in 
Normal individuals and Schizophrenic patients at Sam6 locus 
11.1.5 Sam5: Nine (9) genotypic combinations (Table II.1) were identified in our 
Normal and Schizophrenic study sample. In Normal sample, 24/24 genotype is most 
common one (30%) with 24/26 genotype absent. In Schizophrenic patient sample, 
24/24 is proportionally most prominent genotype (40%) with 21/22 and 21/23 
combinafions absent (Fig.II.1.5). Genotype analysis for (AAT)(n) microsatellite 
markers at locus Sam5 (GRIK2) showed no significant association with the 
Schizophrenia disorder as is evident fi-om the statistical calculation of both aggregate 
Chi square (P=0.121) and Fishers exact test analysis at individual genotypic 
fi-equencies observed at Sam5 (GRIK2) locus in our study sample (Table II. 1). 
11.1.6 Sam6: Seven (7) genotypes at this locus Sam6 (CTGBl) (Table II. 1) were 
detected in our Normal and Schizophrenic study sample. In both Normal and 
Schizophrenia samples, 14/14 genotype was the most prominent genotype (35%) in 
both groups, rest of the genotypes were in 5-15% proportion (Fig. II. 1.6). As per Chi 
square test (P=0.032), analysis of genotypic fi^equencies of CAG VNTRs 
(microsatellites) at this locus (Table II. 1) did not show any significant difference in 
Schizophrenic patients compared to Normal population. Fishers exact test at all 
individual geriotypic frequencies between these two comparative groups showed a 
significant value of difference at 12/14 genotype (0.003) (Table II.1). However, the 
rest of the genotypic combinations showed insignificant values. Odds ratio calculated 
at this genotype (8.14) showed a prominent risk of Schizophrenia to possessor of the 
repeat combinafion. Thus, at Sam6 (CTGBl) locus, 12/14 genotype may be a 
schizophrenia susceptible genotype, however no association of CAG repeat expansion 
with the disorder in the Normal and Schizophrenic North-Indian population was 
recognized in the overall analysis of this locus as per our samples' study. 
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Table 11.2: Frequency of genotypes of gene loci studied with Variable Number of Tandem Repeats 
(VNTR) in Normal Male and Schizophrenic Male and P-values 
Locus 
Sam^ 
Sam2 
Samj 
Sam4 
Samj 
Samg 
Genotype 
9 - 1 1 
1 2 - 1 3 
1 2 - 1 5 
1 3 - 1 5 
1 3 - 1 6 
1 5 - 1 5 
1 5 - 1 6 
1 5 - 1 8 
1 8 - 1 9 
9 - 1 1 
1 2 - 1 3 
1 3 - 1 4 
1 4 - 1 4 
1 4 - 1 8 
1 5 - 1 5 
1 5 - 17 
1 5 - 1 8 
1 9 - 2 1 
6 - 6 
6 - 9 
6 - 10 
6 - 1 1 
9 - 9 
9 - 1 0 
9 - 1 1 
1 0 - 1 0 
3 5 - 3 5 
3 5 - 3 6 
3 5 - 3 7 
3 5 - 3 8 
3 5 - 3 9 
3 6 - 3 7 
3 7 - 3 7 
3 7 - 3 8 
37-39 
3 8 - 3 9 
2 0 - 2 0 
21 - 2 1 
2 2 - 2 3 
2 3 - 2 4 
2 4 - 2 4 
2 4 - 2 5 
1 2 - 12 
1 2 - 1 4 
1 2 - 1 5 
1 4 - 1 4 
1 4 - 15 
14- 16 
Normal Female 
No. of 
Individuals 
4 
2 
2 
2 
4 
2 
0 
4 
0 
4 
4 
0 
2 
4 
2 
0 
0 
4 
2 
2 
0 
2 
2 
4 
2 
6 
2 
2 
2 
2 
2 
2 
2 
4 
0 
2 
2 
2 
4 
4 
8 
0 
4 
6 
2 
6 
2 
0 
Frequency 
0.2 
0.1 
0.1 
0.1 
0.2 
0.1 
0 
0.2 
0 
0.2 
0.2 
0 
0.1 
0.2 
0.1 
0 
0 
0.2 
0.1 
0.1 
0 
0.1 
0.1 
0.2 
0.1 
0.3 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.2 
0 
0.1 
0.1 
0.1 
0.2 
0.2 
0.4 
0 
0.2 
0.3 
0.1 
0.3 
0,1 
0 
SCZFe 
No.of 
individuals 
4 
2 
2 
0 
2 
0 
2 
4 
4 
4 
0 
4 
0 
0 
0 
4 
4 
4 
2 
2 
2 
0 
2 
2 
4 
6 
2 
0 
0 
6 
2 
0 
8 
0 
2 
0 
2 
0 
4 
0 
10 
4 
2 
2 
2 
8 
2 
4 
male 
Frequency 
0.2 
0.1 
0.1 
0 
0.1 
0 
0.1 
0.2 
0.2 
0.2 
0 
0.2 
0 
0 
0 
0.2 
0.2 
0.2 
0.1 
0.1 
0.1 
0 
0.1 
0.1 
0.2 
0.3 
0.1 
0 
0 
0.3 
0.1 
0 
0.4 
0 
0.1 
0 
0.1 
0 
0.2 
0 
0.5 
0.2 
0.1 
0.1 
0.1 
0.4 
0.1 
0.2 
Fishers exact 
P-value 
0.653 
0.698 
0.698 
0.244 
0.331 
0.244 
0.244 
0.653 
0.053 
0.653 
0.053 
0.053 
0.244 
0.053 
0.244 
0.053 
0.053 
0.653 
0.698 
0.698 
0.244 
0.244 
0.698 
0.331 
0.331 
0.634 
0.698 
0.244 
0.244 
0.118 
0.698 
0.244 
0.032 
0.053 
0.244 
0.244 
0,698 
0,244 
0,653 
0,053 
0,376 
0,053 
0,331 
0,118 
0,698 
0,371 
0,698 
0,053 
Chi square 
P-value 
0,221 
0,002 
0,619 
0,021 
0,069 
0,224 
I Normal Male 
ISCZMale I 
Genotype 
Figure 11.2.1: Histogram showing comparative frequency of genotypic combinations 
observed In Normal Male and Schizophrenic Male at Sam1 locus 
I Normal Male 
ISCZMale 
Genotype 
Figure 11.2.2: Histogram showing comparative frequency of genotypic combinations 
observed in Normal Male and Schizophrenic Male at Sam2 locus 
II.2.TNR Genotype Polymorphism between Normal Male vs. 
Schizophrenic Male: Lack of Association with Schizophrenia 
11.2.1 Saml: Nine (9) combinations of genotypes (Table II.2) were detected in male 
intra-gender study. Normal Male had 9/11, 13/16 and 15/18 equally expressed (20%). 
However, of the genotypes expressed 15/16 genotype was absent. In Schizophrenic 
Male 9/11, 15/18 and 18/19 genotypes were detected equally in proportion (20%) in 
our sample but 13/15 and 15/15 genotypes were absent (Fig. II.2.1). Based on 
statistical analysis as per Chi square test (P=0.221) and Fishers exact test at individual 
genotypic frequencies (Table 11.2), no significant difference in frequencies of 
genotypic distributions of the six polymorphisms of the Saml (CTG B33) gene locus 
observed between the Normal Male and Schizophrenic Male patients in our study 
sample. 
11.2.2 Sain2: Nine (9) combinations of (CTG)(n) TNR polymorphic genotypes (Table 
II.2) were detected in our Normal Male and Schizophrenic Male study sample. In 
Nonnal Male 9/11, 12/13, 14/18 and 9/21 were equally expressed (20%) but 
13/14,15/17 and 15/18 were absent. In Schizophrenic Male all the detected genotypes 
were present in equal proportion (20%), however, 12/13, 14/14. 14/18 and 15/15 
genotypes were absent (Fig. 11.2.2). Statistical analysis of genotype frequencies as per 
Chi square test for the Sam2 (CTG-B37) locus between Nonnal Male and 
Schizophrenic Male patients was highly significant (P=0.002) (Table 11.2), thus 
supporting its role as a possible positional candidate gene for schizophrenia. 
However, the statistical analysis of individual genotypic frequencies as per Fishers 
exact test (Table II.2) showed that no particular genotype was associated with 
Schizophrenia. 
11.2.3 Sani3: Eight (8) CTG polymorphic genotypes (Table 11.2) were detected at 
Sam3 (NOTCH4) locus. Of all the genotypes identified in both Normal as well as 
Schizophrenic Male of our study sample, 10/10 was proportionally most common 
(30%) but 6/10 genotype was absent in Normal Male while as 6/1 1 was absent in 
Schizophrenic Male (Fig. II.2.3). Genotype frequency analysis as per Chi square test 
(P=0.619) (Table 11.2) showed no significant association of genotypic polymorphism 
66 
I Normal Male 
ISCZMale 
Genotype 
Figure 11.2.3: Histogram showing comparative frequency of genotypic combinations 
observed in Normal Male and Schizophrenic Male at Sam3 locus 
I Normal Male 
ISCZMale 
Genotype 
Figure 11.2.4: Histogram showing comparative frequency of genotypic combinations 
in Normal Male and Schizophrenic Male at Sam4 locus 
with Schizophrenia at this locus. Fishers exact test analysis at individual genotypic 
frequencies of the locus also showed non-significance (Table 11.2). Thus at Sam3 
(N0TCH4) locus, no association of CTG repeat expansion with the disorder in this 
intra-gender Normal Male and Schizophrenic Male study sample was recognized as 
per our sample study. 
II.2.4 Sain4: Ten (10) types of genotypes representing a high polymorphism (Table 
II.2) were detected in our samples at Sam4 (DTNBPl) locus. Normal Male had 37/38 
genotype as the common (20%) of all the genotypes with absence of one 37/39 
genotype whereas in Schizophrenic Male 37/37 (40%) was expressed the maximum 
times in our sample study but at the same time many genotypes were missing as 
35/36, 35/37, 36/37 and 38/39 (Fig. II.2.4). Aggregate genotypic frequency analysis 
as per Chi square (P=0.021) and individual genotypic frequency analysis by Fishers 
exact test (Table II.2) revealed no significant difference in genotypic distributions of 
the six polymorphisms at the gene locus Sam4 (DTNBPl) between the Normal Male 
and Schizophrenic Male of our study samples. 
IL2.5 Sam5: Six (6) genotypes (Table II.2) were detected at this Sam5 (GRIK2) 
locus. Normal Male had homozygous condition 24/24 as the most common genotype 
(40%) in our sample study with the absence of 24/25 genotype. Schizophrenic Male 
samples of our study also had 24/24 as the most expressed genotype (50%) but some 
genotypes as 21/21 and 23/24 were absent (Fig. II.2.5). Statistical analysis results of 
genotype frequency on Sam5 (GRIK2) locus both in Chi square (P=0.069) and 
Fishers exact test (Table 11.2) indicated that the trinucleotide expansion polymorphism 
of (AAT)(n) repeats was not significantly different in Schizophrenic Male compared 
to Normal Male in North-Indian Male population as per our study sample. 
II.2.6 Sam6: Six (6) genotype combinations (Table II.2) were present in our sample 
study at this locus. In Normal Male sample, 12/14 and 14/14 genotypes were 
proportionally most common both (30%) while 14/16 genotype was not detected in 
our sample. In Schizophrenic Male sample also 14/14 genotype was the most 
common genotype in our study sample (Fig. II.2.6). Statistical analysis of genotype 
frequencies at Sam6 (CTGBl) locus calculated as per Chi square (P=0.224) and 
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I Normal Male 
ISCZMale 
* " " / • / • 4 * 
Genotype / • 
Figure 11.2.5: Histogram showing comparative frequency of genotypic combinations 
in Normal Male and Schizophrenic Male at Sam5 locus 
I Normal Male 
ISCZMale 
Genotype 
Figure 11.2.6: Histogram showing comparatuve frequency of genotypic 
combinations in Normal Male and Schizophrenic Male at Sam6 locus 
Fishers exact test (Table II.2) showed no significance of TNR polymorphism with 
Schizophrenia. Thus our study as per our sample found no association between this 
marker polymorphism and Schizophrenia in North- Indian Male population. 
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Table 11.3: Frequency of genotypes of gene loci studied with Variable Number of Tandem Repeats (VNTR) in 
Normal Female and Schizophrenic Female and P-values. 
Locus 
Sarn^ 
Sam2 
Sam, 
Sam4 
Samj 
Sam^ 
Genotype 
10-10 
12-13 
12-14 
12-15 
13-15 
13-17 
15-15 
18-19 
18-20 
10 -10 
13 -14 
14-18 
15-15 
15-16 
15-17 
19-22 
20 -20 
6 - 6 
6 - 9 
6 - 1 0 
6 - 1 1 
6 - 1 3 
9 - 9 
9 - 1 0 
9 - 1 3 
10 -10 
3 5 - 3 5 
35 -36 
35 -37 
35 -38 
36 -37 
36 -38 
37 -37 
37 -38 
38 -39 
39 -40 
21 - 2 1 
21 - 2 2 
21 - 2 3 
22 -23 
23 -24 
24 -24 
24 -25 
24 -26 
12-12 
12-14 
12-15 
12-16 
14-14 
14-15 
14-16 
Normal Female 
No. of 
Individuals 
2 
0 
4 
0 
4 
4 
2 
4 
0 
2 
4 
4 
2 
0 
4 
4 
0 
2 
0 
4 
0 
0 
6 
4 
0 
4 
2 
0 
2 
6 
2 
2 
2 
0 
4 
0 
0 
2 
2 
2 
4 
6 
4 
0 
2 
6 
0 
2 
8 
0 
2 
Frequency 
0.1 
0 
0.2 
0 
0.2 
0.2 
0.1 
0.2 
0 
0.1 
0.2 
0.2 
0.1 
0 
0.2 
0.2 
0 
0.1 
0 
0.2 
0 
0 
0.3 
0.2 
0 
0.2 
0.1 
0 
0.1 
0.3 
0.1 
0.1 
0.1 
0 
0.2 
0 
0 
0.1 
0.1 
0.1 
0.2 
0.3 
0.2 
0 
0.1 
0.3 
0 
0.1 
0.4 
0 
0.1 
Schizophrenic Female 
No.of 
Individuals 
2 
2 
0 
2 
2 
4 
4 
0 
4 
2 
0 
4 
0 
4 
4 
4 
2 
0 
2 
0 
4 
2 
2 
0 
2 
8 
2 
2 
2 
0 
2 
0 
4 
4 
0 
4 
2 
0 
0 
0 
4 
6 
4 
4 
2 
0 
2 
2 
6 
6 
2 
Frequency 
0.1 
0.1 
0 
0.1 
0.1 
0.2 
0.2 
0 
0.2 
0.1 
0 
0.2 
0 
0.2 
0.2 
0.2 
0.1 
0 
0.1 
0 
0.2 
0.1 
0.1 
0 
0.1 
0.4 
0.1 
0.1 
0.1 
0 
0.1 
0 
0.2 
0.2 
0 
0.2 
0.1 
0 
0 
0 
0.2 
0.3 
0.2 
0.2 
0.1 
0 
0.1 
0.1 
0.3 
0.3 
0.1 
Fishers exact 
P-value 
0.698 
0.244 
0.053 
0.244 
0.331 
0.653 
0.331 
0.053 
0.053 
0.698 
0.053 
0.653 
0.244 
0.053 
0.653 
0.653 
0.244 
0.244 
0.244 
0.053 
0.053 
0.244 
0.118 
0.053 
0.244 
0.15 
0.698 
0.244 
0.698 
0.01 
0.698 
0.244 
0.331 
0.053 
0.053 
0.053 
0.244 
0.244 
0.244 
0.244 
0.653 
0.698 
0.653 
0.053 
0.698 
0.01 
0.244 
0.698 
0.371 
0.01 
0.698 
Chi square 
P-value 
0.027 
0.101 
0.003 
0.007 
0.101 
0.027 
I Normal Female 
ISCZ Female 
Genotype 
Figure 11.3.1: Histogram showing comparative frequency of genotypic combinations in 
Normal Female and Schizophrenic Female patients at Sam1 locus 
I Normal Female 
I SCZ Female 
Genotype 
Figure 11.3.2: Histogram showing comparative frequency of genotypic combinations 
observed in Normal Female nd Schizophrenic Female at Sam2 locus 
lU.Genotypic Frequency comparison between Normal Female vs. 
Schizophrenic Female: No/TNR association with Schizophrenia in 
Intra-Cender Bias. 
11.3.1 SamI: Nine (9) combinations of genotypes (Table 11.3) were detected on this 
locus. In case of Normal Female sample, the genotypes detected were present in 10-
20% proportion but some genotypes 12/13, 12/15, 18/20 observed in Schizophrenic 
Female were not present. In Schizophrenic Female on Saml (CTG B33) locus, 13/17, 
15/15 and 18/20 were the genotypes almost of same proportion (20%) but 12/14 and 
18/19 as such present in Normal samples were undetected in case of Schizophrenic 
Females in our sample (Fig. II.3.1). Genotype distribution frequency analysis as per 
Chi square (P=0.027) and Fishers exact test (Table 11.3) showed insignificant values 
supporting the view that in genotypic polymorphism at this locus in Female patients 
with Schizophrenia was not significantly different from those of the Normal Female 
in our North- Indian study sample. 
n.3.2 Sam2: Eight (8) types of genotypes (Table 11.3) were detected in our Female 
study sample at the Sam2 (CTG-B37) locus. In Nomial Female sample, all the 
genotypes present were in iO-20% proportion except for 15/16 and 20/20 
combinations which were absent in our sample. In Schizophrenic Female, detected 
genotypes were present in 10-20% proportion but 13/14 and 15/15 combinations 
present in Normal were not observed (Fig. 11.3.2). Aggregate statistical analysis of the 
frequency of genotypes at locus Sam2 with Chi square test (P^O.lOl) (Table 11.3) did 
not show any significant difference between the Nonnal Female and Schizophrenic 
Female groups of our study sample. Fishers exact analysis at individual genotypic 
frequencies (Table 11.3) also showed insignificance between the two intra-gender 
groups. The results of our analysis as per our study sample thus provide no evidence 
of association of Schizophrenia in North-Indian Female sex and polymorphism at 
Sam2 (CTG-B37) gene locus. 
II.3.3 Sam3: Nine (9) polymorphic TNR genotypes (Table 11.3) were detected in our 
sample study at this locus. In Normal Female sample, homozygous condition of allele 
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Figure 11.3.3: Histogram showing comparative frequency of genotypic combinations 
observed In Normal Female and Schizophrenic Female at Sam3 locus 
I Normal Female 
I SCZ Female 
Genotype 
Figure 11.3.4: Histogram showing comparative frequency of genotypic combinations 
observed in Normal Female and Schizophrenic Female at Sam4 locus 
9/9 was the most common (30%) genotype markedly accompanied by the absence of 
6/9, 6/11, 6/14 and 9/13 genotypes. Schizophrenic Female had 10/10 genotype as the 
common genotype present (40%) but 6/6, 6/10, 9/10 remained undetected (Fig. 
11.3.3). Statistical analysis of the genotype frequency at Sam3 (N0TCH4) gene locus 
as per Chi square test (P=0.003) detected high significance of genotypic 
polymorphism in Normal and Schizophrenic Female groups in our sample (Table 
II.3). However Fishers exact test at individual genotypic frequencies of the locus 
(Table 11.3) showed none of the combinations with significant values. Thus as per our 
study though none of the genotypic combinations were specifically identified as 
responsible for Schizophrenia but the overall significance showed that the 
polymorphism at this locus may show association with Schizophrenia expression in 
our North-Indian Female study sample. 
11.3.4 Sam4: Highly polymorphic with Ten (10) genotypes (Table II.3) detected at the 
Sam4 (DTNBPl) locus. Normal Female had 35/38 (AAT)(n) repeat allele genotype as 
the common genotype (30%) in our sample but 35/36, 37/38, 39/40 detected in 
Schizophrenic Female were absent in Normal Females in our sample. In 
Schizophrenic Females, genotypes present were in 10-20% proportion in our study 
sample with absence of 35/38, 36/38 and 38/39 genotypes (Fig. II.3.4). Fishers exact 
test analysis of individual genotypic combinations at this locus (Table II.3) all showed 
insignificant values with 35/38 genotype (0.010). Chi square analysis of genotypes, 
however, produced positive result (P =0.007) (Table II.3). Thus, though none of the 
combinations are specifically responsible for the schizophrenia expression in our 
study sample but overall the results provided support for TNR polymorphism at Sam4 
(DTNBPl) locus as a significant susceptibility gene for Schizophrenia in our Female 
study sample. 
11.3.5 Sam5: Eight (8) types of TNR polymorphic genotypes (Table II.3) were 
detected at Sam5 (GRIK2) locus. Normal Female had homozygous 24/24 (AAT)(n) 
repeat allelic genotypes as proportionally the commonest one detected (30%)) and 
21/21 and 24/26 absent whereas in Schizophrenic Female same genotype 24/24 was 
the most common (30%)) but genotypes 21/22, 21/23 and 22/23 were undetected on 
this locus in our study sample (Fig. II.3.5). As per Chi square statistical analysis 
7 0 
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I Normal Female 
ISCZ Female 
Genotype / / / • 
Figure 11.3.5: Histogram showing comparative frequency of genotypic combinations 
observed in Normal Female and Schizophrenic Female at Sam5 locus 
I Normal Female 
I SCZ Female 
Genotype 
Figure 11.3.6: Histogram showing comparative frequency of genotypic combinations in 
Normal Female and Schizophrenic Feamie patients at Sam6 locus 
(Table II.3), genotype frequency distribution at Sam5 (GRIK2) locus between Normal 
Female and Schizophrenic Female was not significant (P=0.101). Fishers exact test at 
individual combinations also did not show any significant values at any of the 
genotypes observed (Table II.3). In the light of these results, the Sam5 polymorphism 
did not confer susceptibility to the pathogenesis of Schizophrenia, atleast in the 
North-Indian Female population as per our study. 
II.3.6 Sam6: Seven (7) genotypic combinations (Table II.3) were detected on Sam6 
(CTGBI) locus. Of the genotypes observed in Normal Female sample of our study, 
14/14 (CAG)(n) repeat allele genotype was found in maximum proportion (40%) with 
12/15 and 14/15 genotypes absent whereas in Schizophrenic Female 14/14 and 14/15 
genotypes were detected in maximum individuals (30% each) with absence of 12/14 
genotype in our study sample (Fig. II.3.6). On statistical analysis as per Chi square 
(P=0.027) and Fishers exact test (Table II.3), comparison of polymorphic genotypes 
of both Normal and Schizophrenic Female groups in our study showed no significant 
difference. Thus our present study suggests that Sam6 (CTGBI) locus polymorphism 
may not confer susceptibility to development of Schizophrenia in the North-Indian 
Female population as per our study sample. 
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Table 11.4: Frequency of genotypes of gene loci studied with Variable Number of Tandem Repeats (VNTR) 
in Schizophrenic IMale and Schizophrenic Female and P-values. 
Schizophrenic Male 
Locus 
Sami 
Sam2 
Sams 
Sam4 
Sams 
Same 
Genotype 
9 - 1 1 
1 0 - 1 0 
1 2 - 13 
1 2 - 15 
1 3 - 1 5 
1 3 - 1 6 
1 3 - 1 7 
1 5 - 1 5 
1 5 - 1 6 
1 5 - 1 8 
1 8 - 1 9 
1 8 - 2 0 
9 - 1 1 
1 0 - 1 0 
1 3 - 1 4 
1 4 - 1 8 
1 5 - 1 6 
1 5 - 1 7 
1 5 - 1 8 
1 9 - 2 1 
1 9 - 2 2 
2 0 - 2 0 
6 - 6 
6 - 9 
6 - 1 0 
6 - 1 1 
6 - 1 3 
9 - 9 
9 - 1 0 
9 - 1 1 
9 - 1 3 
1 0 - 1 0 
3 5 - 3 5 
3 5 - 3 6 
3 5 - 3 7 
3 5 - 3 8 
3 5 - 3 9 
3 6 - 3 7 
3 7 - 3 7 
3 7 - 3 8 
3 8 - 3 9 
3 9 - 4 0 
2 0 - 2 0 
21 - 2 1 
2 2 - 2 3 
2 3 - 2 4 
2 4 - 2 4 
2 4 - 2 5 
2 4 - 2 6 
1 2 - 1 2 
1 2 - 1 4 
1 2 - 1 5 
1 2 - 1 6 
1 4 - 14 
1 4 - 1 5 
1 4 - 1 6 
No. Of 
Individuals 
4 
0 
2 
2 
0 
2 
0 
0 
2 
4 
4 
0 
4 
0 
4 
0 
0 
4 
4 
4 
0 
0 
2 
2 
2 
0 
0 
2 
2 
4 
0 
6 
2 
0 
0 
6 
2 
0 
8 
0 
2 
0 
2 
0 
4 
0 
10 
4 
0 
2 
2 
2 
0 
8 
2 
4 
Frequency 
0.2 
0 
0.1 
0.1 
0 
0.1 
0 
0 
0.1 
0.2 
0.2 
0 
0.2 
0 
0.2 
0 
0 
0.2 
0.2 
0.2 
0 
0 
0.1 
0.1 
0.1 
0 
0 
0.1 
0.1 
0.2 
0 
0.3 
0.1 
0 
0 
0.3 
0.1 
0 
0.4 
0 
0.1 
0 
0.1 
0 
0.2 
0 
0.5 
0.2 
0 
0.1 
0.1 
0.1 
0 
0.4 
0.1 
0.2 
Schizophrenic Female 
No. of 
Individuals 
0 
2 
2 
2 
2 
0 
4 
4 
0 
0 
0 
4 
0 
2 
0 
4 
4 
4 
0 
0 
4 
2 
0 
2 
0 
4 
2 
2 
0 
0 
2 
8 
2 
2 
2 
0 
0 
2 
4 
4 
0 
4 
0 
2 
0 
4 
6 
4 
4 
2 
0 
2 
2 
6 
6 
2 
Frequency 
0 
0.1 
0.1 
0.1 
0.1 
0 
0.2 
0.2 
0 
0 
0 
0.2 
0 
0.1 
0 
0.2 
0.2 
0.2 
0 
0 
0.2 
0.1 
0 
0.1 
0 
0.2 
0.1 
0.1 
0 
0 
0.1 
0.4 
0.1 
0.1 
0.1 
0 
0 
0.1 
0.2 
0.2 
0 
0.2 
0 
0.1 
0 
0.2 
0.3 
0.2 
0.2 
0.1 
0 
0.1 
0.1 
0.3 
0.3 
0.1 
Fishers exact 
P-value 
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Figure 11.4.1: Histogram showing comparative frequency of genotypic combinations 
observed in Schizophrenic IVIale and Schizophrenic Female patients at Sam1 locus 
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Figure 11.4.2: Histogram showing comparative frequency of genotypic combinations 
observed in Schizophrenic Male and Schizophrenic Female patients at Sam2 locus 
II.4. Negative and Positive Intra-Gender Bias: No /Association of 
TNR Polymorphic Genotype between Schizopiirenic Male and 
Schizophrenic Female 
[1.4.1 Saml: Twelve (12) combinations of (CTG)(n) repeat allele genotypes were 
detected (Table II.4) at this locus. Schizophrenic Male had the expressed genotypes in 
10-20% proportion whereas 10/10 13/15, 13/17, 15/15 and 18/20 were absent. In 
Schizophrenic Female expressed genotypes were present in 10-20% proportion but 
9/11, 13/16, 15/16, 15/18 and 18/19 genotypes were absent in our sample study (Fig. 
11.4.1). Statistical analysis of the genotype polymorphism at Saml (CTG B33) locus 
of these two groups of our study sample as per Chi square test (P=0.001) (Table 11.4) 
showed highly significant result. However, Fishers exact test at individual genotypic 
frequencies at this locus (Table 11.4) showed insignificant values persistently 
throughout. Consequently, though not any specific genotypic combination was 
responsible for susceptibility but so far association with disease was concerned, our 
present study as per our North-Indian sample suggested that the Saml polymorphism 
might confer susceptibility to Schizophrenia in the North-Indian Female population in 
comparison to Male gender. 
II.4.2 Sam2: Ten (10) TNR (CTG)(n) genotypes (Table 11.4), detected at this locus in 
our sample were present almost in equal proportion in both Male and Female 
Schizophrenic patients. However, in Male 10/10, 14/18, 15/16, 19/22 and 20/20 
genotypic combinations present in Male sample were absent. In case of Female 9/11, 
13/14, 15/18 and 19/21 were the genotypes absent (Fig. 11.4.2). Statistical analysis as 
per Chi square test (Table 11.4) found a significant difference (P=0.000) between the 
genotype frequencies of Male and Female Schizophrenic groups involved in our study 
sample. Fishers exact test analysis (Table II.4) at individual genotypic frequencies of 
these groups did not show significance at any of the repeat combinations observed. 
Thus on the basis of gender bias, though no specific combination was involved as per 
our study sample but the results of our analysis provide strong evidence of association 
between the polymorphism of Sam2 (CTG-B37) gene locus and susceptibility to 
Schizophrenia in the North-Indian Schizophrenic Female population in comparison 
North-Indian Schizophrenic Male population. 
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Figure 11.4.3: Histogram showing comparative frequency of genotypic combinations 
observed in Schizophrenic IVIale and Schizophrenic Female patients at Sam3 locus 
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Figure 11.4.4: Histogram showing comparative frequency of genotypic combinations 
observed in Schizophrenic Male and Schizophrenic Female patients at Sam4 locus 
11.4.3 Sam3: Ten (10) (CTG)(n) genotypes (Table II.4) were detected at this Sam3 
(N0TCH4) locus in our study sample. 10/10 genotype was most common in both 
Male (30%) and Female (40%) Schizophrenic samples with 6/11, 6/13 and 9/13 
genotypes absent in Male and 6/6, 6/10, 9/10 and 9/11 absent in Female patients (Fig. 
II.4.3). Both, Chi square test (P =0.032) in aggregate and Fishers exact test analysis 
(Table II.4) at individual genotypic combinations showed no significant values of 
difference in the genotype frequencies for CTG)(n) polymorphism between Male and 
Female Schizophrenics patients. Thus as per our study sample, our analysed 
observations showed that Sam3 (N0TCH4) might not be associated with intense 
Schizophrenia expression in Female Schizophrenic patients compared to Male 
Schizophrenic patients of North-Indian descent. 
11.4.4 Sam4: Ten (10) (AAT)(n) repeat allele genotypes (Table 11.4) were detected 
overall in our study sample at Sam4 (DTNBPl) locus. 37/37 homozygous genotype 
was proportionally predominant (40%) in case of Schizophrenic Male with marked 
absence of 35/36, 35/37, 36/37, 37/38 and 39/40 genotypes absent. However, in case 
of Schizophrenic Female, 35/38, 35/39 and 38/39 genotypes were not detected with 
the rest identified genotypes present in 10-20% proportion (Fig. II.4.4). As per our 
statistical analysis (Table II.4), Chi square test (P=0.003) showed the distribution of 
genotypes differed significantly between Schizophrenic Male and Schizophrenic 
Female at this gene locus. However, Fishers exact test analysis at individual genotypic 
frequencies (Table II.4) showed non-significant values persistently throughout. We 
thus conclude that though any specific genotypic combination might not be the cause 
of Schizophrenia in Female patients but the Sam4 (DTNBPl) gene locus 
polymorphism might constitute a risk factor for Schizophrenia in Schizophrenic 
Female compared to Schizophrenic Male patients of North-Indian descent as per our 
study. 
11.4.5 Sam5: Seven (7) types of (AAT)(n) repeat allele genotypes (Table II.4) were 
present at this locus. Homozygous genotype 24/24 was most common genotype in 
both Male (50%) and Female (30%) Schizophrenic patients of our study sample, 
however, 21/21, 23/24 and 24/26 genotypes were absent in Male Schizophrenic 
sample whereas 20/20 and 22/ 23 genotypes were not detected in Female 
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Figure 11.4.5: Histogram showing comparative frequency of genotypic combinations 
observed in Schizophrenic Male and Schizophrenic Female at Sam5 locus 
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Figure 11.4.6: Histogram showing comparative frequency of genotypic combinations 
observed in Schizophrenic Male and Schizophrenic Female patients at Sam6 locus 
Schizophrenic sample in our study sample (Fig. II.4.5). Chi square test analysis (P 
=0.009) (Table II.4) showed a highly significant value of TNP genotype frequencies 
at Sam5 (GRIK2) locus. But Fishers exact test analysis at individual genotypic 
frequencies (Table II.4) showed insignificance throughout. Thus, any individual 
genotypic combination specifically might not be the reason but polymorphism at this 
locus apparently play a role in the pathogenesis of Schizophrenia in the North-Indian 
Schizophrenic Female patient population compared to Male patient population as per 
our study. 
II.4.6 Sam6: At this locus, Seven (7) (CAG)(n) repeat allele genotypes (Table II.4) 
were detected in our study sample with genotype 14/14 most prominently detected in 
Male (40%) and 14/14, 14/15 in Female (30% each) Schizophrenic subjects of our 
sample. However, 12/16 in Male and 12/14 in Female remained undetected in our 
study sample (Fig. II.4.6). Chi square test analysis (P=0.325) of genotype fi-equencies' 
polymorphism (Table II.4) deduced a non-significant difference between Male and 
Female Schizophrenic patients. Fishers exact test analysis of individual genotypic 
frequencies at Sam6 (CTGBl) locus (Table II.4) also showed that TNR 
polymorphism was insignificant throughout the Male and Female Schizophrenic 
subjects of our study sample. Thus on the basis of gender bias, no tentative evidence 
was observed for the contribution of the Sam6 (CTGBl) gene locus polymorphism to 
the etiology of Schizophrenia in Female Schizophrenic subjects compared to Male 
Schizophrenic subjects atleast in the North -Indian Schizophrenic population as per 
our study sample. 
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Table 11.5: Frequency of genotypes of gene loci studied with Variable Number of Tandem Repeats (VNTR) in 
Schizophrenic patients (Mild-Average) and Chronic Schizophrenic patients. 
Locus 
Sam, 
SatTij 
Sarrvs 
Sam4 
Sanv 
Same 
Genotype 
9 - 1 1 
1 0 - 1 0 
1 2 - 1 3 
1 2 - 1 5 
1 3 - 1 5 
1 3 - 1 6 
1 3 - 1 7 
1 5 - 1 5 
1 5 - 1 6 
1 5 - 1 8 
1 8 - 1 9 
1 8 - 2 0 
9 - 1 1 
1 0 - 1 0 
1 2 - 1 3 
1 3 - 1 4 
1 4 - 1 8 
1 5 - 1 6 
1 5 - 1 7 
1 5 - 1 8 
1 9 - 2 1 
1 9 - 2 2 
2 0 - 2 0 
6 - 6 
6 - 9 
6 - 1 0 
6 - 1 1 
6 - 1 3 
9 - 9 
9 - 1 0 
9 - 1 1 
9 - 1 3 
1 0 - 1 0 
3 5 - 3 5 
3 5 - 3 6 
3 5 - 3 7 
3 5 - 3 8 
3 5 - 3 9 
3 6 - 3 7 
3 7 - 3 7 
3 7 - 3 8 
3 8 - 3 9 
3 9 - 4 0 
2 0 - 2 0 
2 1 - 2 1 
2 2 - 2 3 
2 3 - 2 4 
2 4 - 2 4 
2 4 - 2 5 
2 4 - 2 6 
1 2 - 1 2 
1 2 - 1 4 
1 2 - 1 5 
1 2 - 1 6 
1 4 - 1 4 
1 4 - 1 5 
1 4 - 1 6 
Schizophren 
No. of 
Individuals 
4 
0 
4 
0 
2 
2 
0 
2 
2 
0 
4 
0 
4 
0 
0 
4 
0 
0 
4 
4 
4 
0 
0 
2 
2 
0 
2 
0 
4 
0 
2 
0 
8 
0 
2 
0 
4 
2 
2 
6 
2 
2 
0 
2 
2 
0 
4 
8 
4 
0 
2 
2 
2 
0 
8 
2 
4 
. (Mild-Avg.) 
Frequency 
0.2 
0 
0.2 
0 
0.1 
0.1 
0 
0.1 
0.1 
0 
0.2 
0 
0.2 
0 
0 
0.2 
0 
0 
0.2 
0.2 
0.2 
0 
0 
0.1 
0.1 
0 
0.1 
0 
0.2 
0 
0.1 
0 
0.4 
0 
0.1 
0 
0.2 
0.1 
0.1 
0.3 
0.1 
0.1 
0 
0.1 
0.1 
0 
0.2 
0.4 
0.2 
0 
0.1 
0.1 
0.1 
0 
0.4 
0.1 
0.2 
Chronic Schizophrenia 
No.of 
Individuals 
0 
2 
0 
4 
0 
0 
4 
2 
0 
4 
0 
4 
0 
2 
0 
0 
4 
4 
4 
0 
0 
4 
2 
0 
2 
2 
2 
2 
0 
2 
2 
2 
6 
4 
0 
2 
2 
0 
0 
6 
2 
0 
4 
0 
0 
4 
0 
8 
4 
4 
2 
0 
2 
2 
6 
6 
2 
Frequency 
0 
0.1 
0 
0.2 
0 
0 
0.2 
0.1 
0 
0.2 
0 
0.2 
0 
0.1 
0 
0 
0.2 
0.2 
0.2 
0 
0 
0.2 
0.1 
0 
0.1 
0.1 
0.1 
0.1 
0 
0.1 
0.1 
0.1 
0.3 
0.2 
0 
0.1 
0.1 
0 
0 
0.3 
0.1 
0 
0.2 
0 
0 
0.2 
0 
0.4 
0.2 
0.2 
0.1 
0 
0.1 
0.1 
0.3 
0.3 
0.1 
Fishers exact 
P-value 
0.053 
0.244 
0.053 
0.053 
0.244 
0.244 
0.053 
0.698 
0.244 
0.053 
0.053 
0.053 
0.053 
0.244 
0.000 
0.053 
0.053 
0,053 
0.653 
0.053 
0.053 
0.053 
0.244 
0.244 
0.698 
0.244 
0.698 
0.244 
0.053 
0.244 
0.698 
0.244 
0.371 
0.053 
0.244 
0.244 
0.331 
0.244 
0.244 
0.634 
0.698 
0.244 
0.053 
0.244 
0.244 
0.053 
0.053 
0.626 
0.653 
0.053 
0.698 
0.244 
0.698 
0.244 
0.371 
0.118 
0.331 
Chi square 
P-value 
0.000 
0.000 
0.113 
0.028 
0.014 
0.325 
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Figure 11.5.1: Histogram showing comparative frequency of genotypic combinations 
observed in Schizophrenia(Mild-Avg.) and Chronic Schizophrenic patient groups at Sam1 
locus 
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Figure 11.5.2: Histogram showing comparative frequency of genotypic combinations 
observed in Schizophrenia(IVIiid-Avg.) and Chronic Schizophrenia at Sam2 locus 
II.5. Association between TNR Polymorphism in Genotypes: Positive 
/ Negative Result between Schizophrenia (Mild-Avg.) and Chronic 
Schizophrenia 
11.5.1 Saml: Twelve (12) genotypes were detected (Table II.5) in our sample study at 
Saml (CTG B33) locus. In Schizophrenic (Mild-Avg.) sample, genotypes were 
present in varied proportion of 13/15, 13/16, 15/15, 15/16 (10%) 9/11, 12/13, 18/19 
(20%) with few genotypes undetected as 10/10, 12/15, 13/17, 15/18 and 18/20. In 
Chronic Schizophrenic patients, genotypes detected in our sample were proportioned 
as 10/10, 15/15 (10%) and 12/15, 13/17, 15/18, 18/20 (20%) accompanied by marked 
absence of 9/11, 12/13, 13/14, 15/18, 19/21 genotypes (Fig. II.5.1). Chi square 
statistical analysis (Table II.5) of our study (P=0.000) showed that genotyping a CTG 
microsatellite marker at Saml (CTG B33) locus showed a highly significant 
association between the Schizophrenic condition (Mild-Avg.) and Chronic 
Schizophrenic subjects. However, as per Fishers exact test analysis (Table II.5), 
individual genotypic frequencies showed no significant value difference between the 
two groups. Thus Saml (CTG B33) polymorphism provided evidence for the 
involvement of the genotypic polymorphism at this locus with Schizophrenia 
expression intensity between Mild Schizophrenia and Chronic Schizophrenic subjects 
in our North-Indian study sample though no specific repeat combination was 
identified as the reason. 
11.5.2 Saml: Overall Eleven (11) (CTG)(n) repeat allele genotypes (Table II.5) were 
detected in our Schizophrenic study sample at Sam2 (CTG-B37) locus .In 
Schizophrenic condition (Mild-Avg.), the genotypes observed, were expressed in 20% 
proportion each with 10/10, 12/13, 14/18, 15/16, 19/22 and 20/20 genotypes absent. 
Chronic Schizophrenic subjects had 10-20% proportioned genotypes with absence of 
9/11, 12/13, 13/14, 15/18, 19/21 genotypes (Fig. II.5.2). Statistical analysis of 
genotype frequencies' polymorphism (Table II.5) as per Chi square test (P=0.000) 
deduced a highly significant difference between Schizophrenic condition (Mild-Avg) 
and Chronic Schizophrenic groups. However, Fishers exact test analysis at individual 
genotypic frequencies (Table II.5) showed no significant value difference between the 
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Figure 11.5.3: Histogram showing comparative frequency of genotypic combinatins 
observed in Schizoplirenia(Mild-Avg.) and Chronic Schizophrenia at Sam3 locus 
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Figure 11.5.4: Histogram showing comparative frequency of genotypic combinations 
observed in Schizohrenia(IVIild-Avg.) and Chronic Schizophrenia at sam4 locus 
two groups. Thus though none of the repeat combinations was specifically responsible 
but (CTG)(n) repeat allele genotypes at this Sam2 (CTG-B37) locus overall showed a 
highly positive inclination of genetic polymorphism to the disease intensity 
expression in our North-Indian study sample. 
11.5.3 Sam3: Ten (10) (CTG)(n) TNR genotypic combinations (Table 11.5) were 
detected in our sample study at this locus. (CTG)(n) TNR expansion genotype 10/10 
was the most prominent of genotypes in both Schizophrenic (Mild-Avg.) (40%) and 
Chronic Schizophrenic (30%) subjects in our sample study. 6/10, 6/13, 9/0 and 9/13 in 
Schizophrenic (Mild-Avg.) and 6/6 and 9/9 combinations were absent in Chronic 
Schizophrenia (Fig. 11.5.3). Fishers exact test at individual genotypic frequencies and 
overall Chi square (P=0.I13) statistical analysis of TNR polymorphic genotype 
frequencies between Schizophrenic (Mild-Avg.) and Chronic Schizophrenic subjects 
(Table 11.5) showed insignificant values. Our results thus suggested that the TNPs of 
Sam3 (N0TCH4) locus showed no evidence for association with the disease 
expression and were unlikely to play a major role in the susceptibility to 
Schizophrenia intensity in the North-Indian Schizophrenic patients as per our study. 
11.5.4 Sam4: Ten (10) types of (AAT)(n) repeat allele genotypes (Table 11.5) were 
detected in both the Schizophrenia (Mild-Avg.) and Chronic Schizophrenia samples 
of our study at this locus. Homozygous condition 37/37 (AAT)(n) repeat allele was 
the most common genotype (30%) detected in both the samples. However, 35/35, 
35/37 and 39/40 genotypes were absent in Schizophrenia (Mild-Avg.) while as 35/36, 
35/39, 36/37 and 38/39 genotypes were absent in Chronic Schizophrenia (Fig. II.5.4). 
Chi square (P^O.028) and Fishers exact test analysis (Table 11.5) of the genotype 
frequencies of the Sam4 (DTNBPl) locus polymorphism showed no significant 
differences between (Mild-Avg.) and Chronic Schizophrenic patients. These results 
indicated that TNR polymorphism of (AAT)(n) repeats at Sam4 gene locus when 
compared on the basis of disease intensity was not associated with Schizophrenia 
expression in North-Indian Schizophrenic population. 
n.5.5 Sam5: Seven (7) genotypes (Table 11.5) were detected in Schizophrenia (Mild-
Avg.) and Chronic Schizophrenia in our sample study at this Sam5 (GRIK2) locus. 
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Figure 11.5.5: Histogram showing comparart lve frequency of genotypic combinations 
observed in Schizophrenla(Mild-Avg.) and Chronic Schizophrenia at Sam5 locus 
ISCZ(Mild-Avg.) 
I Chronic SCZ 
14/15. 14/16, 
Figure 11.5.6: Histogram showing comparative frequency of genotypic combinations 
observed in Schizophrenia(Mild-Avg.) and chronic schizophrenia at Sam6 locus 
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Homozygous condition 24/24, AAT)(n) repeat allele genotype Wefe t^he most 
prominent detected in both these groups. 22/23 and 24/26 genotypes were absent in' * 
SCZ (Mild-Avg.) and 20/20 21/21 and 23/24 were undetected in Chronic 
Schizophrenia (Fig. 11.5.5). We analysed comparatively the genotype frequencies of 
the TNR polymorphism at this locus in a small independent (20/20) sample from 
North-Indian Schizophrenic population, no statistically significant differences were 
found in genotype frequencies between SCZ (Mild-Avg.) and Chronic SCZ subjects 
both as per Chi square test (P=0.014) and Fishers exact test (Table II.5). This 
suggested that on the basis of disease expression intensity, as per our study sample, 
Sam5 (GRIK2) locus TNR polymorphism does not play a role as a susceptibility gene 
for Schizophrenia intensity in North-Indian Schizophrenic population. 
II.5.6 Sam6: Genotypic polymorphism based on CTG TNR expansion of Sam6 
(CTGBl) gene locus studied in Schizophrenia (Mild-Avg.) and Chronic 
Schizophrenia detected Seven (7) combinations of genotypes (Table 11.5) in our 
sample study. 14/14 homozygous genotype was the most common genotype in 
Schizophrenia (Mild-Avg.) (40%) and 14/14, 14/15 genotypes in Chronic 
Schizophrenia (30%), however, in case of Schizophrenia (Mild-Avg.) 12/16 genotype 
was undetected while as in Chronic Schizophrenia 12/14 genotype was not observed 
in our study sample (Fig. II.5.6). Overall statistical analysis as per Chi square test 
(P=0.325) and Fishers exact test for individual genotypic combinations at this locus 
(Table 11.5) showed the value in study samples insignificant. Thus no association was 
found between the genotype polymorphism of studied Sam6 (CTGBl) gene locus and 
Schizophrenia disease intensity expression in North-Indian Schizophrenic population 
as per our study samples. 
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DISCUSSION 
Discussion 
1. Selection of Subjects and genetic polymorphism 
1.1 Selection of subjects 
Our method was a retrospective study model where the aim was to ascertain the effect 
of TNR expansion polymorphism on Schizophrenia disease. The forty (40) patients 
were carefully selected from 80 subjects diagnosed with this disease. We chose 
patients who were admitted to psychiatric wards with severe mental illness or patients 
who were being treated since a long time span for the Schizophrenia disease. The 
selection criterion ensured that the Schizophrenia patients of our study were 
authentically diagnosed by medical experts of the field. 
We wanted to have a balanced heterogeneous Schizophrenia patient sample, 
hence reason we included patients with varied disease expression - Schizophrenia 
(Mild-Avg.) and Chronic Schizophrenia in equal number. In addition, patients whose 
Schizophrenia symptoms might have resulted from neurological disease were also 
included. 
1.2 Selection of genetic polymorphisms 
For our study certain criteria were applied in selecting the type of gene loci 
polymorphism. We considered Trinucleotide Repeat Expansion (TNR) polymorphism 
as the study criteria. The reason was triplet codes apparently in DNA sequencing 
could identify with discreet amino acids. Also ours being retrospective study model, 
the gene loci of the Tri Nucleotide Repeat (TNR) polymorphism were of major 
interest as work was done on these gene loci in many ethnic populations. We 
considered gene loci associated with neurological diseases because there were 
evidences in some population based studies of their correlation to Schizophrenia. 
There were mounting evidences which suggested that genes associated with 
neurological (brain) development might cause the brain-related diseases which would 
be worth studying and therefore the following gene loci were selected: - Saml (CTG 
B-33), Sam2 (CTG B-37), Sam3 (NOTCH4), Sam4 (DTNBPl), Sam5 (GluR6), 
Sam6 (CTG-Bl). Associated with the risk of SCZ, these are good candidate gene loci 
for molecular genetic study. Most of these gene predicts have been reported to be 
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present in different concentrations in the brain of patients with Schizophrenia than in 
normal individuals like NOTCH4 polymorphism is associated with prefrontal 
functioning and volumes and has been shown to be increased in SCZ patients' dorso-
lateral prefrontal cortex and was positively correlated with TNR expansion in many 
ethnic studies. 
2. Genetic polymorphism and association to Schizophrenia 
The main goal of this study was to find genetic polymorphism, which would predict 
effect of TNR expansion on disease expression in SCZ patients. The aim was 
assessment of negative or positive results in North-Indian population because the 
majority of the population based positive results in the molecular genetics of 
Schizophrenia have not been replicated in individual ethnic studies' samples. There 
are only few and in some none TNR expansion studies concerning Schizophrenia 
positives in Asiatic population studies. 
The traditional goal of molecular genetic studies in Schizophrenia has been 
sequence study of Dopamine receptor genes and genes associated with Dopamine 
transport or metabolism. However, some data suggested that TNR expansion at 
neurodevelopmentally active proteins gene loci and the related gene loci may also be 
significant in the expression of Schizophrenia in subjects. 
Of all the gene loci studied which affects CNS, TNR expansion has been most 
frequently studied for its association with Schizophrenia. There may be ethnic based 
polymorphism at these gene loci. Thus possible fianctional polymorphisms in 
population for gene locus may be worth studying in relation to Schizophrenia. 
However, in ethnic based study of normal and Schizophrenic patient populations, only 
one study has evaluated the association between Sam3 (N0TCH4) TNR 
polymorphism and Schizophrenia (Wei J, Hemmings GP; 2000). They found 
association in British population but unfortunately could not be replicated in other 
ethnic populations, especially the Asians (hnia K etal; 2001). Our TNR expansion 
study results suggested that Saml (CTG-B33) and Sam3 (N0TCH4) - CTG 
polymorphism was not associated with Schizophrenia expression in patients of 
North-Indian descent. At locus Saml CTG 20 repeat allele-the highest expansion was 
observed in our sample at this allele and was exclusively present in Schizophrenia 
patients and 18 repeat allele was more frequent in Schizophrenia patients than 
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Normal. At Sam3 locus CTG 11 repeat allele was more frequent and 13 repeat allele 
present only in Schizophrenia patients. These observations showed apparent 
significance but neither allelic polymorphisms of TNR expansion nor their genotypes 
at any of the gene loci studied were associated with TNR expansion. The statistical 
analysis results suggested both Saml and Sam3 gene loci TNR expansion does not 
cause Schizophrenia in North-Indian population. However these results are 
preliminary and should be replicated and the functional importance of the 
polymorphisms should be studied as well. Studying several other polymorphisms in 
theses genes may also provide a more precise estimation of their values in the 
molecular genetics of Schizophrenia. 
Sam2 (CTG B-37) and Sam6 (CTG-Bl) CAG TNR polymorphism was 
studied in fixed population by many scientists. Few early positive associations 
reported were refuted in many other ethnic studies. Sam2 (CTG B-37) and Sam6 
(CTG-Bl) locus TNP-CAG polymorphism was not significantly associated with 
Schizophrenia in our population study. Apparently our result suggested that the effect 
of certain CAG polymorphisms on Sam2 (CTG B-37) and Sam6 (CTG-Bl) loci 
significantly predicted response to TNR expansion as reason for Schizophrenia. 
Genotypic combinations of 15/16 CAG repeat alleles on Sam2 locus showed posifive 
susceptibility in our study sample. Thus these repeat combinations are assumed to 
play role in disease expression in patients with SCZ. Sam2 locus had CAG 16 repeat 
and 20 repeat allele present only in Schizophrenic patients and CAG 15 repeat allele 
more frequent in Schizophrenic patients than normal (histogram). But statistical 
analysis nullified the visual significance. Our results suggested TNR-CAG expansion 
polymorphism had no positive impact on Schizophrenia expression in patients of 
North-Indian descent. However caution should be exercised when interpreting these 
results. Our results on the association of TNR expansion polymorphism on Sam2 and 
Sam6 loci with Schizophrenia in North-Indian population should be taken to be 
tentative and replications are needed to evaluate its true value in clinical decision-
making. 
Also in Sam4 (DTNBPl) and SamS (GluR6) gene locus, the AAT TNR 
polymorphism was rendered insignificant by analysis in our study sample. At either 
locus apparent appearance of longest TNR allele in the Schizophrenic patients - 40 
AAT repeat only in Schizophrenics and 37 repeat significantly more frequent in 
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Schizophrenics than Normals at Sam4 locus and at Sam5 locus, AAT 26 repeat only 
in Schizophrenics with 25 and 24 repeats more in frequency in Schizophrenic 
patients, does not confirm this TNR polymorphism association to Schizophrenia in 
our ethnic population sample. Our results suggested that repeat expansion of TNR in 
the specific gene loci that we examined are unlikely to be major etiological factors for 
Schizophrenia in North-Indian population Only few previous studies have 
investigated the association between Sam4 (DTNBPl) and Sam5 (GluR6) locus AAT 
polymorphism and most of them reported in negative. Our results also support the 
negative viewpoint. However, other polymorphisms should also be studied at these 
loci. In addition Sam4 and Sam5 allele fi-equency may be influenced by 
environmental factors and our evaluations need further ethnic investigations and 
replications for authentic observations at these loci atleast in North-Indian population. 
3. Genetic polymorphisms and disease intensity of sub-groups in 
Schizophrenia 
Schizophrenia (SCZ) is a heterogeneous disease involving both genetic and 
environmental factors (Schulz and Anderson; 1999). Multifactorial concept has also 
estimated that one single gene may have only a very limited effect on the total risk of 
Schizophrenia (Weiberger; 2002) and also more relevant subgroups of Schizophrenia 
are needed for genetic studies. Molecular genetic studies may even lead to meaningful 
subgroups in Schizophrenia and study of Schizophrenia appearance in sub-groups as 
per intensity can be clinically useful for diagnostic study. 
In our endeavor to work on comparative basis between Schizophrenic sub-
groups, our preliminary results suggest that Saml- CTG polymorphism does show 
association with the intensity of expression in Schizophrenic patients and Sam3 loci-
CTG polymorphism on contrary does not affect the Schizophrenia expression 
intensity in North-Indian population. On Saml locus-20 repeat allele, highest in the 
range, is present only in Chronic Schizophrenia and 15 and 18 repeat alleles more 
frequent in Chronic Schizophrenia than Schizophrenia (Mild-Avg.). The highest range 
genotypic combination 18/20 of Saml (CTG-B33) was also observed only in chronic 
Schizophrenia. Our study strongly supported the CTG TNR expansion at Saml locus 
to be associated with the intensity of Schizophrenia expression. On Sam3 locus-13 
repeat allele, highest in the range, is present in Chronic Schizophrenia. This apparent 
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significance was not found positive in statistical analysis. Also, genotype 
combinations on Sam3 (N0TCH4) locus were more or less equal in Schizophrenia 
(mild-avg.) and Chronic Schizophrenia. Sam3 locus TNR expansion polymorphism 
does not seem to be a responsible factor for disease expression variability in North-
Indian population. 
On Sam2 and Sam6 locus- CAG TNR expansion studied revealed both 
positive and negative associations with disease intensity. On Sam2 locus-22 repeat 
allele, highest in the observed range was present in Chronic Schizophrenia only. 15 
repeat allele and onwards, majority of TNR expansion alleles were present in chronic 
Schizophrenia. Highest repeat combinations as 19/22, 20/20 genotypes were observed 
exclusively in Chronic Schizophrenia samples of our study. This apparent 
significance was strongly endorsed by statistical analysis and a high degree of 
association between the CAG TNR expansion polymorphism and SCZ intensity was 
quite evident at Sam2 locus in North-Indian population. On Sam6 locus - Repeat 
allele with 14 CAG TNR was observed in greater proportion in Chronic 
Schizophrenia compared to Schizophrenia (Mild-Avg.) and other expansion alleles 
were equally present almost in same proportion. Both genotypic combinations and 
allele frequencies showed no positive impact of the CAG TNR expansion 
polymorphism at this locus on disease intensity of Schizophrenic patients in North-
Indian population. CAG repeat polymorphism study showed TNR expansion on 
different loci can have variable expression effect, so same polymorphism at different 
loci does not necessarily deduce the same result. Positive effect at one locus and 
negative impact at other in our study justifies the observation. However our study 
shall not be taken as the final assessment of these loci study. Further study is strongly 
recommended because of our sample being ethnic based and its limited size. 
At Sam4 and SamS loci - TNR AAT expansion observed in our North-Indian 
Schizophrenic population sample showed no possible association between disease 
intensity and Schizophrenia patients at either loci. On Sain4 locus, the allele with 
highest expansion repeat- 40 repeats was present in Chronic Schizophrenia. The 
observed genotypic combinations were more uniform in both the comparative 
Schizophrenia Samples as 39/40 genotype in Chronic Schizophrenia and 38/39 in 
Schizophrenia (Mild-Avg.) patient samples of our study. These observations showed 
none of the observed genotypes as specific combination of polymorphic expansions 
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possibly might increase intensity of disease at this locus. Statistical insignificance at 
allelic level and genotypic level endorsed our negative observation. Likewise, on 
SamS locus- TNR AAT expansions' apparent positive significance to disease 
intensity in patients' like allele with AAT repeat 26, highest of the range observed, 
present in Chronic Schizophrenia and genotypic combination of 24/26 present 
exclusively in Chronic Schizophrenia was nullified by statistical analysis which 
showed no association of AAT TNR polymorphism with disease intensity in patients' 
of North-Indian descent. However, because of the small sample size and several other 
limitations of the study these results should be considered speculative. 
4. Gender Differences 
4.1 Intra-Gender Differences 
Same gender differences could help to establish a threshold for the Schizophrenia 
appearance if the significance was seen and help at molecular level to establish the 
TNR polymorphism as identification criteria for disease. In our study we analyzed 
both intra-gender groups, Normal Male - Schizophrenia Male and Normal Female-
Schizophrenia Female for the TNR polymorphism on Saml (CTG B-33) and Sam3 
(NOTCH4) loci for CTG, Sam2 (CTG B-37) and Sam6 (CTG-Bl) loci for CAG, 
Sam4 (DTNBPl) and SamS (GluR6) loci for AAT TNR expansion. In Normal Male 
-SCZ Male except CAG polymorphic combinations at Sam2 locus, TNR expansion 
pol3'morphisms at all the loci studied were not associated with SCZ expression in 
patients' samples of our study. Though genotypic polymorphisms were not equally 
distributed between Normal and Schizophrenia samples as on Saml locus, 18/19 was 
present exclusively in SCZ male. 15/17,15/18 combinations were observed exclusively 
in SCZ Male on Sam2 locus, 24/25 genotype observed in SCZ Male only on Sam5 
locus, 14/16 genotype on Sam6 locus in our study. Also, in our study population of 
males, alleles with higher TNR repeat expansion were more frequent in Schizophrenic 
Males than Normal Male sample-19 repeat allele on Sam2 locus, 16 repeat allele on 
Sam6 locus exclusively in SCZ Male. This gave an apparent idea of TNR expansion 
correlated to Schizophrenia expression in male population. But it was not confirmed 
by statistical analysis. However, significant value at Sam2 locus showed some 
genotypic combinations of TNR expansion might be susceptible to Schizophrenia in 
North-Indian Male population. 
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In Female population study, Normal Female- Schizophrenia Female the TNR 
polymorphism on Saml (CTG B-33) and Sam3 (N0TCH4) loci for CTG expansion, 
Sam2 (CTG B-37) and Sam6 (CTG-Bl) loci for CAG, Sam4 (DTNBPl) and Sam5 
(GluR6) loci for AAT TNR expansion did not show any positive association with 
Schizophrenia expression in female population of North-Indian origin. Though the 
apparent inclination of greater repeat expansion was towards Schizophrenia like in 
Saml- 20, Sam3- 11 and 13, Sam4- 40, Sam5- 26, the highest of the respective repeat 
alleles at concerned loci, were observed in SCZ female only. At Sam6 locus, 15 
repeat allele of the range was double in proportion in Schizophrenia patient. Also 
genotypic combinations at Saml-18/20, Sam6-14/15, 20/20, Sam5-24/26 present 
exclusively in Schizophrenia patient samples showed the apparent association with 
Schizophrenia in female gender which was not endorsed by statistical analysis. 
However, genotypic combinations at Sam4 locus with highest AAT repeat 39/40 and 
Sam3 with CTG 9/13 combinations exclusively in Schizophrenia only, showed 
positive association of TNR expansion to Schizophrenia in female gender of North-
India as apparent also. TNR expansion at the gene loci Sam3 and Sam4 was 
associated with Schizophrenia expression in patients in intra-gender comparison. 
However there was no clear explanation why NOTCH4 polymorphism has a different 
effect in male and female patients. These very small subgroups and possibly could not 
perform meaningful statistical analysis in order to find out if there was a difference 
between these polymorphisms of TNR expansion between Normal and Schizophrenic 
subjects. So the results obtained in our North-Indian Female population sample should 
be replicated. 
4.2 Inter-Gender Differences 
Schizophrenia seems to be more common in men (Aleman et al.; 2003) and some 
major features of the disease differ between Male and Female patients. The difference 
may be due to hormonal reasons (Halbreich et al.; 2003) but genetic factors may also 
play a significant role in the course of disease between male and female patients 
(Gourion et al.; 2004). Thus it may be relevant to analyse the results in genetic studies 
comparatively in Male and Female subjects, however, dividing the sample into 
subgroups weakened the statistical power and confounds the interpretation of the 
results. 
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For the reason mentioned above our results concerning difference between 
male and female should be seen as preliminary. Saml (CTG-B33) CTG TNR 
expansion showed highly significant association and probably plays an important role 
in Schizophrenia expression in Female compared to Male patient population at this 
locus in North-Indian population. Apparently, repeat 22, the highest in the range was 
observed in Female only, as supported by analysis but Sam3 (N0TCH4) CTG TNR 
expansion polymorphism was not associated with Schizophrenia expression. Thus 
same TNR expansion at different loci does have different effects. 
A strong gender bias may or may not be seen within population for the results 
of expansion. There is some research supporting the meaningfulness of studying the 
effect of Sam2 (CTG-B33) locus. CAG TNR alleles show high significance repeat 
15-22 almost all present in female gender and analysis supports the association of 
Schizophrenia expression in Female patients with CAG TNR expansion at this locus 
but Sam6 (CTG-Bl) CAG TNR polymorphism showed no significant association 
between TNR expansion and Schizophrenia expression in this gender bias study of the 
two comparative groups. 
At certain loci, the TNR expansion at individual alleles might not be reason 
for disease expression in a population but the genotypic combination of such alleles in 
an individual might cause the disease. Sain4 (DTNBPl) and Sam5 (GluR6) TNP 
AAT alleles of gene locus individually were not associated with Schizophrenia in 
Male or Female patients. But our study showed in genotypic combination analysis, 
high degree of association of TNP and Schizophrenia expression in patients of Female 
gender. So, TNR expansion of same type can have variable effect depending upon the 
gene loci and not the expansion as could be thought of 
Though the apparent appearance of TNP alleles showed Female sample having 
an edge over the Male sample at many loci as Saml (CTG-B33), Sam2(CTG-B33), 
Sam4 (DTNBPl) and Sam5(GluR6) supported by statistical analysis. However, these 
preliminary results obtained in our study sample needs to be further investigated. 
5. Limitations of tlie Study 
The small sample size constitutes the major limitation of the present study, however, 
we selected the Schizophrenia (SCZ) patients carefully with the help of expert 
psychiatrists in the area of study of North India. 
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Due to the retrospective study model we used the standard primers already 
used in other population based studies for the disease in defining the expansion 
response. The results might be different if RFLP was used and new primers used. 
There was some selection because the most suspicious patient did not wanted 
to participate in this kind of study, this was probably an important factor that might 
even contradict results in different patient populations in different study designs. The 
patients with drug or alcohol were excluded. Substance abuses being particularly 
common in Male patients might have lead to significant selection in Male study 
population. So there was selection bias. 
Because TNR expansions' association with early age onset in Schizophrenics 
compared with normal has been debated, there might be connection at genetic level. 
The present research frame could not clarify this question. 
Controls were chosen fi-om a randomly selected group of blood donors (n=50) 
and they underwent no specific examination for psychiatric status. However, the 
eligibility of blood donors entails a verbal interview regarding health status at every 
donation session. 
The results of all the parameters of this thesis are exploratory in nature and 
therefore no correction for multiple testing was carried out. There is a predefined 
decision in this study model. If multiple statistical comparisons were made in this 
kind of study some important and significant results might be lost. Such studies need 
to be replicated in any case, using a larger sample size and the investigation of more 
TNPs will be necessary to confirm the association, if any and only several replication 
studies can be an adequate proof of the usefiilness of the genetic tests. 
86 
Summary and Conclusion 
The major findings of the study were: 
• Saml (CTG-B33) gene locus polymorphism (CTG TNR) was not associated 
with the Schizophrenia expression in overall and single sex biased - intra-
gender population, thus the studied CTG polymorphism is not risk factor for 
Schizophrenia in North-Indian Population. However, within the Schizophrenic 
patient population, CTG expansion might play role in gender biased (SCZ 
Male vs. SCZ Female) and disease intensity (SCZ (Mild - Avg.) vs. Chronic 
SCZ) of expression. (I) 
• Sain2 (CTG B-37) gene locus CAG TNR polymorphism was not associated 
with the risk of Schizophrenia in the overall population study sample - Normal 
vs. Schizophrenic sample analysed as whole. However, intra-gender bias in 
Male population shows CAG genotypic polymorphism as risk factor in SCZ 
expression in Male population. The inter-gender bias within the SCZ 
population shows inclination of disease expression towards Female population 
and CAG expansion might play role in expression intensity of the North-
Indian SCZ population. (II) 
• Sam3 (NOTCH4) gene locus CTG TNR polymorphism comparison in 
Schizophrenic sample with the Normal control of our North-Indian sample, 
intra-gender Male and inter-gender sex-bias, disease intensity showed no 
association of TNR expansion with Schizophrenia expression. But the CAG 
genotypic polymorphism observed an association of SCZ expression in 
Female population of North-Indian descent. (Ill) 
• Sam4 (DTNBPl) gene locus AAT TNR allelic as well as genotypic jfrequency 
analysis signifies no association with Schizophrenia in- Normal/ 
Schizophrenic, Intra-Gender (Normal Male / Schizophrenic Male), Disease 
Intensity (SCZ (Mild - Average) / Chronic SCZ) comparisons carried out in 
our North-Indian population sample. However, the Intra-Gender (Normal 
Female / SCZ Female) and Inter-Gender (SCZ Male / SCZ Female) genotypic 
polymorphism showed AAT TNR expansion might play as a risk factor in 
Schizophrenia expression. 
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• Sam5 (GRIK2) gene locus AAT TNR expansion lacks association with 
Schizophrenia in all the comparative studies except in SCZ Male - SCZ 
Female where genotypic combinations showed positive association. Effect of 
AAT polymorphism on disease expression might be gender biased at this 
locus carried out in our North-Indian population sample. 
• Sam6 (CTG-Bl) gene locus CAG TNR polymorphism does not show any 
association with Schizophrenia in the overall population and the sub-groups' 
comparative study - Normal / SCZ, Intra-Gender (Normal Male / SCZ Male, 
Normal Female / SCZ Female), Inter-Gender (SCZ Male / SCZ Female), 
Disease Intensity (SCZ (Mild-Average)/ Chronic SCZ) in our North-Indian 
population sample. 
Since our study of association of TNR polymorphism with Schizophrenia was based 
on retrospective studies of these gene loci in many other populations. Our study 
revolved around the confirmation of either positive or negative study at these gene 
loci in North-Indian population. Our results were in favour of negative association as 
per the overall population study and this is especially interesting as it goes in 
consensus with most of the Asiatic population studies carried out so far. Possible 
reasons for disagreement with the positive studies may depend on the differences of 
ethnicity, population admixture, sample size and methodology. However, in the sub-
groups within the Schizophrenic population of North-India, most of the gene loci in 
one or the other comparative group showed results in favour of association. This is of 
more interest as most of the Asiatic populations have reported negative observations 
in such sub-group studies. This can prove to be an endorsement of hypothetical views 
that TNR polymorphism and its implications in the causation of genetic disease 
especially the psychiatric ones might be ethnic-based. 
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